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Abstract 
 
Corneal disease is a major cause of global blindness accounting for around 
2% of severe visual impairment in the UK.  Corneal dystrophies are a group of 
rare, bilateral conditions with a genetic basis. 
 
In conjunction with the British Ophthalmic Surveillance Unit (BOSU), a 
national incidence for new cases of corneal dystrophy in patients aged below 
40 years was identified. 73 cases were reported to BOSU with 27 cases 
(42%) returned by questionnaire. There was a positive family history in 48% of 
cases. A minimum UK incidence for new cases per annum of 6.7 cases per 
10 000 000 population was calculated.  
 
To investigate the link between Congenital Hereditary Endothelial Dystrophy 
(CHED), Harboyan syndrome and Fuchs Endothelial Corneal Dystrophy 
(FECD), a longitudinal observational study was performed. CHED and 
Harboyan syndrome (CHED with sensorineural hearing loss) are both caused 
by biallelic mutations in SLC4A11. All four of the CHED patients examined 
had varying degrees of hearing loss at high frequencies, suggesting that 
CHED and Harboyan syndrome are the same condition at different 
developmental stages. In addition, two of the four parents of CHED patients 
examined had guttata, suggesting that the parents are at risk of developing 
FECD. 
 
FECD is a common, complex corneal endothelial disease. The relative 
contributions of the TCF4 SNP rs613872, the intronic TCF4 CTG18.1 
trinucleotide expansion and LOXHD1 variants in a UK Caucasian FECD 
cohort ethnically-matched controls were compared. The results of segregation 
of the CTG18.1 expansion and whole exome sequencing in three local FECD 
families indicated that the CTG18.1 expansion was causative for the FECD in 
two of the three families. This indicated that the TCF4 expansion is a major 
contributor to the pathogenesis of FECD. Whole exome sequencing in the 
third family revealed some good gene candidates, which were considered for 
further screening in the FECD cohort.   
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1  Introduction 
1.1 Gross Anatomy and Function of the Human Eye 
 
The human eye comprises the anterior segment that includes the cornea, iris, 
trabecular meshwork, aqueous humour and the lens, and the posterior 
segment, consisting of the vitreous gel, retina and the optic nerve. The retina 
consists of a neural layer and pigmented retinal pigment epithelium (RPE). 
The macula is a specialised area at the centre of the posterior retina (Snell 
and Lemp, 1997). A schematic diagram of the eye in sagittal cross-section is 
shown in Figure 1.1. 
 
 
 
Figure 1.1 Diagram of the human eye in sagittal view, indicating the gross 
structures. Reproduced with permission from WebMD (http://www.webmd.com/eye-
health/picture-of-the-eyes). 
 
The optical components of the eye are the cornea, aqueous humour, lens and 
vitreous body. The speed with which light travels through these structures is  
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inversely proportional to it density. Therefore light waves striking the cornea 
are slowed differentially, as the refractive index of aqueous humour is greater 
than that of air (Elkington et al., 1999). Light traverses these structures and 
focuses onto the retina. This process relies on the cornea and lens 
transparency, enabling the light to focus on a single point on the retina where 
the light signal is converted into a neural signal by the phototransduction 
cascade. This neural signal is transferred through the optic nerve eventually 
forming an image at the brain visual cortex. The biology of the anterior 
segment is orientated towards achieving clear transmission and sharp 
focusing of light on the retina (Hejtmancik and Nickerson, 2015). The opaque 
scleral coat forms the posterior five-sixths of the eyeball. The sclera itself is a 
relatively avascular structure, however the anterior ciliary arteries form a 
dense episcleral plexus. The tough fibrous structure protects the intraocular 
contents from trauma and mechanical displacement. The intervening layer 
between the retina and the sclera is the choroid, a soft brown, vascular coat 
lining the inner surface of the sclera. This layer provides nourishment for the 
retina as well as for absorbing excess light (Snell and Lemp, 1997).  
 
1.2 Embryological Development of the Human Eye 
 
The eye develops from several embryonic layers. The ectoderm gives rise to 
the lens and the corneal epithelium. The neuroectoderm forms the pigmented 
epithelium and the neural retina. The neural crest cells develop into the 
corneal stroma, the ciliary and iris muscles and the vascular choroid layer 
together with the fibrous sclera. The mesoderm contributes to the cornea and 
forms the angioblasts of the choroid layer. The first evidence of eye formation 
is the formation of the optic sulcus at 22 days of human development. At day 
24, the cranial neuropore closes, by which time the optic stalk is evident 
(Larsen et al., 2009). By the sixth week, the rudimentary eye including the 
optic cup and partially encapsulated lens vesicle are visible. The bilayered 
optic cups, partially encapsulating the lens vesicles have formed (Figure 1.2) 
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(Ali and Sowden, 2011). As the subject of this thesis is the cornea, its 
embryogenesis and development are covered in greater detail below. 
 
 
Figure 1.2 The embryonic development of the human eye a. At early stages of 
eye development, the surface ectoderm thickens and invaginates together with the 
underlying neuroepithelium of the optic vesicle. b. The inner layer of the bilayered 
optic cup gives rise to neural retina and the outer layer gives rise to the retinal 
pigmented epithelium (RPE) c. The mature neural retina. Reproduced with 
permission (Ali and Sowden, 2011). 
 
1.2.1 Corneal Embryogenesis 
 
The formation of the cornea is induced by the lens and the optic cup, and is 
the last series of major inductive events during eye development at around 5 
to 6 weeks of human gestation (18mm stage), when the surface ectoderm 
interacts with the lens vesicle (Figure 1.3). When completely separated, the 
space between them is filled with perinuclear mesenchyme cells from the 
neural crest. The mesenchyme condenses and forms several layers 
separated by extracellular matrix. The mesenchymal cells closer to the lens 
become the endothelium and the surface ectoderm on the anterior surface, 
become the corneal epithelium (Larsen et al., 2009, Zavala et al., 2013). 
Therefore, the corneal layers are derived from differing embryonic origins. 
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Figure 1.3 Formation of the cornea. The cornea begins to develop when the 
surface ectoderm closes after the formation of the lens vesicle and its detachment 
from the surface ectoderm. Mesenchymal cells (neural crest cells) invade the cornea 
and form the corneal stroma after condensation. Reproduced with permission 
(Zavala et al., 2013). 
 
1.2.2 Development of the Corneal Endothelium and Descemet’s 
Membrane 
 
The neural crest cells undergo epithelial-to-mesenchymal transition (EMT) 
and form a cell monolayer that occupies the posterior surface of the cornea. 
The presumptive corneal endothelium begins as a loosely arranged 
monolayer at about 8 weeks gestation. The zonula occludens (tight junctions 
in between the endothelial cells) are present by week 17, although the 
endothelial pump function (Section 1.3.6) is not fully established. The early 
endothelium is evident during the fourth month of human gestation. It secretes 
the basement membrane, Descemet’s membrane (DM), as a multilaminated 
layer between the endothelial cell layer and the posterior stroma. It is a cell-
free matrix consisting predominantly of collagens (Waring et al., 1982) 
(Lwigale, 2015). 
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1.3   Detailed Anatomy of the Adult Human Cornea 
 
The cornea, the major refracting structure of the human eye, occupies one 
third of the external eyeball. It consists of six layers: the epithelium, epithelial 
basement membrane, Bowman’s layer, the stroma, DM and the endothelium 
at the posterior surface of the cornea. These are numbered sequentially in 
Figure 1.4. 
 
Figure 1.4 Histology of the cornea. The layers are numbered sequentially; the 
epithelium (1), epithelial basement membrane (2), Bowman's layer (3), corneal 
stroma (4), DM (5), and endothelium (6). Reproduced with permission (Krachmer et 
al., 2011). 
 
1.3.1 The corneal epithelium 
 
The epithelium comprises four to six layers of non-keratinised stratified 
squamous epithelial cells, and is 50μm in thickness. The superficial two to 
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three layers consist of flat, polygonal cells which have microvillae and 
micropliae on the apical surface. The cell periphery exhibits tight junctions 
which prevent the entry of microorganisms into the cornea. Basal epithelial 
cells are the posterior-most layer of the corneal epithelium and are 
responsible for laying down the basement membrane. Perilimbal basal cells 
differentiate and migrate anteriorly to regenerate the cornea. They utilise 
hemidesmosomes to adhere to the underlying basement membrane (Eghrari 
et al., 2015b). There is little variation in cell density and morphology of basal 
epithelial cells amongst individuals (Harrison et al., 2003). 
 
1.3.2 Basement Membrane 
 
The basal cells of the corneal epithelium are anchored to the basement 
membrane (BM) which is 40-60nm thick (Krachmer et al., 2011). The BM is 
composed of four primary components – collagens (predominantly collagen 
type IV), laminins, heparin sulphate proteoglycans (HSPG) and nidogens.  
Laminins are the most abundant non-collagenous proteins in the BM, and 
interact with collagen networks via nidogens. They have the unique ability to 
self-assemble into sheet-like structures. The most prevalent HSPG is 
perlecan, a multidomain protein which mediates the migration, proliferation 
and differentiation of a variety of cells by mediating cell signalling events 
(Torricelli et al., 2013).  
 
1.3.3 Bowman’s Membrane 
 
Bowman’s layer is an acellular, non-regenerating layer that is posterior to the 
epithelial BM. It is approximately 8-12μm in depth and decreases in thickness 
with age. It consists of collagen fibrils, which are two-thirds the thickness of 
those of the stroma, and which merge with those of the anterior stroma 
(Eghrari et al., 2015b). 
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1.3.4   Stroma or Substantia Propria 
 
This layer forms 90% of the corneal thickness (Figure 1.5 ). It is transparent, 
fibrous and compact. Stromal fibrils consist mainly of type I collagen, with 
smaller amounts of types III, V and VI (Snell and Lemp, 1997). The stroma 
comprises over 200 sheets of lamellae each 1-2µm thick of collagen fibrils 
approximately 36nm in diameter. This arrangement is highly ordered such that 
they lie in parallel, an arrangement essential for maintaining corneal clarity. 
Keratocytes are interspersed between the lamellae forming an interlinking 
network. The main glycosaminoglycan present is keratin sulphate. The stroma 
has a natural tendency to absorb water and swell due to the hydrophilic 
nature of the proteoglycan matrix surrounding the collagen fibrils. The 
mechanism by which the stroma of the cornea remains relatively dehydrated 
is deturgescence (Freegard, 1997).  
 
 
Figure 1.5 Corneal histology image of the human cornea. The stroma occupies 
90% of the corneal thickness, as indicated by the two black arrows (courtesy of Dr 
Hardeep S Mudhar, Consultant Ophthalmic Histopathologist, Royal Hallamshire 
Hospital, Sheffield, UK). 
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1.3.5   Descemet’s Membrane 
 
DM is a basement membrane of the corneal endothelium and measures 3μm 
in children and 8-10μm in adults. Transmission electron microscopy reveals 
the anterior banded layer, approximately 3μm thick, which consists of a 
latticework of collagen fibrils with periodic banding at 110nm intervals. On 
tangential section, the layer reveals a hexagonal formation of collagen fibrils. 
After birth the endothelial cells secrete the relatively homogeneous posterior 
non-banded layer which has a fine granular appearance, and which thickens 
with age (Johnson et al., 1982).  
 
DM contains collagen types IV and VIII fibrils, type VIII being specific to DM. 
Similar to the stroma the ECM protein fibronectin, laminin, keratin sulphate, 
herparin sulphate and dermatin sulphate are also present (Eghrari et al., 
2015b). Fibronectin may play a role in the adhesion of the endothelial cells to 
the DM (Waring et al., 1982). The DM is shown by the black arrow in 1.6A and 
is also labelled in 1.6B. 
 
 
Figure 1.6 The posterior aspect of the human cornea. A. Histopathology image of 
the showing the endothelium and DM. The black arrow indicates DM. The endothelial 
cell layer is indicated by the purple arrow (courtesy of Dr Hardeep S Mudhar, 
Consultant Ophthalmic Histopathologist, Royal Hallamshire Hospital, Sheffield, UK). 
B. Electron micrograph of corneal endothelium underlying DM. Reproduced with 
permission (Zavala et al., 2013). 
 
A. B. 
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1.3.6   Corneal Endothelium 
 
The human corneal endothelial surface (Figure 1.6) is 130mm2 and comprises 
a monolayer of polygonal corneal endothelial cells, which cover the posterior 
surface of DM in a mosaic pattern (Figure 1.7). These cells are 5µm in 
thickness, 20µm in width and are polygonal, mostly hexagonal, in shape. The 
cell density in a 3 to 6-year-old child is 3500–4000 cells per mm2 but this 
value decreases with age. The normal endothelial cell count in a 30 year old 
ranges from between 2700 to 2900 per mm2 and that in an adult over 75 
years old ranges from 2400 to 2600 per mm2 (McCarey et al., 2008). The 
corneal endothelium maintains corneal clarity by keeping the stroma in a state 
of relative dehydration, as well as providing a barrier and pump function. The 
active transport of bicarbonate ions into the aqueous humour is thought to be 
a major role of the endothelial pump function, although the transport of 
sodium and potassium ions also plays a role (Waring et al., 1982). Endothelial 
cells contain a large nucleus and abundant cytoplasmic organelles including 
mitochondria, endoplasmic reticulum, free ribosomes, and Golgi apparatus, 
suggesting that they are highly metabolically active (Krachmer et al., 2011). 
When the endothelial cell counts drops to 400-700 cells per mm2 or less, 
corneal decompensation (corneal oedema resulting from failure of the 
endothelium to maintain deturgescence) occurs, which suggests that there is 
a substantial reserve (Edelhauser, 2006). When the endothelial cell count is 
low, the loss of zonula occludens allows more fluid to enter the stroma, thus 
disrupting the parallel arrangement of the stromal collagen fibrils and 
compromising corneal clarity. 
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Figure 1.7 Normal corneal endothelium as photographed by specular 
microscopy. The regular array of hexagonal cells, all having nearly the same area, 
is seen. Reproduced with permission (Krachmer et al., 2011). 
 
1.3.7 Regenerative Capacity of the Corneal Endothelium 
 
Individuals are born with differing numbers of endothelial cells (Yuen et al., 
2005). Traditionally, it was thought that endothelial cells do not divide and are 
arrested in the G1 phase of the cell cycle (Bourne, 2003). Therefore, as the 
endothelial cells die with age, the cells that remain have a limited regenerative 
capacity (Waring et al., 1982). However, recently this theory has been 
challenged by a study, which suggests that the corneal periphery contains a 
reservoir of stem-like cells that replace damaged or dead endothelium (He et 
al., 2012). The authors evaluated the microanatomy of 88 whole endothelia. In 
61% of the corneas, they noted that the cells located at the extreme periphery 
(the peripheral 200μm of the endothelium) were organized in small clusters, 
estimated to occupy one third of the circumference of the cornea. Additionally, 
in 68% of the corneas, peripheral endothelium formed radial rows, which were 
variable in length but occupied around 86% of the corneal circumference. On 
staining, these cells were less differentiated but expressed stem cell specific 
markers. 
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1.4   Epidemiology of Eye Disease 
1.4.1 Global Burden of Eye Disease 
 
There are approximately 161 million people worldwide with low vision, 37 
million of whom are severely sight-impaired. This figure excludes those with 
uncorrected refractive error (Resnikoff et al., 2004). The main causes of 
global blindness are cataract, glaucoma, corneal scarring, age-related 
macular degeneration (ARMD) and diabetic retinopathy. All of these are 
considered avoidable except for ARMD. The World Health Organisation 
(WHO) Prevention of Blindness programme and the International Agency for 
the Prevention of Blindness set up the VISION 2020 - Right to Sight initiative 
in 1999 to eliminate 80% of avoidable blindness by the year 2020. It sought to 
do this by focusing on the diseases, which are the main causes of blindness 
and for which proven cost-effective interventions are available. The most 
recent global action plan for the period 2014-2019 aims to reduce visual 
impairment as a global public health problem and secure access to 
rehabilitation for visually impaired services (http://www.iapb.org/vision-2020). 
It has been calculated using economic and epidemiological modelling that 
without global initiatives the number of blind individuals would increase to 76 
million in 2020. The cost impact of blindness can be assessed in “blind 
person-years” defined as one year of blindness for one individual. A 
successful VISION 2020 initiative would avoid 429 million blind person-years 
(Frick and Foster, 2003). The impact of this initiative was assessed in 2005. 
The estimates of global blindness were 15 million blind person-years less than 
projected and indicated that VISION 2020 was reducing global blindness 
(Foster and Resnikoff, 2005, Foster et al., 2008).  
 
Visual acuity is the ability to resolve detail, for instance to be able to detect a 
gap between two objects in space. It is a commonly used proxy measure for 
the degree of visual acuity as it is easy to measure and is understood by the 
lay public (https://www.rcophth.ac.uk/professional-
resources/revalidation/clinical-sub-specialties/cataract/visual-acuity/).  
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Snellen acuity (Figure 1.8A) has been used to measure visual acuity since 
1862, however this has more recently been superseded by its assessment 
using a logarithmic method, LogMAR visual acuity (Figure 1.8B) 
(https://www.rcophth.ac.uk/wp-content/uploads/2015/11/LogMAR-vs-
Snellen.pdf). 
 
 
Figure 1.8 An example of A. a Snellen chart  B. LogMAR for testing visual 
acuity. 
 
The International Statistical Classification of Diseases and Related Health 
Problems 10th Revision 2015 
(http://apps.who.int/classifications/icd10/browse/2015/en#!/H53) currently 
classifies visual impairment as outlined in Table 1.1. 
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Table 1.1 Categories of visual impairment (ICD-10 Version 2016) 
(http://apps.who.int/classifications/icd10/browse/2016/en#/H53). Visual acuity is 
shown in both Snellen and LogMAR forms. 
 
1.4.2 Childhood Visual Impairment Epidemiology and Case 
Identification 
 
Childhood blindness is the second largest category of blind-person years. 
Globally about 70 million blind person years are caused by childhood 
blindness (Yorston, 1999). In the UK, an epidemiological study of 439 children 
with severe visual impairment (SVI) was carried out. The results indicated that 
SVI had an incidence of 4 per 100,000 and occurred more frequently in 
conjunction with co-existing non-ophthalmic impairments. The authors found 
that children at the most risk were those of low-birth weight and from ethnic 
minority groups. Cerebral visual impairment was the most common cause of 
SVI in children. SVI caused by sclerocornea and corneal opacity accounted 
for 2% of patients (Rahi and Cable, 2003). Cases of visual impairment may be 
identified by a parent, carer or teacher, through perinatal or pre-school 
screening. Cases may also be identified through assessment following a 
family history of sight loss, or a medical condition with an ophthalmic 
manifestation (https://www.rcophth.ac.uk/professional-resources/information-
from-the-paediatric-sub-committee-for-healthcare-professionals/). 
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1.4.3   Visual Impairment in Adults 
 
Researchers examining the causes of certifiable visual impairment (CVI) in 
working age adults recently found for the first time in five decades the leading 
cause of certifiable blindness was not diabetic retinopathy/maculopathy but 
hereditary retinal disorders (20.2%). This was followed by diabetic 
retinopathy/maculopathy (14.4%), optic atrophy (14.1%) and corneal disease 
which accounted for 45/1756 (2.6%) (Liew et al., 2014).  Overall in adults 
macular degeneration was the most common cause of CVI with corneal 
disorders accounting for 100/7437 (2.1%) of the total number of CVI cases 
(Bunce et al., 2010). A form of corneal disease is the focus of this thesis. 
 
1.5 Overview of Corneal Dystrophies 
 
Corneal dystrophies are defined as a group of bilateral, genetically 
determined, non-inflammatory diseases that are, in the majority of cases, 
limited to the cornea (Klintworth, 2009). There are however exceptions to 
every part of this definition (Weiss et al., 2015). They are both clinically and 
genetically heterogeneous. Many of these conditions are important causes of 
congenital corneal opacity (Nischal, 2015). They can occur as isolated 
conditions or with systemic manifestations. 
 
The International Corneal Dystrophy (IC3D) committee was formed in 2005 
with the purpose of reducing confusion regarding corneal dystrophy 
nomenclature, to critically evaluate the literature and remove outdated 
information. The committee held its first meeting in October 2005 and 
proposed a new classification of corneal dystrophies in 2008 (Weiss et al., 
2008) which consisted of five categories: Epithelial and Subepithelial 
Dystrophies, Bowman Layer Dystrophies, Stromal Dystrophies and Descemet 
Membrane and Endothelial Dystrophies. Additionally, a series of descriptive 
evidential categories indicating the level of evidence supporting the existence 
of each given dystrophy was outlined (Table 1.2). It was postulated that with 
increased knowledge about a dystrophy, its category should progress over 
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time from 4 to 1, and that dystrophies that remain in category 4 should be 
eventually removed from the nomenclature. 
 
Category 1
A well-defined corneal dystrophy in which the gene has been mapped and 
identified and specific mutations are known.
Category 2
A well-defined corneal dystrophy that has been mapped to 1 or more 
specific chromosomal loci, but the gene(s) remains to be identified. 
Category 3
A well-defined corneal dystrophy in which the disorder has not yet been 
mapped to a chromosomal locus. 
Category 4
This category is reserved for a suspected new, or previously documented, 
corneal dystrophy, although the evidence for it, being a distinct entity, is 
not yet convincing. 
Table 1.2 Levels of evidence supporting the existence of corneal dystrophies, 
as described by the IC3D Committee (Weiss et al., 2008). 
 
The traditional anatomic classification of corneal dystrophies described 
(Weiss et al., 2008) was thought to have limitations and in 2015 corneal 
dystrophies were reclassified into four groups; Epithelial and subepithelial, 
Epithelial-stromal TGFβI, Stromal and Endothelial dystrophies (Weiss et al., 
2015). These four classes of corneal dystrophy are summarised below, with 
examples of each given.  
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Class of Corneal Dystrophy Dystrophy MIM Category of Evidence Mode of Inheritance Locus Gene
Epithelial Basement membrane dystrophy (EBMD) 
majority degenerative
MIM #121820 rarely C1 Unknown 5q31 TGFβI
Epithelial recurrent erosion dystrophies (EREDs)
                Franceschetti corneal dystrophy (FRCD) C3 Autosomal Dominant Unknown Unknown
  Dystrophia Smolandiensis (DS) C3 Autosomal Dominant Unknown Unknown
 Dystrophia Helsinglandica (DH) C3 Autosomal Dominant Unknown Unknown
Subepithelial mucinous corneal dystrophy (SMCD) MIM #612867 C4
Autosomal Dominant (but X-linked 
not excluded) Unknown Unknown
Meesmann corneal dystrophy (MECD) C1 Autosomal Dominant 12q13 (KRT3) KRT3
                             - Stocker-Holt variant C1 Autosomal Dominant 17q12 (KRT12) KRT12
Lisch epithelial corneal dystrophy (LECD) MIM #300778 C2 X-chromosomal Dominant Xp22.3 Unknown
Gelatinous drop-like corneal dystrophy (GDLD) MIM #204870 C1 Autosomal Recessive 1p32 TACSTD2
Reis–Bücklers corneal dystrophy (RBCD) MIM #608470 C1 Autosomal Dominant 5q31 TGFβI
Thiel-Behnke corneal dystrophy (TBCD) MIM #602082 C1 Autosomal Dominant 5q31 TGFβI
Lattice corneal dystrophy, type 1 (LCD1), variants 
(III, IIIA, I/IIIA,IV) of lattice corneal dystrophy
MIM #122200 C1 Autosomal Dominant 5q31 TGFβI
Granular corneal dystrophy, type 1 (GCD1) MIM #121900 C1 Autosomal Dominant 5q31 TGFβI
Granular corneal dystrophy, type 2 (GCD2) MIM #607541 C1 Autosomal Dominant 5q31 TGFβI
Macular corneal dystrophy (MCD) MIM #217800 C1 Autosomal Recessive 16q22 CHST6
Schnyder corneal dystrophy (SCD) MIM #21800 C1 Autosomal Dominant 1p36 UBIAD1
Congenital stromal corneal dystrophy (CSCD) MIM #610048 C1 Autosomal Dominant 12q21.33 DCN
Fleck corneal dystrophy (FCD) MIM #121850 C1 Autosomal Dominant 2q34 PIKFYVE
Posterior amorphous corneal dystrophy (PACD) MIM #612868 C1 Autosomal Dominant 12q21.33 KERA, LUM, DCN, 
EPYC
Central cloudy dystrophy of François (CCDF) MIM #217600 C1 Unknown Unknown Unknown
Pre-Descemet corneal dystrophy (PDCD) 
- isolated PDCD C4 Unknown Unknown Unknown
-associated with X-linked ichthyosis C1 Autosomal Dominant Xp22.31 STS
Fuchs endothelial corneal dystrophy (FECD) 
- Early-onset FECD MIM #136800 (FECD1) C1 Autosomal Dominant 1p34.3–p32 (FECD1) COL8A2
MIM #610158 (FECD2) 13pter-q12.13 (FECD2)
  MIM #613267 (FECD3) 18q21.2-q21.3 (FECD3) TCF4, LOXHD1
MIM #613268 (FECD4) C2 in patients with defined genetic loci 20p13-p12 (FECD4) 
  MIM #613269 (FECD5) C3 in patients without known inheritance  5q33.1-q35.2 (FECD5) 
 MIM #613270 (FECD6) 10p11.2 (FECD6) TCF8
 MIM #613271 (FECD7)  9p24.1-p22.1 (FECD7)
 MIM #615523 (FECD8)  15q25 (FECD8)  AGBL1
Posterior polymorphous corneal dystrophy (PPCD) 
MIM #122000 (PPCD1) 
MIM #609140 (PPCD2) 
MIM #609141 (PPCD3) 
C1 - PPCD 2 and PPCD 3                   
C2 -  PPCD 1
Autosomal Dominant Isolated cases 
with no known inheritance pattern
PPCD 1: 20p11.2-q11.2 
PPCD 2: 1p34.3-p32.3 
PPCD 3: 10p11.22
PPCD1: unknown  
PPCD2: COL8A2      
PPCD 3: ZEB1
Congenital hereditary endothelial dystrophy (CHED) MIM #217700 C1 Autosomal Recessive 20p13 SLC4A11
X-linked endothelial corneal dystrophy (XECD) none C2 X-chromosomal Dominant Xq25 Unknown
Cases without known inheritance are 
most common. Some cases with 
Autosomal Dominant inheritance. 
Complex and heterogeneous, 
demonstrating variable expressivity 
and incomplete penetrance
Epithelial and Subepithelial Dystrophies
Epithelial-stromal TGFβI
Stromal Dystrophies
Endothelial Dystrophies
MIM #122400
MIM #122100
none
- Late-onset FECD
 
Table 1.3 Table outlining each corneal dystrophy, its category of supporting evidence (Table 1.2), mode of inheritance, locus and 
gene if known. 
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1.5.1 Epithelial and Subepithelial Dystrophies 
 
Epithelial Basement Membrane Dystrophy (EBMD) (MIM#121820), the most 
common anterior corneal dystrophy, was first described by Cogan (Cogan et 
al., 1964) and is characterised by the presence of subepithelial dots, map-like 
changes (so-called as they are shaped like maps) and blebs Figure 1.9. The 
patient may be asymptomatic or may present with recurrent corneal erosions 
(Schorderet, 2015). Mutations in the Transforming Growth Factor β Induced 
gene (TGFβI) (Section 1.5.2) have been reported in two families with 
autosomal dominant inheritance as well as sporadic cases (Boutboul et al., 
2006). 
 
 
Figure 1.9 Epithelial Basement Membrane Dystrophy A. Map-like changes in 
EBMD. B. Both microcystic changes and map-like changes together. Reproduced 
with permission (Krachmer et al., 2011). 
 
Meesman Corneal Dystrophy (MECD) MCD, (MIM#122100), another 
condition affecting the corneal epithelium, is characterised by distinct tiny 
bubble-like, round to-oval punctate opacities which present during infancy 
(Klintworth, 2009). Dominant mutations in both Keratin 3 (KRT3) 
(MIM*148043) on chromosome 12 and Keratin 12 (KRT12) (MIM*601687) on 
chromosome 17 have been implicated (Irvine et al., 1997). Lisch Epithelial 
Corneal Dystrophy (LECD) (MIM%300778) is characterised by feather shaped 
opacities and microcysts in the corneal epithelium (Lisch et al., 1992). 
Painless blurred vision may begin after 60 years (Klintworth, 2009). Linkage 
A. B. 
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analysis in a large German multi-generational family mapped the disease to a 
locus on chromosome Xp22.3 (Lisch et al., 2000), although the LOD score 
was below 3 (2.93) therefore the  linkage to this region was tentative. 
 
1.5.2  Epithelial-stromal Transforming Growth Factor beta Induced 
(TGFβI) Dystrophies 
 
The corneal dystrophies described below are all caused by heterozygous 
mutations in the TGFβI gene on chromosome 5 and are inherited as dominant 
conditions (Lisch et al., 2000, Munier et al., 2002). 
 
Reis-Bucklers Corneal Dystrophy (RBCD) (MIM#608470) presents with 
bilateral symmetrical irregular ring-shaped subepithelial opacities, which 
become evident in the first few years of life and are associated with pain, 
redness and photophobia (Waring et al., 1978a). Thiel-Behnke Corneal 
Dystrophy (TBCD) (MIM#602082) is similar to RBCD in that it is characterised 
by subepithelial corneal opacities. However clinically the lesions can be 
differentiated by their honeycomb pattern and a clear area near the corneo-
scleral limbus (Krachmer et al., 2011). Although most causative mutations are 
in the TGFβI gene, the disease has been also been mapped to chromosome 
10q23-q24 (Yee et al., 1997). However, when the original linkage data was 
reviewed (Jonsson et al., 2015) a synonymous variant in COL17A1 
c.3156C>T was identified. This variant introduced a cryptic donor site and 
resulting in aberrant pre-mRNA splicing, and therefore was likely to be 
pathogenic. 
 
Lattice Corneal Dystrophy Type I (LCD1) (MIM#122200) presents during the 
first decade. Clinically a network of interdigitating branching filaments is seen 
within the corneal stroma (Klintworth, 2009). Accumulations of amyloid 
material in the stroma distort the architecture of the corneal lamellae (Figure 
1.10A and B). Granular Dystrophy Type I (GCD1) (121900) is a disease of the 
corneal stroma. Characteristic bilateral breadcrumb-like corneal deposits in 
the anterior stroma give rise to glare, reduced vision and photophobia 
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(Krachmer et al., 2011) (Figure 1.10C). Granular Dystrophy Type II (GCD2) 
(MIM#607541) shares some features with Lattice Dystrophy. Clinically and 
histopathologically GCD2 it can be considered to have features of both GCD1 
and LCD1 (Schorderet, 2015) (Figure 1.10D). 
 
TGFβI encodes the transforming growth factor β protein (TGFβI), also known 
as keratoepithelin, a 68-kDa protein composed of 683 amino acid residues. It 
contains a secretory signal peptide sequence, a cysteine-rich EMI domain, 
four homologous fasciclin 1 (FAS1) domains which each contain 140 amino 
acid residues at the N-terminus, and an arginine-glycine-aspartate (RGD) 
motif, which binds to integrin at the C-terminus. It is known to be expressed in 
other organs including the heart, liver, pancreas, bone, tendon, endometrium 
and kidney (Han et al., 2016).  TGFβpI is a member of the TGFβ family of 
cytokines, which regulate diverse cellular processes including proliferation, 
apoptosis, differentiation and ECM homeostasis (Kim et al., 2015a). 
 
1.5.3 Stromal Dystrophies 
 
These dystrophies are those that affect the corneal stroma but are not caused 
by dominant mutations in the TGFβI gene. One such condition, Macular 
Corneal Dystrophy (MCD) (MIM#217800), is an autosomal recessive disease. 
Faint stromal white opacities are seen in the first decade. The opacities 
progress over time and a grainy haze develops (Yanoff and Duker 3rd, 2009).  
MCD is not entirely stromal, as over time the deposits extend to DM and the 
endothelium, giving rise to endothelial decompensation and corneal oedema. 
The disease is caused by recessive mutations in Carbohydrate 
Sulfotransferase 6 (CHST6) on chromosome 16. The encoded protein is an 
enzyme which catalyses the transfer of a sulphate group to the N-
Acetylglucosamine amino acid residue of keratan (Akama et al., 2000). 
Keratan sulphate is a major component of the corneal stroma and helps to 
maintain corneal clarity (Section 1.3.4).  
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Figure 1.10 Corneal photographs of two TGFβI stromal dystrophies. A. Lattice 
Corneal Dystrophy Type I (courtesy of Mr James Ball, Consultant Ophthalmic 
Surgeon, St James’s University Hospital, Leeds).	 B. Lattice corneal dystrophy type I 
variant. The amyloid within the corneal stroma viewed under ultraviolet light after 
staining the fluorescent dye Thioflavin T. C. Granular corneal dystrophy type I. 
Numerous irregular shaped discrete crumb-like corneal opacities. D. Granular 
corneal dystrophy type II. Variable sized crumb-like opacities in the corneal stroma 
that have become fused in areas giving rise to elongated and stellate shapes. Figure 
1.10 B-D reproduced with permission (Klintworth, 2009). 
 
1.5.4 Endothelial Dystrophies 
 
Several dystrophies that primarily affect the corneal endothelium have been 
described. These are Congenital Hereditary Endothelial Dystrophy (CHED), 
Posterior Polymorphous Corneal Endothelial Dystrophy (PPCD), X-Linked 
Endothelial Dystrophy (XECD) and Fuchs Endothelial Corneal Dystrophy 
(FECD). These conditions are all outlined in more detail in separate sections 
below.  
 
A
. 
B
.. 
C. A.D 
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1.6    Congenital Hereditary Endothelial Dystrophy 
1.6.1 Clinical Features 
 
Congenital Hereditary Endothelial Dystrophy (CHED) (MIM#217700) was first 
described by Maumenee (Maumenee, 1960) who recognised that the primary 
pathology originated in the corneal endothelium. The hallmark of CHED is 
corneal oedema and opacification presenting at birth or shortly after birth 
(Patel and Parker, 2015). Kirkness et al reported a large case series of 23 
patients which were divided into recessive and dominant, providing a detailed 
description of clinical features, management and pathology (Kirkness et al., 
1987). They noted that progression of corneal signs, including development of 
corneal stromal scarring and deposition of plaques, was observed in four of 
the recessive and three of the dominant cases. Additionally, they examined 26 
corneal buttons, noting thickening of DM in the majority of cases, and 
described more marked thickening in the recessive group. The endothelium 
was discernable in most cases but loss of cells and degeneration was a 
common finding.  
 
The original author’s subsequent report (Judisch and Maumenee, 1978) 
attempted to differentiate the clinical appearance of CHED according to its 
recessive or dominant inheritance. They described what they thought was an 
autosomal dominant CHED patient as having clear corneas at birth with 
slowly progressive corneal opacification and felt that “infantile” might be a 
more descriptive name for the dominant variant.  It was therefore previously 
thought that CHED may be inherited in a dominant (CHED1, MIM#121700) or 
a recessive manner (CHED2, MIM#217700) (Callaghan et al., 1999). CHED2 
was thought to be more common and characterised by a more severe 
phenotype than CHED1. However, CHED1 is insufficiently distinct to be 
considered a unique dystrophy (Nischal, 2015). In the most recent corneal 
dystrophy classification (Weiss et al., 2015), CHED1 was reclassified 
following a review of the original clinical and pathological descriptions, 
concluding that all the families could have PPCD (Section 1.7). Consequently, 
CHED1 has been eliminated from the corneal dystrophy classification and the 
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previously described CHED2 is now simply referred to as CHED, and will be 
throughout this thesis.  
 
1.6.2   Association with Glaucoma 
 
The normal intraocular pressure (IOP) is 12-22mmHg. The upper limit of 
22mmHg is the traditional cut-off for European-derived populations, however 
some Asian populations have a lower mean IOP and a pressure above 
19mmHg might be considered abnormal in such individuals (Yanoff and Duker 
3rd, 2009). The association of raised intraocular pressure (IOP) with CHED 
has been documented (Pedersen et al., 1989, Keates and Cvintal, 1965), and 
has the potential to pose a diagnostic and therapeutic dilemma as it may 
mimic primary congenital glaucoma (PCG). Additionally, stromal oedema can 
give rise to a false artificially raised IOP. PCG may present with additional 
signs of increased corneal diameter, Haab striae (horizontal striae seen on 
the corneal endothelium) and enlarged axial length (Ko et al., 2015). Kirkness 
et al revealed that 5/23 of their case series of CHED patients had undergone 
a surgical glaucoma procedure. It has also been suggested in retrospective 
analysis of 10 CHED patients that CHED and congenital glaucoma may co-
exist in some patients (Ramamurthy et al., 2007).  
 
1.6.3 The genetic basis of CHED  
 
CHED was originally mapped to chromosome 20p13 (Toma et al., 1995). 
Subsequently recessive mutations in solute carrier family 4, sodium borate 
transporter, member 11 (SLC4A11) (MIM*610206) were found to be the 
cause of CHED (Vithana et al., 2006). The authors described 10 families of 
Myanmar, Pakistani and Indian origin. Missense mutations accounted for the 
condition in 8 out of 10 families. In one family, of Indian origin, there was a 
frameshift mutation with 11 amino acid residues followed by a premature stop 
codon, indicating that CHED was cause by a loss-of-function mutation. 
Mutation screening of the coding exons and promoter of SLC4A11 in a cohort 
of 20 Indian CHED families only identified mutations in 11 families leading the 
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authors to speculate that genetic heterogeneity may exist for CHED 
(Hemadevi et al., 2008).  
 
1.6.4  Harboyan Syndrome 
 
Harboyan syndrome (MIM#217400) is characterised by CHED in association 
with progressive sensorineural hearing loss. Typically, the hearing loss does 
not present at birth but within the age range of 10-25 years, affecting mainly 
the 20-50db range (mild to moderate in severity) and affecting the higher 
frequencies (Desir et al., 2007). Recessive mutations in SLC4A11 also 
account for this phenotype, and the authors, who studied six families with 
Harboyan syndrome and one with CHED and possible Harboyan syndrome 
from varying ethnic backgrounds, concluded that some SLC4A11 mutations 
caused CHED while others caused Harboyan syndrome. The reason for 
which remained unclear. Over 60 different homozygous or compound 
heterozygous mutations in SLC4A11 have been reported to cause either 
CHED or Harboyan syndrome with little evidence to support a genetic basis 
for the difference between these phenotypes (Desir and Abramowicz, 2008, 
Mehta et al., 2010). 
 
1.6.5 Solute Carrier Family 4, Member 11 
 
Much of the previous work on the human Solute Carrier Family 4, Member 11 
gene (SLC4A11) was performed on the NM_032034 transcript, which consists 
of 19 exons spanning 11,774 base pairs (bp) of genomic DNA and encodes 
an 891 amino acid protein (Vilas et al., 2011). However, the largest mRNA 
transcript described NM_001174090 consists of 20 exons and encodes a 918 
amino acid protein.  Expression of SLC4A11 has been demonstrated in the 
human corneal endothelium on transcriptome analysis (Chng et al., 2013). 
The Slc4a11 mouse knockout was shown to exhibit increased endothelial cell 
size and decreased endothelial cell density with increasing age (Han et al., 
2013). The gene is also expressed in the fibrocytes of the stria vascularis in 
the inner ear in mice (Lopez et al., 2009, Groger et al., 2010) and in the 
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kidney (Groger et al., 2010, Han et al., 2013). It has been postulated that as 
the intermediate cells of the striae vascularis share a common neural crest 
origin with corneal endothelial cells, the absence of a borate dependent effect 
on the proliferation of these cells might give rise to sensorineural hearing loss, 
or alternatively that this might result from fluid imbalance in the inner ear 
(Desir et al., 2007). 
 
The SLC4A11 protein is expressed on the cell membrane and has 14 
transmembrane domains. It was previously thought to be a sodium borate 
transporter and was originally named Bicarbonate Transporter-related Protein 
1 (BRT1). When SLC4A11 expression constructs were transfected into 
human embryonic kidney cells (HEK293) with the mutant and wild-type 
SLC4A11 cDNAs, immunoblots indicated that there was little or no expression 
on the cell surface of the predicted 120kDa mutant protein compared to the 
wild-type BRT1. The mutant protein therefore appeared not to be processed 
through the endoplasmic reticulum and subsequently failed to reach the cell 
membrane to fulfil its role as an ion transporter (Vithana et al., 2006, Vilas et 
al., 2012b). More recent studies have indicated that the SLC4A11 protein is a 
Na+:OH- transporter with no significant affinity to borate or bicarbonate ions, 
but with a role in transporting Na+ coupled to OH contributing to pH regulation 
in the corneal endothelium (Ogando et al., 2013, Jalimarada et al., 2013, Kao 
et al., 2015). 
 
1.7 Posterior Polymorphous Corneal Dystrophy 
1.7.1 Clinical Features 
 
Posterior Polymorphous Dystrophy (PPCD) (PPCD1 MIM#122000, PPCD2 
MIM#609140, PPCD3 MIM#609141) is an autosomal dominant condition 
characterised by deep corneal lesions of varying shape including nodular, 
vesicular and blister-like lesions. It is rarely present in the immediate post-
natal period and clinically shows a slow or non-progressive course 
(Schorderet, 2015). PPCD shares some of the corneal features with the non-
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inherited condition iridocorneal endothelial syndrome. The clinical history (in 
particular the presence of a family history) is useful in distinguishing the two 
conditions, and specular microscopy has also been shown to play a useful 
diagnostic role (Laganowski et al., 1991). 
 
1.7.2   The genetic basis of PPCD 
 
Dominant mutations in collagen type VIII, alpha-2 (COL8A2) (MIM*120252) 
have been implicated in PPCD in the same study that found COL8A2 
mutations to be causative for early-onset FECD (Section 1.10.2). The authors 
sequenced the COL8A2 gene in one a PPCD family with two affected family 
members (the structure of the pedigree was not shown) both of whom had 
undergone previous penetrating keratoplasty, and ultrastructural analysis of 
the corneal button had confirmed PPCD. A c.1364C>A;p.Gln455Lys mutation 
was detected in the affected family members but not in any of the 15 
unrelated sporadic cases of PPCD, nor was it present in ethnically-matched 
controls (Biswas et al., 2001). Mutations in COL8A2 have not been identified 
in PPCD in any other study (Kobayashi et al., 2004, Yellore et al., 2005) 
suggests the possibility that this variant may be a rare polymorphism in the 
PPCD family described (Biswas et al., 2001).  
 
The evidence for mutations in Transcription Factor 8 (TCF8) (MIM*189909) 
(Section 1.10.4) also known as Zinc Finger E Box-binding Homeobox 1 
(ZEB1), as causative for PPCD is more convincing. Screening of 14 affected 
family members in three generations of a large PPCD family revealed a 2bp 
deletion 2916_2917delTG in the last exon of TCF8. This was present in all 
family members, however there were also unaffected family members who 
harboured the mutation. Frameshift mutations in TCF8 were found in 4 other 
PPCD families of the 10 that were screened (Krafchak et al., 2005). 
Functional studies involving the transfection of mutant constructs 
corresponding to TCF8 truncating mutations into a human corneal endothelial 
cell line indicated that certain truncating mutations were associated with 
altered nuclear localisation, whereas TCF8 missense changes did not. The 
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resulting reduction of protein abundance in truncating mutations compared 
with the TCF8 wild type construct led the authors to postulate that the 
observed decrease in protein levels was likely the result of nonsense-
mediated decay, which in turn would lead to haploinsufficiency (Chung et al., 
2014). Mutational analysis of 18 unrelated patients with PPCD in another 
study further supported the finding that truncating mutations in TCF8 give rise 
to PPCD. By contrast, missense mutations caused two other progressive eye 
conditions with a genetic basis, Fuchs Endothelial Corneal Dystrophy 
(described fully in Section 1.9) and Keratoconus (Lechner et al., 2013). 
Liskova et al performed whole exome sequencing, SNP arrays and long PCR 
to ascertain the chromosomal deletion breakpoints in the 3 patients of a 
PPCD family, along with a cohort of 14 unrelated PPCD patients previously 
found to be negative for TCF8 mutations. A large heterozygous deletion of 
around 3.3Mb encompassing the TCF8 gene was found all affected patients 
in the PPCD family. Two additional deletions with different breakpoints were 
identified in two other unrelated patients (Liskova et al., 2015).  
 
Causative mutations in the Visual System Homeobox Gene 1 (VSX1) 
(MIM*605020) gene on chromosome 20 have been detected in both PPCD 
and Keratoconus. VSX1 is a member of the Vsx1 group of vertebrate paired-
like homeodomain transcription factors. These transcription factors are 
distinguished by the presence of the CVC domain, a highly conserved region 
of unknown function, which lies C-terminal of the homeodomain (Héon et al., 
2002).  Recently, non-coding mutations in the promoter of Ovo-Like 2 
(OVOL2) (MIM*616441) on Chromosome 20p have been implicated in PPCD. 
OVOL2 encodes ovo-like zinc finger 2, a C2H2 zinc-finger transcription factor 
which induces epithelial-to-mesenchymal transition (EMT) via direct 
repression of TCF8 expression (Davidson et al., 2016). 
 
1.8 X-Linked Endothelial Dystrophy 
 
A large multi-generational pedigree from Western Austria was described with 
a total of 60 family members of whom 35 were individuals affected with a 
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corneal endothelial dystrophy which followed X-linked inheritance 
(MIM%300779) (Schmid et al., 2006).  Males were more severely affected 
than females and there were no examples of male-to-male transmission. The 
one-year-old proband presented with a bilateral, milky ground-glass corneal 
opacification. Other males had abnormalities of the endothelium resembling 
moon craters, complicated by severe band keratopathy. Females presented 
with moon crater-like appearance on slit-lamp examination of the corneal 
endothelium. Ten eyes from six patients underwent penetrating keratoplasty. 
Light microscopy of the corneal button of one of the affected males revealed 
irregular thinning of the epithelium and Bowman’s layer. DM was irregularly 
thickened with occasional excavations. Endothelial cells were atypical and 
multi-layered, with areas of DM devoid of endothelial cells. Linkage analysis 
utilised a panel of 25 microsatellite markers covering the X chromosome in 50  
family members. On multipoint analysis a maximum LOD score of 10.90 was 
obtained, indicating strong evidence of linkage in this family. The 14.79Mb 
interval between markers DXS8057 and DXS1192 on chromosome predicted 
to contain 72 genes. However, the mutation, gene and protein involved have 
yet to be identified. 
 
1.9  Fuchs Endothelial Dystrophy 
 
Prior to the advent of slit-lamp biomicroscopy, Fuchs endothelial corneal 
dystrophy (FECD) was originally described by an Austrian ophthalmologist, 
Ernst Fuchs, as “dystrophia epithelialis” (Fuchs, 1910) due to epithelial 
involvement at the advanced stages. The primary pathology however is 
located in the corneal endothelium. FECD is the most common endothelial 
dystrophy and tends to occur as a late-onset disease. FECD accounts for 
22% of corneal transplants in the UK (Keenan et al., 2012). Its genetic basis is 
complex and heterogeneous, demonstrating variable expressivity and 
incomplete penetrance.  
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1.9.1  Epidemiology of FECD 
 
FECD is more common in women than men (Krachmer et al., 1978). There 
are no prevalence studies for FECD in the UK and few large-scale studies 
world-wide. Many of the studies published examine their study populations for 
the prevalence of guttata (Section 1.9.2.1). Lorenzetta et al examined a 
multicultural cohort of 1016 individuals (783 females and 233 males) in a US 
outpatient clinic. The author stratified the recruited patients by age, sex and 
race, and concluded that 3.9% of individuals over the age of 40 years old 
exhibited confluent guttata and found the sex preponderance of corneal 
guttata to be equal between males and females (Lorenzetti et al., 1967). The 
Reykjavik Eye Study assessed the prevalence of corneal guttata in 774 study 
in subjects 55 years or older. Guttata were seen in 11% of females and 7% of 
males (Zoega et al., 2006). By contrast a Japanese study found the 
prevalence of guttata to be 3.8% in patients aged over 56 years old (Nagaki et 
al., 1996). 
 
1.9.2  Clinical Features of FECD 
1.9.2.1 Corneal Guttata 
 
FECD is characterised by focal accumulations of collagen posterior to the DM, 
known as guttata, and by loss of endothelial cells. The remaining endothelial 
cells exhibit altered morphology and degeneration, and there are wide 
intercellular spaces and an absence of intercellular junctions (Waring et al., 
1978b). A longitudinal study of 4 FECD patients monitored by corneal 
photographs taken up to 30 months apart revealed that the relative positions 
of individual guttata remained unchanged, very few guttata disappeared and 
the emergence of many new guttata was observed (Gottsch et al., 2006). 
Increased numbers of guttata have been correlated with a statistically 
significant reduction in endothelial cells counts (Jackson et al., 1999). This 
causes an influx of fluid into the stroma, leading to oedema and loss of 
corneal clarity followed by disrupted vision. End-stage disease is typified by 
painful epithelial bullae (small vesicles) (Figure 1.11D) as the cornea 
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decompensates in its ability to maintain stromal hydration (Eghrari et al., 
2015a). 
 
1.9.2.2 Clinical Presentation and Course 
 
FECD exists in early-onset and late-onset forms, the former being very rare. 
Early-onset FECD represents a distinct phenotypic variant, typically with 
smaller guttata than are seen in late-onset FECD, and may present as early  
as the first decade. Late-onset FECD generally presents in the fifth or sixth 
decade (Weiss et al., 2015). The patient may complain of glare, diminished 
vision and discomfort, which is typically worse on awakening due to increased 
epithelial and stromal oedema. Corneal examination reveals endothelial 
guttata, as shown in Figure 1.11A. These are seen on retroillumination prior to 
the patient becoming symptomatic. As the disease progresses, guttata 
coalesce and the endothelial cell numbers are reduced giving rise to stromal 
oedema and full corneal oedema with epithelial involvement (Krachmer et al., 
2011). Subepithelial fibrous scarring and superficial vascularisation may also 
be seen in advanced cases. In 1979, Dr Jay Krachmer and colleagues 
proposed a scale for grading FECD which is shown in Table 1.4. 
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Figure 1.11 Fuchs endothelial corneal dystrophy. A. Central guttata viewed in 
retroillumination and in the slit beam (shown with the yellow arrow) B. Cornea guttata 
as seen in specular reflection (red arrow). C. Advanced stromal oedema. D. 
Advanced endothelial decompensation with epithelial microcyst (purple arrow) and 
bullous oedema. Reproduced with permission (Weiss et al., 2008). 
 
 
Table 1.4 The FECD Krachmer Grading Scale (Krachmer et al., 2011). 
 
No apparent disease.
Up to 11 central guttata.
Definitive onset of the disease.
Twelve or more central, non-confluent guttata in at least one eye.
Grade 2 A zone of confluent central guttata 1 to 2 mm in horizontal width.
Grade 3 A zone of confluent central guttata 2 to 5 mm wide.
Grade 4 A zone of confluent central guttata greater than 5 mm wide.
Grade 5
A zone of confluent central guttata greater than 5 mm wide plus oedema of 
the corneal stroma and/or corneal epithelium.
Grade 0
Grade 1
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1.9.3  FECD Associations 
 
A link between FECD and angle closure glaucoma has been described, but 
with conflicting results. One study described a series of 24 patients with FECD 
and found a statistically significant difference between axial 
hypermetropia/shallow anterior chamber and FECD (Pitts and Jay, 1990). 
However, a further series of 23 FECD patients found no association between 
the FECD and angle closure glaucoma (Loewenstein et al., 1991). 
 
One retrospective analysis of 257 patients with FECD compared with 584 
controls indicated no statistically significant association in open angle 
glaucoma between cases and controls (Rice et al., 2014). 107 of the 1610 
eyes (6.6%) enrolled as part of the FECD Multicentre Study were noted to 
have glaucoma or ocular hypertension whereas the prevalence in the control 
group was 6.0%. Although there was little overall difference in the prevalence 
between the controls and the FECD cohort, the prevalence of glaucoma or 
ocular hypertension was higher in index cases (11.2%) with a FECD grading 
of 4-6 (Table 1.4) compared with controls (Nagarsheth et al., 2012). The 
authors concluded that patients with more clinically severe FECD should be 
monitored for the development of glaucoma.  
 
Given the observed association between endothelial dystrophies and hearing 
loss (Desir et al., 2007, Desir and Abramowicz, 2008) and the overlap in 
genetic aetiology between CHED and FECD (Vithana et al., 2006, Vithana et 
al., 2008), the possibility of hearing impairment in FECD patients has been 
explored. A cross-sectional observational case-control study was carried in 
the Netherlands (Stehouwer et al., 2011). A cohort of 72 FECD patients and 
180 matched controls were interviewed by means of a telephone 
questionnaire about their hearing. A higher percentage of the FECD group 
(45.8%) reported hearing disability compared with the control group (34.7%) 
(odds ratio of 1.59). 
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An analysis of risk factors from the FECD Multicenter Study found that female 
sex increased the odds of developing FECD by 34%. Smoking increased the 
odds of developing FECD by 30% (Zhang et al., 2013). 
 
1.10   FECD Genetics 
1.10.1 Summary of FECD Genetics 
 
FECD appears to exist most commonly in the absence of family history but 
familial forms with dominant inheritance have been documented (Krachmer et 
al., 1978, Rosenblum et al., 1980). Studies of such families have implicated a 
number of genes in FECD. Two studies have identified dominant mutations in 
COL8A2 (MIM*120252) (p.Gly455Lys and p.Leu450Trp) on chromosome 1 as 
a cause of early-onset FECD (Biswas et al., 2001) (Gottsch et al., 2005). 
Dominant mutations causing late-onset FECD have been identified in five 
other genes implicating them in late-onset FECD, four of which (SLC4A11 
(MIM*610206) (Vithana et al., 2008), ZEB1/TCF8 (MIM*189909) (Riazuddin et 
al., 2010c), LOXHD1 (MIM*613072) (Riazuddin et al., 2012) and AGBL1 
(MIM*615496) (Riazuddin et al., 2013)), appear to account for only a small 
proportion of cases. The fifth was identified by Baratz et al, who performed a 
relatively small-scale genome-wide association study (GWAS) using only 130 
FECD cases and 260 controls. Their results showed a strong association 
between FECD and common non-coding variants in the gene encoding 
transcription factor 4 (TCF4) (MIM*602272) on chromosome 18 (Baratz et al., 
2010). Subsequently a trinucleotide expansion in TCF4 (Baratz et al., 2010, 
Wieben et al., 2012) was found in 79% of cases compared to only 3% of 
controls, which suggests that this expansion account for most cases of the 
condition. 
 
The FECD Genetics Multicentre Study Group which ultimately aims to map 
genes for FECD published the baseline characteristics of recruited cases and 
controls, and calculated heritability estimates. The group investigated 322 
families, 650 sibling pairs and 304 controls and found heritability estimates of 
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0.304 for severe disease and concluded that the clinical phenotype of FECD 
was highly heritable in a general Caucasian population. They also showed 
that central corneal thickness was more strongly heritable than FECD, with an 
overall heritability measure of 0.466 (Louttit et al., 2012). 
 
1.10.2 Collagen, Type VIII, Alpha-2  
 
Family members of a large Caucasian multi-generational pedigree from the 
north-east of England identified has having early-onset FECD were 
independently examined by three ophthalmologists. All 15 affected individuals 
and unaffected individuals over the age of 50 were selected for linkage 
analysis. The authors demonstrated linkage to chromosome 1p34.3-p32, and 
felt that Collagen, Type VIII, Alpha-2 (COL8A2) represented a strong 
candidate gene. COL8A2 is a large 2-exon gene, which encodes the alpha 2 
chain of the type VIII collagens. Type VIII collagens are heterotrimeric 
proteins composed of alpha-1(VIII) (COL8A1) and alpha-2(VIII) (COL8A2) 
polypeptides in a 2:1 ratio. They are members of the 'short chain collagen' 
subfamily. COL8A2 encodes a 644-amino acid protein with a distinct N-
terminal domain, a central triple-helical domain and C-terminal non-triple 
helical domain. Transcriptome analysis showed that the COL8A2 mRNA is 
present in the corneal endothelial transcriptome (Chng et al., 2013) and is a 
major component of DM (Muragaki et al., 1991). Sanger sequencing of all 
family members revealed a mutation in COL8A2, c.1364C>A;p.Gln455Lys. 
This mutation was also found to segregate with the phenotype in two 
additional early-onset FECD families and a PPCD family (Biswas et al., 2001). 
COL8A2 mutations have also been implicated in two further reported early-
onset FECD families (Gottsch et al., 2005, Liskova et al., 2007) and in 15 
early-onset FECD patients from six pedigrees of Korean origin (Mok et al., 
2009). However, the lack of COL8A2 mutations in early-onset FECD cohorts 
in other studies (Aldave et al., 2006, Kobayashi et al., 2004, Kuot et al., 2013) 
suggests mutations in this gene are a rare cause of this disease.  
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1.10.3  Solute Carrier Family 4, Member 11 
 
Recessive mutations in Solute Carrier Family 4, Member 11 (SLC4A11) cause 
CHED (Vithana et al., 2006) (Section 1.6.5). Dominant mutations in SLC4A11 
are also a rare cause of FECD (Vithana et al., 2008). In Vithana et al’s 2008 
study, the authors recruited 89 patients to their study, 64 of whom were of 
Chinese ethnicity from Singapore and Hong Kong. On Sanger sequencing of 
all 19 exons of the SLC4A11 gene in these patients, four heterozygous 
mutations were identified that consisted of 3 missense mutations and one 2bp 
deletion, all of which were absent from 354 ethnically-matched controls. The 
paper also showed that combinations of mutant (CHED and FECD) and wild-
type constructs gave differing amounts of expression on the cell surface. It 
postulates a dominant negative mechanism with the FECD missense 
mutations. A full description of the SLC4A11 gene is provided in Section 
1.6.5. 
 
1.10.4  Transcription Factor 8 
 
Transcription Factor 8 (TCF8), located on chromosome 10, encodes a zinc-
finger homeodomain protein, a transcription factor that binds to DNA at a 
conserved sequence (CACCTG). It plays a critically important role both in 
development and disease through the repression of transcription of genes 
important for maintaining the epithelial phenotype (Vandewalle et al., 2009). 
Heterozygous frameshift mutations in the TCF8 gene were previously 
identified as causing PPCD (Krafchak et al., 2005) (section 1.7.2). 
Subsequently, heterozygous missense mutations in TCF8 were identified as 
causing FECD (Riazuddin et al., 2010a). As SLC4A11 mutations are 
causative for CHED (Vithana et al., 2006) and a small proportion of FECD 
cases (Vithana et al., 2008), and TCF8 mutations had been identified as 
causative for PPCD (Krafchak et al., 2005) the authors described this as their 
rationale for screening a large FECD pedigree with 12 affected patients in two 
generations for TCF8 mutations. They found a heterozygous missense 
mutation c.2519A>C; p.Q840P which was present in 5/12 affected family 
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members, and additionally found a further 4 missense mutations on screening 
192 unrelated FECD patients. They performed a functional assessment by 
suppressing TCF8 expression in zebrafish embryos, which gave rise to 
shortened body axis and pronounced detachment of cells along the dorsal 
axis. These phenotypes were then rescued with constructs containing the WT 
TCF8 mRNA. Although the authors were cautious in extrapolating the results 
of a developmental assay to late-onset corneal condition, they postulated that 
the TCF8 mutations they identified had a loss-of-function effect.  
 
1.10.5  Lipoxygenase Homology Domain-containing 1   
 
In 2012, mutations in Lipoxygenase Homology Domain-containing 1   
(LOXHD1) (MIM*613072) were implicated in FECD (Riazuddin et al., 2012). 
They analysed three families previously linked to a locus on chromosome 18q 
(Sundin et al., 2006a). Whole exome sequencing was carried out on one 
affected and one unaffected individual from each family, however in two of the 
families no causal mutation was found. They identified a c.1639C>T, 
p.Arg547Cys variant in the third FECD family then went on to identify an 
additional 14 predicted pathogenic variants which they proposed accounted 
for 7.2% of FECD cases of their cohort of 207 unrelated FECD patients. The 
authors approached their analysis as a complex disorder not as a traditional 
Mendelian disorder. Out of 288 controls (576 chromosomes) only 8 potentially 
pathogenic alleles were observed (1.4% of alleles), suggesting significant 
enrichment of putative pathogenic variants in FECD cases over controls. 
 
The authors then went on to detect the distribution of LOXHD1 in mouse 
corneas using a rabbit polyclonal antibody, detecting it in the epithelium and 
the endothelium. They then assessed the LOXHD1 distribution in a corneal 
button from an affected individual of one of their FECD pedigrees found to 
harbour a LOXHD1 mutation, and compared this with two control corneal 
buttons. Examination of the corneal sections, showed an increase in staining 
in the endothelium and DM of the proband with the c.1639C>T; p.Arg547Cys 
LOXHD1 mutation compared with both controls. 
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LOXHD1 is a large gene consisting of 40 exons with a main transcript which is 
179,774bp in length. The LOXHD1 protein consists of 15 PLAT 
(polycystin/lipooxygenase/alpha-toxin) domains, 120 amino acid domains 
which form two opposing anti-parallel beta sheets to make a structures known 
as a beta-sandwich. LOXHD1 is thought to be involved in targeting proteins to 
the plasma membrane. It is expressed in the mechanosensory hair cells in the 
inner ear, and recessive mutations in this gene lead to auditory deafness 
(Grillet et al., 2009) (Edvardson et al., 2011) (MIM#613079). Although the 
exact pathogenic mechanism of LOXHD1 in FECD is not known, it has been 
postulated that, due to the presence of marked precipitates in the corneas of 
the index family, a proportion of FECD cases might be caused by aggregation 
defects similar to those seen in other late-onset diseases such as Parkinson’s 
disease. As LOXHD1 is present in low abundances in the normal cornea, the 
authors (Riazuddin et al., 2012) speculated that cytotoxic effects of increased 
LOXHD1 concentrations might have a role in the pathogenesis of FECD in 
these cases. 
 
1.10.6  Transcription Factor 4 
 
The role of Transcription Factor 4 (TCF4) in FECD was first described by 
Baratz et al (Baratz et al., 2010), who performed a small-scale GWAS using 
130 FECD cases and 260 controls. Control subjects were 60-years-old or 
over and had no guttata observed. They identified one SNP, rs613872, in 
intron 3 of TCF4, that reached genome-wide significance, with minor allele G 
enriched in FECD cases compared to controls. The odds ratio for one copy of 
the risk allele was 5.47. 
 
Following the publication of this GWAS (Baratz et al., 2010), there was 
speculation as to potential mechanisms by which TCF4 gives rise to FECD. 
The largest TCF4 transcript is 21 exons in length, however multiple 
alternatively spliced transcripts exist  (https://genome.ucsc.edu/index.html). 
Heterozygous missense mutations cause Pitt-Hopkins syndrome (MIM 
#610954) (Sweatt, 2013). The TCF4 protein is a member of the E-protein 
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family of class I basic helix-loop-helix (bHLH) transcription factors and is 
known to upregulate TCF8, which in turn has a role in the repressing of E-
cadherin, which can be associated with epithelial-to-mesenchymal transition 
(EMT). Although little is known about EMT in the cornea, one hypothesis 
proposed before the start of this PhD was that corneal stem cells that are 
located in a niche at the corneal endothelial periphery require EMT in order to 
migrate toward and replace damaged endothelium (Wright and Dhillon, 2010). 
It was postulated that mutations in TCF4 might reduce this protective process. 
 
The association of the SNP rs613872 has since been replicated in many 
studies in Caucasians (Igo et al., 2012, Li et al., 2011, Eghrari et al., 2012, 
Kuot et al., 2012, Stamler et al., 2013). The rs613872 minor G allele was not 
found in one study of Chinese patients (Wang et al., 2013). In another study 
of a Chinese population, the rs6137872 SNP was also not found to be 
polymorphic, but the authors found two other TCF4 SNPs (rs17089887 and 
rs17089925) to be associated with FECD, conferring a >2.3-fold increase in 
disease risk per copy of risk allele compared to the wild-type (Thalamuthu et 
al., 2011). 
 
Subsequently, Wieben et al (Wieben et al., 2012) found that a known intronic 
trinucleotide repeat in TCF4, located 43 kilobases away from rs613872, was 
even more strongly associated with FECD than rs613872. Of their cohort, 
79% of cases carried at least one TCF4 allele with more than 50 trinucleotide 
repeats, compared with only 3% in controls. This was independently 
replicated by Mootha et al (Mootha et al., 2014) who used a PCR-based 
method, previously used to test for repeats in Myotonic Dystrophy (Warner et 
al., 1996), to confirm the association of the expanded CTG18.1 allele with 
FECD. 
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1.10.7 ATP/GTP-Binding Protein-like 1 
 
Riazuddin et al reported that dominant mutations in ATP/GTP-Binding 
Protein-like 1 (AGBL1), a 24-exon gene on chromosome 15q, were causative 
of FECD. The authors described a 3-generational FECD family and initially 
performed linkage analysis but the resulting lod scores were not significant. 
As they did note some signal from chromosome 3p and 15q, they performed 
WES of one unaffected and two affected individuals to identify a heterozygous 
nonsense mutation on chromosome 15q. The variant c.3082C>T;p.Arg1028* 
was not seen in 384 ethnically-matched controls, but was found on the Exome 
Variant Server at a low frequency of 0.35%. The variant did not however 
segregate fully with the disease in the family with multiple FECD affecteds. 
Screening of their FECD cohort revealed two additional unrelated FECD 
individuals who harboured this mutation. In addition, a further heterozygous 
missense mutation c.2969G>C;p.>Cys990Ser was also seen in another case 
from their FECD cohort. They suggested that AGBL1 mutations accounted for 
1-2% of the genetic burden of FECD (Riazuddin et al., 2013). The gene 
encodes a member of the cytosolic carboxypeptidase family, which catalyses 
the deglutamylation of polyglutamated proteins (Rogowski et al., 2010). The 
authors (Riazuddin et al., 2013) also concluded that AGBL1 altered protein-
protein interactions with TCF4, although given that now the pathogenic effect 
of TCF4 is thought to be due to the toxic effect of the TCF4 trinucleotide 
expansion on the cells, their proposed mechanism seems less plausible.  
 
1.10.8  Other FECD Loci 
 
In addition to the mutations in the genes described above, 3 dominant loci on 
chromosomes 5 (FECD5, MIM%613269) (Riazuddin et al., 2009), 9 (FECD7, 
MIM%613271) (Riazuddin et al., 2010a) and 13 (FECD2, MIM%610158) 
(Sundin et al., 2006b) have been reported. One locus for FECD was mapped 
to on chromosome 18q21.2–21.32 (FECD3) (Sundin et al., 2006a). The 
authors identified three large late-onset pedigrees and established linkage to 
chromosome 18 (maximum LOD score 3.41) in one of the families and 
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tentative linkage (maximum LOD scores 2.89 and 2.45) in the other two 
families. There were, however 8 phenocopies in 36 individuals with no 
disease overall in the three families and one example of non-penetrance. The 
causative gene in this locus was subsequently identified as LOXHD1, 
although TCF4 also lies within this locus and may be the reason for the 
positive LOD scores in this linkage study. 
 
1.11   Mitochondrial disease and Oxidative Stress in FECD 
 
Theories of oxidative stress have been proposed in FECD. One case report 
described a 48-year-old woman who had FECD as well as sensorineural 
hearing loss, diabetes, cardiac conduction defects, ataxia and hyperreflexia 
(defects usually associated with another eye condition Leber’s Hereditary 
optic neuropathy which is strongly associated with mitochondrial missense 
mutations). Lymphocyte mitochondrial DNA (mtDNA) studies were carried out 
and showed missense mutations at mt15257 (G to A, aspartate to asparagine 
in cytochrome b) and mt4216 (T to C, tyrosine to histidine in ND1), suggesting 
that mitochondrial defects might play a role in the pathogenesis of FECD 
(Albin, 1998). Another study conducted in Poland (Wojcik et al., 2015) 
examined the relationship between 5 polymorphisms in base excision repair 
genes in FECD cases and controls. The c.1196A>G polymorphism of the 
XRCC1 gene was positively correlated with FECD. Other mitochondrial 
polymorphisms have also been reported to be associated with FECD. Ten 
mtDNA variants were identified as part of a study of GWAS of 530 FECD 
cases and 498 controls of European descent. Many of the variants identified 
were also associated with other human diseases including Alzheimers 
disease, Parkinson disease, as well as other ocular diseases ARMD, POAG 
and Keratoconus (Li et al., 2014). Furthermore, it has been demonstrated that 
when FECD lymphocytes are subject to oxidative stress, the damage to 
mtDNA is not fully repaired and the number of lesions remaining is higher 
when compared with controls (Czarny et al., 2014), thus supporting the 
hypothesis that mutagenesis of mtDNA might cause susceptibility to FECD. 
As the cornea is part of the anterior segment, it is potentially exposed to 
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greater levels of UV light than other parts of the eye. One of the main inducers 
of apoptosis is oxidative stress, and FECD endothelia are more susceptible to 
oxidative stress compared with that of normal controls (Jurkunas et al., 2010, 
Azizi et al., 2011). It is therefore feasible that FECD patients have less 
efficient systems of repair, and that mtDNA mutations could feasibly reduce 
the cells’ capacity to repair DNA, leaving it susceptible to oxidative stress and 
apoptosis. 
 
1.12   Gene expression in the corneal endothelium 
 
Gene expression in FECD patients has been carried out using serial analysis 
of gene expression (SAGE), which looked at the upregulation and 
downregulation of RNA transcripts compared with normal human 
endothelium. The study identified 9,530 tags from normal endothelium and 
9,606 from FECD endothelium. The expression of 18 transcripts were 
upregulated and 36 that were down-regulated compared with control tissue 
(Gottsch et al., 2003). Expression analysis of cultured corneal endothelial 
cells from both young and old donors has been carried out using high 
throughput RNA sequencing methods (Chng et al., 2013). The study involved 
the dissection of corneal endothelial cells from donor corneas, RNA 
sequencing and annotation of the variants, and reported a comprehensive 
expression profile for the ageing human corneal endothelium. 
 
1.13   Imaging of the Corneal Endothelium 
 
Although the measurement of central corneal thickness allows the pump 
function of the endothelium to be inferred, endothelial cells can be directly 
visualised using a non-contact method known as specular microscopy (SM) 
(Maurice, 1974) which provides a high magnification view of specular light 
reflected from the corneal endothelium. It has the disadvantage of giving poor 
image quality in the presence of severe corneal oedema. This can be 
overcome by the use of confocal microscopy (Kaufman et al., 2004), although 
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in general the method of choice is SM as it is relatively user friendly and 
widely available (Chiou et al., 1999).  
 
From the SM images several morphological variables can be calculated, 
including the mean cell density, mean cell area, the coefficient of variation of 
mean cell area (CV) (a measure of variation in cell size, polymegathism). In 
the healthy cornea, 70-80% of endothelial cells are hexagonal. Deviation from 
hexagonality is referred to as pleomorphism (Bourne and McLaren, 2004). 
 
1.14   Management of Endothelial Dystrophies 
 
The initial treatment for FECD is temporizing and supportive. Medical 
management includes the use of hypertonic saline solutions and of a hair-
dryer to increase tear evaporation (Yanoff and Duker 3rd, 2009). 
 
The mainstay of surgical management for endothelial disease remains 
corneal graft surgery (keratoplasty), which involves replacing the diseased 
corneal tissue with donor tissue. Penetrating Keratoplasty (PK) (full-thickness 
graft) is still the primary surgical procedure for CHED. A large case series 
suggested that delayed keratoplasty, even in the presence of nystagmus, 
seemed to offer more favourable outcome compared with those operated on 
early (before the age of 12 years) (Ozdemir et al., 2012).  
 
Corneal graft techniques have evolved in recent years (Guell et al., 2014). 
Corneal graft surgery performed in the UK (Keenan et al., 2012) and the US 
(Park et al., 2015) for FECD and PPCD is increasingly carried out using a 
lamellar technique, Descemet’s stripping endothelial keratoplasty (DSEK), a 
method described originally by Melles (Melles et al., 1998). This involves 
replacing only the defective endothelial layer of the cornea with donor DM and 
a posterior stroma, leaving behind the healthy epithelium and anterior 
stroma. Further refinement of DSEK has taken place with the development of 
Descemet’s Membrane Endothelial Keratoplasty (DMEK) where the donor 
tissue is composed solely of DM and endothelium (Melles et al., 2006). 
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Comparison of the two lamellar techniques has indicated faster and more 
complete visual rehabilitation with the use of DMEK (Tourtas et al., 2012). In 
CHED patients, successful DSEK has been reported (Mittal et al., 2011). A 
paired-eye comparison of PK and DSEK in a series of CHED patients 
indicated earlier visual rehabilitation and stabilisation of refraction in the eyes 
managed with DSEK (Ashar et al., 2013). 
 
The regenerative capacity of the corneal endothelium, as discussed in Section 
1.3.7, might ultimately prove more forgiving than some of the current surgical 
approaches. Minimizing surgical intervention and thus avoiding surgical 
complications may greatly benefit endothelial dystrophy patients (Bruinsma et 
al., 2013) but before this point can be reached further knowledge about 
disease pathogenesis and new treatments are required. As the cornea is an 
easily visualized and accessible tissue, it is potentially an ideal target for 
future gene therapies (Williams and Klebe, 2012). A sound understanding of 
the genetics of the disease may well lead to the successful tailoring of 
treatments in endothelial dystrophy. 
 
1.15   Objectives of this Study 
 
The aims of this study are: 
 
1. A British Ophthalmic Survey Unit (BOSU) study carried out in conjunction 
with the Royal College of Ophthalmologists is presented in Chapter III. It 
examines the epidemiology of corneal dystrophies in patients of 40 years or 
less.  
 
2. The second aim is to determine whether recessively inherited CHED, 
Harboyan syndrome and late-onset FECD may all coexist over time within 
one family, as the result of the same mutation. Two previously reported CHED 
families (Vithana et al., 2006) are revisited. A newly-recruited CHED patient is 
also analysed along with one of his parents who was available for 
examination. This work is presented in Chapter IV. 
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3. The genetics of FECD are explored in Chapter V.  The relative 
contributions of the TCF4 SNP rs613872, the intronic CTG18.1 trinucleotide 
expansion and LOXHD1 variants in a UK Caucasian FECD cohort are 
compared in order to clarify the significance of the original findings at the 
FECD3 locus. The results of both segregation of the TCF4 CTG18.1 
expansion and whole exome sequencing in three local FECD families are also 
presented.  
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2   Materials and Methods 
 
2.1 Solutions 
 
1 x Tris-EDTA (TE) Buffer (pH8.0) 
 
10mM Tris (pH 8.0) 
1mM ethylenediaminetetraacetic acid (EDTA) 
Adjust to pH 8.0 with concentrated hydrochloric acid 
 
Tris Borate-EDTA (TBE) Electrophoresis Buffer (10x) 
 
0.89M Tris 
0.89M Orthoboric acid (B(OH)3) 
25mM EDTA (pH 8.0) 
 
TAE Tris-acetate-EDTA Electrophoresis Buffer (1x) 
 
40 mM Tris base      
20mM Glacial acetic acid C2H402   
1mM EDTA (pH8.0)    
 
10x Gel Loading Dye 
 
3x TBE 
20%[w/v] Ficoll 400 
0.1% [w/v] Bromophenol blue 
0.2% [w/v] Xylene cyanol 
 
Red Cell Lysis Solution 
 
155mM Ammonium Chloride (NH4Cl) 
 45 
10mM  Potassium Bicarbonate (KHCO3) 
1mM  Ethylenediaminetetraacetic Acid (EDTA) 
 
White Cell Lysis Solution 
 
25mM  EDTA (pH 8.0) 
2% [v/v] Sodium dodecyl sulphate (SDS) 
 
 
Cell Lysis Buffer – DNA 
 
10mM  Tris pH 8.0 
100mM  EDTA 
20ug/ml  RNAase A 
0.25% [v/v]  SDS 
Make up to 1ml with deionized water. 
 
 
2.2 Patient Recruitment 
 
The project was approved by Leeds East Research Ethics Committee 
(reference 10/H1306/63) under the title “Investigation of human inherited 
corneal dystrophies: genetic, tissue and transplant analyses” and adhered to 
the tenets of the Declaration of Helsinki. This application was initiated by Dr 
Aine Rice (AR) then completed by the author (SS) during the PhD after AR 
left Leeds, and all project management was handled by SS. All researchers 
involved in patient recruitment underwent training in taking informed consent 
for research, Good Clinical Practice (GCP) and NHS information governance. 
Local FECD patients were identified by AR, SS and other members of the 
corneal clinical team at St James’s University Hospital (SJUH). The project 
was adopted onto the National Institute of Health Research (NIHR) portfolio 
(UKCRN portfolio no. 11297) in December 2011. Pinderfields Hospital, 
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Wakefield was changed from a Patient Identification Centre to a main 
recruiting site in August 2013. 
 
FECD patients were ascertained in outpatient and operating theatre lists at 
SJUH, Leeds by AR, SS and research nurses Frances Cassidy (FC), 
Charmain Tidswell (CT) and Alice Van Lare (AVL) and from Bradford Royal 
Infirmary and Pinderfields Hospital, Wakefield, UK. When SS took over the 
role of PI, all patients on forthcoming corneal operating theatre lists who were 
identified as having endothelial dystrophies as documented in electronic 
casenote letters and the Medisoft database (http://www.medisoft.co.uk) were 
sent a written invitation with the relevant patient information leaflet, and were 
then subsequently approached about joining the study. These patients had 
undergone a detailed slit-lamp examination and specular microscopy analysis 
(Tomey EM-3000 specular microscope, Tomey GmbH, Erlangen-Tennenlohe, 
Germany) at the time of listing and satisfied the criteria of FECD Grade 1 or 
above were selected for recruitment following their informed consent. 
Peripheral blood (2-6ml) was collected by venepunture into BD vacutainer® 
EDTA blood collection tubes (BD Biosciences, Oxford, UK) and genomic DNA 
was extracted by Yorkshire Regional Genetics (SJUH) from blood leukocytes 
according to standard procedures (Section 2.7).  
 
Amendments to the research protocol were sought through the Leeds East 
Research Ethics Committee to enable blood samples to be collected from 
controls individuals. Control patients were subject to slit lamp examination at 
NHS cataract clinics and were identified as suitable with normal endothelia 
and with no family history of eye disease by Consultant Ophthalmologist John 
Buchan. They were recruited following their informed consent. 
 
Human random control panels, HRC-1 and HRC-3, (Public Health England, 
Porton Downs, UK) consisting of 192 genomic DNA samples extracted from 
EBV-immortalised single donor lymphoblastoid cell lines were obtained 
commercially (Sigma-Aldrich).  
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2.3   British Ophthalmic Survey Unit (BOSU) - Incidence of 
Young Onset Corneal Dystrophy  
 
The BOSU study was set-up by Kamron Khan. Cases were defined as a new-
onset corneal dystrophy in a patient aged below 40 years. New cases were 
ascertained using population based active surveillance through the BOSU at 
the Royal College of Ophthalmologists. All permanently employed consultant 
and associate specialist ophthalmologists in the UK received a monthly 
reporting card for a 24-month period commencing November 2011. 
Respondents were asked to indicate any new cases of young-onset corneal 
dystrophy or confirm that there were no new cases to report. Following 
notification, information on patients’ ophthalmic history, examination findings, 
further treatment and follow-up was sought by questionnaire. Questionnaires 
were collected and the results analysed by SS. The questionnaire is shown in 
Appendix I. 
 
2.4 Audiometry 
 
CHED patients underwent audiometry screening using either the Madsen 
Aurical audiometer (GN Otometrics A/S, Taastrup, Denmark) at Bradford 
Royal Infirmary or an AD229 diagnostic audiometer (Interacoustics A/S, 
Assens, Denmark) Institute of Ophthalmology, Mexico City according to the 
manufacturers’ instructions. 
 
2.5 Corneal Tissue  
 
2.5.1 Collection of Human Corneal Tissue  
 
Corneal tissue was retrieved from SJUH Ophthalmology operating theatres 
from patients undergoing graft surgery who had given their informed consent 
for their tissue to be collected for research.  
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Amendments to the research protocol were sought through the local research 
ethics committee to enable control corneal tissue to be collected. Therefore, 
corneal tissue both from corneal endothelial dystrophy patients as well as 
donor tissue not utilised in lamellar surgery was collected from SJUH 
operating theatre. Control tissue was only collected where the donor had 
consented for their tissue to be used for medical research. All tissue was 
stored in RNAlater (Thermo Fisher Scientific) immediately following dissection 
in theatre. 
 
Control tissue was processed, stored, assessed and packaged according to 
Manchester Eye Bank standards (Appendix II), and was deemed fit for clinical 
use. All eyes had been enucleated as soon as possible post mortem and 
always within 24 hours of death. On the intended day of grafting, corneal graft 
tissue stored in Eagles Minimal Essential Medium containing 2% Foetal 
Bovine Serum and antibiotic preparations (Appendix II) was couriered to 
SJUH operating theatre. Following dissection under sterile operating 
conditions all tissue was stored in RNAlater. 
 
2.5.2 Collection of Bovine Tissue 
 
Bovine eyes were enucleated from freshly culled cows by Professor Chris 
Inglehearn (CFI) at Dunbia Abattoir, Sawley, then brought back to the LIMM 
on ice. Ocular structures were dissected immediately by SS. Corneal tissue 
was grossly dissected from the eyes then whole corneal buttons were 
removed using a 9mm corneal graft trephine. Corneal tissue was either stored 
as a whole corneal button or further dissected into endothelium and stroma. 
Cornea (and other ocular structures such as lens, iris and retina) were 
dissected and preserved in formalin, snap frozen in liquid nitrogen or stored in 
RNAlater. 
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2.6   Collection of Human Enucleated Eyes 
 
Pairs of eyes donated for medical research were enucleated by Aidan 
Hindley, the Leeds GIFT Tissue Bank Coordinator 
(http://www.gift.leeds.ac.uk/). The donor’s gender, age, and cause of death 
were recorded.  
 
The eyes were transported in a container with moist cotton wool soaked in 
saline by SS. Corneal debris was removed under magnification using forceps. 
Two openings were created using a 25 Gauge needle 3mm posterior to the 
limbus. One eye was embedded in paraffin and the other prepared for 
cryopreservation. 
 
2.6.1 Eye Fixed for Embedding in Paraffin  
 
The eye was placed in 4% paraformaldeyde (PFA), ensuring that it was 
completely submerged.  After 48 hours, the eye was washed in Phosphate 
Buffered Saline (PBS) and stored in 70% ethanol for 48 hours. 
 
After processing both eyes were then passed to LIMM pathologist Mike Shires 
for paraffin embedding using the Leica ASP200 Fully Enclosed Tissue 
Processor (Leica, Milton Keynes, UK) and then subject to the conditions 
described in Table 2.1. 
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Table 2.1 The paraffin embedding conditions that sectioned tissue was subject 
to. (Ethanol (Sigma-Aldrich), Xylene (Fisher Scientific UK, Loughborough, UK), Wax 
(Cellpath, Powys, Wales)).  
    
2.6.2 Eye for Cryopreservation 
 
The eye was placed in 4% PFA, ensuring that it was completely submerged 
for 2 hours. It was then stored in 10% w/v sucrose in PBS for 12 hours, 20% 
w/v sucrose in PBS for 12 hours then 30% w/v sucrose in PBS for 12 hours. 
 
After processing both eyes were then passed to LIMM pathologist Mike Shires 
for cryopreservation using the following protocol: 
 
Fresh tissue was carefully dissected with a sharp blade and handled with 
care. Fresh Sterile saline was used to prevent tissue dehydration. 
 
70% 
ethanol 30 min 37
80% 
ethanol 30 min 37
90% 
ethanol 30 min 37
95% 
ethanol 30 min 37
100% 
ethanol 1:00h 37
100% 
ethanol 1:00h 37
100% 
ethanol 1:30h 37
Xylene 1:00h 37
Xylene 1:30h 37
Xylene 1:30h 37
Wax 1:00h 65
Wax 1:00h 65
Wax 1:00h 65
Time Temperature (°C)
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1. Freshly excised tissue blocks approximately 5mm3 was placed in a 
drop of Optimal Cutting Temperature (OCT) medium on a cork disc. 
The tissue was quickly covered in OCT and frozen at the earliest 
opportunity. 
 
2. A beaker of liquid isopentane was carefully placed in liquid nitrogen 
until a slush of liquid and frozen isopentane is present.  
 
3. The tissue was immersed in the isopentane slush for 30 seconds using 
long forceps.  
 
4. The tissue was wrapped in aluminium foil and place in a labelled air 
tight container. 
 
5. The tissue was stored at -70°C. 
 
2.7 DNA Extraction Protocol 
2.7.1 Salt Precipitation 
 
In general, a salt precipitation technique was performed to extract DNA from 
blood samples that had not been frozen. Briefly, 3ml of whole blood was 
aliquoted into polypropylene tubes and 9ml of red cell lysis solution (Section 
2.1) was added. After shaking for 10 minutes, samples were spun at 2000 x g 
for a further 10 minutes and the supernatant removed, leaving the white cell 
pellet containing DNA. The pellet was resuspended in 3ml white cell lysis 
solution (Section 2.1) and cells lysed by pipetting. To remove any 
contaminating protein, 1ml of protein precipitation solution (10M ammonium 
acetate) was added and samples mixed well for 20 seconds before 
centrifuging for 10 minutes at 2000 x g. The supernatant, containing the DNA, 
was aliquoted into fresh tubes and DNA was precipitated using isopropanol at 
2000 x g, followed by two washes in 70% ethanol. The precipitate was air 
dried and redissolved in TE buffer (Section 2.1). 
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2.7.2 Phenol-Chloroform Extraction 
 
To extract DNA from blood samples that had been frozen, a phenol-
chloroform extraction procedure was performed. Briefly, 3ml of whole blood 
was aliquoted into polypropylene tubes and 9ml of red cell lysis solution 
(Section 2.1) was added. After shaking for 10 minutes, samples were spun at 
2000 x g for 10 minutes. The supernatant was removed, leaving the white cell 
pellet, to which 500µl of cell lysis buffer - DNA (Section 2.1) was added. After 
a 1-hour incubation at 37°C, proteinase K was added to a final concentration 
of 100µg/ml followed by an incubation at 55°C for 1 hour. 500µl of 1:1 
phenol:chloroform was subsequently added and the tube inverted several 
times. The tube was then mixed well until a milky solution formed and 
centrifuged for 10 minutes at 3100 x g. The upper aqueous phase was 
removed into a fresh tube and an equal volume of chloroform added to this. 
The tube was inverted several times and centrifuged at 3100 x g for 5 
minutes. After aliquoting the upper aqueous phase into another fresh tube, 
sodium chloride (NaCl) was added to a final concentration of 0.2M and a 
further 2 volumes of 100% ethanol added before mixing and centrifuging at 
3100 x g for 5 minutes. The supernatant was discarded and 75% ethanol was 
added to the pellet, followed by a further centrifugation at 3100 x g for 5 
minutes. After removal of the supernatant, the resulting pellet was dried and 
redissolved in deionised water. 
 
2.8  Primer Design and Optimisation 
 
Oligonucleotide primer pairs were designed using either Primer3 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi), ExonPrimer 
through the UCSC Genome Browser (https://ihg.helmholtz-muenchen.de/cgi-
bin/primer/ExonPrimerUCSC.pl?db=hg19&acc=uc010zqf.2) or Autoprimer 3 
software (http://sourceforge.net/projects/autoprimer3). The different primer 
design software used reflected a change in preference as new software was 
developed during the fellowship. The reference sequence for all genes was 
downloaded from UCSC Genome Browser (http://genome.ucsc.edu) (Section 
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2.16). Details of the primer sequences and PCR conditions can be found in 
Appendices IIII and IV.  
 
2.9  DNA Polymerase Chain Reaction (PCR) Amplification 
 
For standard PCR, DNA was amplified in a final reaction volume of 10µl using 
50ng of genomic DNA (2µl of DNA and 8µl of DNA mastermix). Mastermix 
comprised PCR buffer (Invitrogen), 1.5mM MgCl2, 200µM of each dNTP 
(Invitrogen), 10 pmol/µl primers, and 1.0 unit of Taq polymerase. A standard 
PCR cycle, Touchdown and Hotshot cycles are shown. 
 
Standard PCR cycle 
 
95°C for 2 minutes (Denaturation) 
40 Cycles of: 
94°C for 30 seconds (Denaturation) 
53 - 65°C for 45 seconds (Annealing) 
72°C for 45 seconds (Extension) 
72°C for 5 minutes (Final Extension) 
 
Touch Down 
 
98°C for 30 seconds (Denaturation) 
45 cycles of: 
98°C for 10 seconds (Denaturation) 
70°C* for 20 seconds (Annealing) 
72°C for 90 seconds (Extension) 
*Reduce temperature by one degree each cycle for 5 cycles then complete 40 
cycles at 64°C 
Final Extension step 72°C for 10 minutes (Final Extension) 
 
Hotshot 
 
95°C for 10 minutes (Denaturation) 
40 Cycles of: 
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94°C for 30 seconds (Denaturation) 
53 - 65°C for 45 seconds (Annealing) 
72°C for 45 seconds (Extension) 
72°C for 5 minutes (Final Extension) 
 
Reactions using HotShot mastermix (Client Life Science, Stourbridge, UK) 
were carried out in a 10µl volume using the manufacturer’s instructions.  
 
2.10    Whole Genome Amplification 
 
Whole genome amplification was performed using the Illustra GenomiPhi V2 
DNA Amplification kit (GE Healthcare Life Sciences, Little Chalfont, UK) 
according to the manufacturer's instructions. After amplification, samples were 
diluted 1/30 in sterile distilled water and a test PCR was performed to ensure 
DNA was at a concentration sufficient for PCR amplification. The standard 
PCR conditions utilised are outlined in Section 2.9. 
 
2.11   DNA Visualisation and Size Fractionation using 
Agarose Gel electrophoresis 
 
PCR products were mixed with gel loading dye (solution from Section 2.1) and 
loaded using a pipette into the wells of a 1.5% agarose gel. The 1.5% agarose 
gel was made up with 0.5x TBE or 1xTAE and ethidium bromide at a final 
concentration of 0.5µg/ml. DNA products were quantified and sized using 
Easy Ladder 1 (Bioline Reagents Limited, London, UK). The agarose gels 
were visualized on a Bio-Rad UV transilluminator and displayed using Image 
Lab Software (Bio-Rad Laboratories Limited, Hemel Hempstead, UK).  
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2.12   Genotyping and Linkage Analysis 
 
Genotyping was performed using fluorescently tagged microsatellite markers. 
The chromosomal position of the markers was located against the hg19 
version of the Genome Browser. PCR was carried out in a 10µl volume (as 
described in Section 1.7). Following the amplification step, PCR products 
were size fractionated. Samples were denatured and run on an ABI Genetic 
Analyser (Life Technologies Ltd, Paisley, UK) using polymer POP-7 and the 
FragmentAnalysis36_POP7-1 module 3130xl using a 500 ROX size standard 
(Life Technologies Ltd) and subsequently analysed using GeneMapper v4.0 
software (Life Technologies Ltd). Linkage analysis was performed under the 
assumption of a dominant inheritance model with penetrance of 99% and zero 
phenocopy rate (disease allele frequency = 0.001). Multipoint LOD scores 
were calculated using Superlink (http://bioinfo.cs.technion.ac.il/superlink/) 
(Fishelson and Geiger, 2002). Marker allele frequencies were estimated on 
the basis of data from CEPH (http://www.cephb.fr). All microsatellite markers 
used can be found in Appendix IV. 
 
Genotyping of trinucleotide repeat expansions was carried out using the 
method previously described by Warner et al and adapted by Mootha et al 
(Warner et al., 1996, Mootha et al., 2014) (Figure 2.1). 
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Figure 2.1 Overview of the TP PCR to genotype the CTG18.1. A general method 
for the detection of large repeat expansions by fluorescent PCR described by 
Warner et al. A. the STR assay uses primers P1 and P2 that flank the CTG repeat, 
but the allele fails to genotype expanded alleles. B. The specific 3’ end of the P4 
binds at numerous sites within the CTG repeat within the early rounds of 
amplification, resulting in a mixture of products. P4 is quickly consumed due to the 
33:1 molar concentration of P3 to P4. C. P3 amplifies from the end of the mixture of 
products of the prior cycles. Reproduced with permission (Warner et al., 1996). 
 
2.13  Sanger Sequencing 
 
PCR products were treated with 1.5μl Exo-SAP-IT (GE Healthcare Life 
Sciences) then place in the thermal cycler for 37°C for 30 minutes, then 80°C 
for 15 minutes Purified products were subsequently sequenced using the 
BigDye terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems) 
with one of the original PCR primers according to the manufacturer’s 
instructions. The samples were subject to an initial denaturation step of 96°C 
for 10 seconds followed by 25 cycles of 96°C for 10 seconds, 50°C for 5 
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seconds and 60°C for 4 minutes. After the sequencing reaction, 5µl of 125mM 
EDTA was added and the PCR products were precipitated by adding 60µl of 
100% ethanol, mixing and centrifuging at 3900 revolutions per minute (rpm) 
for 30 minutes at 22°C using the Eppendorf Centrifuge 5180R (Fisher 
Scientific UK, Loughborough, UK). The supernatant was carefully removed 
and the pellet was washed with 70% ethanol and centrifuged at 2000rpm for 
15 minutes at 4°C. After resuspending the pellet in Hi-Di Formamide (Applied 
Biosystems), the sequencing reactions were analysed on the ABI 3130xl 
Genetic Analyser using polymer POP-7 and the default RapidSeq36POP7 
module. SeqScape v2.5 and Sequencing Analysis version 5.2 (Life 
Technologies Ltd) software were used to analyse the resulting sequence data. 
 
2.14   RNA extraction and Reverse Transcription PCR 
 
Patient and bovine corneal tissues stored in RNAlater were thawed on ice, 
homogenized using the Ribolyser (Hybaid Ltd, Teddington, UK) and RNA 
extracted using TRIzol Reagent (Sigma-Aldrich) and the RNAeasy Plus 
Universal Minikit (Qiagen) according to the manufacturer’s instructions.   
 
 RNA was treated with Ambion DNAase treatment kit to prevent degradation 
of RNA by nucleases. cDNA synthesis was carried out using reverse 
transcriptase (RT) PCR. Samples were thawed on ice and 1mM Oligo (dT)18 
primers (Thermo Scientific), Random Hexamer primers (Thermo Scientific) 
and Diethylpyrocarbonate (DEPC) water were added. Samples were 
incubated at 70°C for 5 minutes then chilled on ice. A mastermix was 
prepared of 4mM dNTP, BioscriptTM RT (BiolineTM), 2x RT Buffer (BiolineTM), 
40mM DTT and DEPC-treated water. 10 µl of the mastermix was added to the 
reaction and the samples incubated at 42°C for 30 minutes. The reaction was 
then terminated by incubating at 85°C and the cDNA purified using the 
QIAquickTM PCR Purification columns (Qiagen Ltd, Manchester, UK) 
according to the manufacturer’s instructions. The samples then underwent a 
standard PCR reaction for p53 as a house-keeping gene. The sample 
products were size fractionated on a 1.5% agarose gel as described before 
 58 
(Section 1.10). Additionally, the samples were quantified and assessed for 
purity on the Agilent 2100 Bioanalyser (Agilent Technologies LDA UK Ltd, 
Stockport, UK) using the Agilent RNA 6000 Nano Guide (Agilent 
Technologies). 
 
2.15  Whole Exome Sequencing (WES) 
 
Genomic DNA sample concentrations were measured using a Qubit 
fluorometric quantification assay (ThermoFisher Scientific).  Whole exome 
sequencing (WES) was carried out either on a HiSeq2000 using the 
Nimblegen v2 chip by Otogenetics Corporation (Norcross, GA), or on an 
Illumina Genome Analyser HiSeq2500 in the Leeds University Next 
Generation Sequencing Facility following library preparation using the Agilent 
SureSelect All Exon v4 exome enrichment kit for target capture. Libraries 
were prepared either by SS, Layal Abi Farraj or Clare Logan. The sequencing 
output consisted of 80 base pair reads. An overview of the sample preparation 
work flow is given in Figure 2.2. 
 
2.16     Bioinformatics 
 
The UCSC Genome Browser  (https://genome.ucsc.edu) contains the 
reference sequence and working draft assemblies for a large collection of 
genomes. Bioinformatic searches of genomic regions and initial information 
about genes of interest were obtained using this website, including exon and 
intron sequences, mRNA sequences, protein sequences and the location of 
polymorphisms. Literature searches for information on known genes and loci 
were performed using Pubmed (http://www.ncbi.nlm.nih.gov/pubmed). 
Variants identified by Sanger sequencing were annotated using Mutation 
Mapper (http://sourceforge.net/projects/mutationmapper). The reverse 
compliment of an oligonucleotide sequence was calculated using Reverse 
Complement (http://sourceforge.net/projects/revcomp/). 
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Figure 2.2  Overview of sequencing sample preparation using the Agilent 
SureSelectXT Target Enrichment System for Illumina Paired-End Sequencing 
Library. 
 
2.17  Assessment of Variant Pathogenicity 
 
In order to determine the potential pathogenicity of missense mutations, 
variants were assessed using a selection of online matrices. A description of 
these is given below. Given that a single database could grade a variant 
incorrectly, these were used in combination with each other to prioritise 
variants. 
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2.17.1   BLOSUM62 
 
The BLOSUM62 substitution matrix (Henikoff and Henikoff, 1992) 
(http://www.uky.edu/Classes/BIO/520/BIO520WWW/blosum62.htm) 
was developed from 2000 blocks of aligned sequence segments 
characterising more than 500 groups of related proteins. The authors 
calculated a log-odds score for each of the 210 possible substitution pairs of 
the 20 standard amino acids. The scores range from -4 to +3 for a non-
synonymous amino acid substitution, with -4 meaning that the change is 
highly unlikely to be benign and a +3 that the change was highly likely to be 
benign. 
 
2.17.2    Polyphen2  
 
Polyphen2 (Polymorphism Phenotyping) (Adzhubei et al., 2010) 
(http://genetics.bwh.harvard.edu/pph2) uses eight sequence based and three 
structure based predictive features as part of its algorithm for determining 
variant pathogenicity. The programme compares features of the wild type and 
mutant protein and characterises how well the two human alleles fit into the 
pattern of multiple sequence alignment of homologous proteins. Two datasets 
have been used to develop Polyphen, HumDiv and HumVar. In the most 
recent version of Polyphen the user can choose which dataset can be used 
for analysis. The authors recommend the use of HumVar for distinguishing 
Mendelian mutations with drastic effects from normal human variation, and 
HumDiv for evaluating rare alleles in complex diseases. The output gives a 
score of between 0 and 1, 0 being Benign and 1 Damaging. A score of below 
0.2 is scored as Benign, 0.2-0.85 as Possibly Damaging and above 0.85 is 
Probably Damaging. 
 
2.17.3   SIFT  
 
SIFT (Sorting Intolerant from Tolerant) (http://sift.jcvi.org) is a programme 
which uses sequence homology to predict whether an amino acid affects 
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protein function (Ng and Henikoff, 2001). Like Polyphen, it can only be used 
for the assessment of missense variants. SIFT differentiates variants which 
are “Tolerated” and “Damaging”. The score ranges from 0-1, <=0.05 predicted 
as damaging and >0.05 predicted as tolerated. 
 
2.17.4   PROVEAN  
 
PROVEAN (http://provean.jcvi.org/index.php) (Protein Variation Effect 
Analyser) is a software tool which predicts whether a variant has an impact on 
the biological function of the protein (Choi et al., 2012). It can be used to 
assess nonsynonymous single nucleotide variants and indels. A clustering of 
BLAST hits is performed with a parameter of global sequence identity. The 
top 30 clusters of closely related sequences form a supporting sequence set 
which is used to predict the effect of the variant. An alignment score is 
calculated for the variant and the scores averaged to generate a final 
PROVEAN score. If the PROVEAN score is equal to or below the threshold 
(the default threshold is -2.5), the protein variant is predicted to have a 
"deleterious" effect. If the PROVEAN score is above the threshold, the variant 
is predicted to have a "neutral" effect. 
 
2.17.5   Mutation Taster 
 
Mutation taster (http://www.mutationtaster.org) employs a Bayes Factor (BF) 
classifier to predict the disease potential of a variant (Schwarz et al., 2010b). 
Analyses consist of evolutionary conservation, splice-site changes, loss of 
protein features and changes that could affect mRNA levels. There are four 
possible outputs: 
 
1. Disease-causing - i.e. probably deleterious 
2. Disease-causing automatic - i.e. known to be deleterious 
3. Polymorphism - i.e. probably harmless 
4. Polymorphism automatic - i.e. known to be harmless 
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The output score for amino acid substitutions also gives a prediction 
probability value (ranging from 0-1). A value closer to 1 indicates a high 
certainty of the prediction. No numerical score is provided for amino acid 
insertions and deletions. Like PROVEAN, Mutation Taster has the ability to 
process indels.  
 
2.17.6  Combined Annotation Dependent Depletion (CADD)  
  
Many of the databases described above utilise a single type of information, for 
example conservation or protein- based metrics. CADD scores (Kircher et al., 
2014) integrate diverse genome annotations and score any single nucleotide 
variant (SNV) or small Indel (Kircher et al., 2014). This can be used to grade 
nonsense, missense and splice site variants as well as those in intronic 
regions. A variant with a CADD score greater than or equal to 10 is predicted 
to be within the 10% most deleterious substitutions in the human genome.  A 
score of greater or equal to 20 indicates the 1% most deleterious. 
 
2.17.7  Splice prediction tools  
 
The pathogenicity of potential splice site variants was assessed using 
Berkeley Drosophila Genome Project (BDGP) splice prediction site 
(http://www.fruitfly.org/seq_tools/splice.html). This is based on a neural 
network, which is trained to recognise splice donor or acceptor sites using a 
set of known sequences. The input sequence is compared with the training 
sets, and the probability of the input containing a splice site is calculated.  
 
2.18   Assessment of Conservation 
 
To assess whether the normal amino acid residue was evolutionarily 
conserved, protein sequences from different species were downloaded from 
the NCBI (http://www.ncbi.nlm.nih.gov) and aligned using ClustalW 
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(http://www.ebi.ac.uk/Tools/msa/clustalw2) (Larkin et al., 2007) or from NCBI 
Homologene (http://www.ncbi.nlm.nih.gov/homologene).  
 
Clustal W is a multiple sequence alignment programme for DNA or proteins. 
Homologous DNA sequences from multiple species can be pasted into the 
document and are then aligned as closely as possible. This was used to align 
orthologous proteins of interest, allowing the conservation of a particular 
amino acid sequence to be determined. 
 
NCBI Homologene database is an automated system for constructing putative 
homology groups from a wide range of eukaryotic species. The programme 
also aligns protein sequences of interest from different organisms and 
compares these with one another.  
 
2.19  Tools to Aid Candidate Gene Prioritisation  
 
Candidate genes were prioritized using several tools. Mouse Genome 
Informatics (MGI) (http://www.informatics.jax.org) is an international database 
of genetic and biological data from the laboratory mouse. STRING (Search 
Tool for the Retrieval of Interacting Genes/Proteins) (http://string-db.org) is a 
database of known and predicted protein interactions. Published human 
corneal endothelial cells RNA sequencing data (Chng et al., 2013) was also 
utilsed to prioritise candidates. 
 
2.20   Public Databases 
 
The 1000 Genomes (http://www.1000genomes.org), Exome Variant Server 
(EVS) (http://evs.gs.washington.edu/EVS) and Exome Aggregation 
Consortium (http://exac.broadinstitute.org) databases of samples that have 
been whole exome sequenced were utilized to exclude common 
polymorphisms prior to the comparison of missense changes in FECD cases 
versus controls. The frequency of 1000 Genomes SNPs was viewed in 
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SNPedia (http://www.snpedia.com/index.php/SNPedia). 
 
2.21   Next Generation Sequencing (NGS) Bioinformatic 
Analysis Pipeline 
 
Whole exome data was processed using two pipelines, summarised in Table 
2.2. Briefly, reads were aligned to hg19 using Bowtie version 2 (http://bowtie-
bio.sourceforge.net/bowtie2/index.shtml) (Langmead and Salzberg, 2012). 
The resulting SAM files were sorted and indexed using Samtools 
(http://samtools.sourceforge.net) and processed using the Genome Analysis 
Toolkit (GATK) (https://www.broadinstitute.org/gatk/) (McKenna et al., 2010) 
with Picard (http://broadinstitute.github.io/picard/) to perform indel realignment 
and duplicate removal. SNVs and indel variants were called using the 
UnifiedGenotyper feature of GATK. Variants were annotated using Annovar 
(http://annovar.openbioinformatics.org/en/latest/) (Wang et al., 2010). 
 
Step Programme Website
Alignment Bowtie2 http://bowtie-bio.sourceforge.net/bowtie2/index.shtml
Removal of non-unique reads N/A
Sorting and indexing to the 
reference file Samtools
(http://samtools.sourceforge.net) 
Local realignment around indel: 
Create list of dubious alignments 
Realign over dubious regions
GATK https://www.broadinstitute.org/gatk/
Removal of duplicate reads Picard http://broadinstitute.github.io/picard/
Variant Calling (SNPs and Indels) GATK as above
Recalibration of SNPs GATK as above
Apply recalibration of SNPs GATK as above
Combine list of recalibrated SNPs 
and Indels 
GATK as above
Annotation of variants Annovar http://annovar.openbioinformatics.org/en/latest/
Table 2.2 Bioinfomatic Pipeline 1 for the processing of NGS FASTQ files 
 
A second pipeline was utilised which incorporated the use of CADD scores at 
the annotation stage (Table 2.3). For the second pipeline reads were aligned 
using Novolign (http://www.novocraft.com). SAM files were then sorted using 
Samtools and duplicates marked using Picard. Indel realignment and SNPs 
recalibrated took place using GATK. Following variant calling in GATK, 
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variants were then annotated using Variant Effect Predictor (VEP) 
(http://www.ensembl.org/info/docs/tools/vep/index.html). 
 
Step Programme Website
Alignment Novolign http://www.novocraft.com
Sorting and indexing to the 
reference file Samtools
(http://samtools.sourceforge.net) 
Removal of duplicate reads Picard http://broadinstitute.github.io/picard/
Local realignment around indel: 
Create list of dubious alignments 
Realign over dubious regions
GATK https://www.broadinstitute.org/gatk/
Recalibration of base quality 
scores
GATK  as above
Variant Calling GATK as above
Annotation of Variants VEP http://www.ensembl.org/info/docs/tools/vep/index.html
Table 2.3 Bioinfomatic Pipeline 2 for the processing of NGS FASTQ files 
 
2.22   Filtering  
 
Following annotation, Variant Call Format (VCF) files from individual affected 
family members were merged into a single file of shared variants using in-
house perl scripts and the Agile Variant Selector software. For those families 
that had data from an unaffected individual, two files were created; one with 
just affected patients and one with affected patients excluding variants from 
the unaffected family member. 
 
Homozygous variants were filtered out in the first instance, then all variants in 
known published FECD genes were analysed. Synonymous and intronic 
variants were then filtered out. Splice site variants in positions 1 to 5 were 
retained along with exons and exon/splicing (variants within the exon but 
close to the intron/exon boundary) variants. Variants that had a frequency of 
more than 2% on the EVS and 1000 Genomes databases were excluded. 
Variants were then prioritised on the basis of variant pathogenicity scores 
(Section 2.17, the RNAseq expression data and MGI (Section 2.19)). This 
process is summarised in Figure 2.3. 
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Figure 2.3 Flowchart summarising the process of filtering and prioritisation of 
variants generated from WES 
 
2.23  CNV Analysis 
2.23.1  ExomeDepth 
 
The ExomeDepth software uses read depth to call CNVs from exome 
sequencing data (Plagnol et al., 2012). 
(https://cran.rproject.org/web/packages/ExomeDepth/index.html). It compares 
this data to an aggregate reference set generated from exomes run at the 
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same time on the same lane of the sequencer. The programme ranks the 
CNV calls using the BF which quantifies the statistical support for each CNV. 
This is the log10 of the likelihood ratio of data for the CNV called divided by 
the null (normal copy number). Therefore, the higher the BF value, the greater 
the confidence regarding the presence of a CNV. The type of CNV can be 
indicated by the ratio of the observed and expected reads: 
 
0 homozygous deletion 
0.5   heterozygous deletion 
  1.5   heterozygous duplication 
2.0   homozygous duplication 
 
The programme is able to identify and annotate common CNV as identified in 
the Conrad database (Conrad et al., 2010). FASTQ files for cases and 
controls were processed using Pipeline 1 described in Table 2.2, up to the 
variant-calling step. The resulting BAM files were run on the ExomeDepth 
programme by Evi Panagiotou. 
 
2.24   Statistical analysis 
 
PLINK 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007) 
was used to analyse the genotyped alleles and examine Hardy-Weinberg 
equilibrium (HWE) with Fischer’s exact test but also to calculate odds ratios 
(OR) with standard error confidence limits (CI). This was carried out by Dr 
Jose Ivorra. The degree of linkage disequilibrium (r2) between rs613872 and 
the CTG18.1 polymorphism was calculated using Haploview (Barrett et al., 
2005).  
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3 A study of young-onset corneal dystrophies in 
conjunction with the British Ophthalmic 
Surveillance Unit (BOSU) 
 
3.1 Introduction 
 
Corneal dystrophies are a heterogeneous group of non-inflammatory diseases 
that are, in the majority of cases, limited to the cornea (Klintworth, 2009). 
They can occur as isolated cases but most are familial with a genetic basis 
and affected patients can manifest symptoms from birth, during childhood or 
in adult life. The traditional anatomic classification of dystrophies was thought 
to have limitations and in the 2015 International Corneal Dystrophy (IC3D) 
classification (Weiss et al., 2015), corneal dystrophies were reclassified as 
Epithelial and subepithelial, Epithelial-stromal TGFβI, Stromal  and 
Endothelial Dystrophies. Most of these dystrophies follow a dominant 
inheritance pattern, but documented examples of autosomal recessive 
corneal dystrophies also exist (Akama et al., 2000, Vithana et al., 2006).  
 
Although corneal dystrophies are rare, the commonest, Fuchs endothelial 
corneal dystrophy (FECD), is adult onset and accounts for 22% of corneal 
transplants performed in the UK (Keenan et al., 2012). FECD has been 
estimated to affect 4% of the US population over 40 (Lorenzetti et al., 1967). 
The prevalence of the remaining corneal dystrophies is essentially unknown 
and varies worldwide, with the highest numbers found in countries associated 
with a common founder mutation. For example, gelatinous drop-like corneal 
dystrophy (GDCD) is prevalent in Japan, where the incidence is estimated to 
be 1 in 300,000 people (Tsujikawa et al., 1998), whereas X-linked endothelial 
dystrophy has only been reported once in a multigenerational family from 
Western Austria (Schmid et al., 2006). 
 
Most corneal dystrophies cause corneal opacity and result in visual 
impairment or even blindness (Nischal, 2015). Severe visual impairment (SVI) 
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caused by corneal opacity accounts for 2% of patients (Rahi and Cable, 
2003). Corneal disease as a whole accounted for 45/1756 (2.6%) of 
Certificates of Visual Impairment (CVI) in working age adults in the UK in the 
year 2009/10 (Liew et al., 2014). Previous BOSU studies of rare ocular 
disease in the UK population (Papadopoulos et al., 2007), have suggested a 
higher prevalence in certain communities where consanguineous marriages 
are the cultural norm. Advances in gene mapping and the advent of next 
generation sequencing have, in the last decade, led to significant 
improvement  in our ability to characterise the genotypes that are associated 
with these phenotypes at a molecular level. Given the rarity of many of these 
corneal dystrophies, there is great potential benefit to patients in studying 
them collaboratively. There is however a lack of studies examining the 
incidence of corneal dystrophies. 
  
This chapter presents data that aims to advance our knowledge of the 
epidemiological aspects of young onset corneal dystrophies (presenting 
before the age of 40 years) by establishing an incidence rate in the UK, as 
there are currently no national studies in this field. 
 
3.2 Results 
 
The British Ophthalmological Surveillance Unit (BOSU) runs a nation-wide 
surveillance system across the United Kingdom for the epidemiological 
investigation of the incidence and clinical features of rare eye conditions of 
public health or scientific importance (https://www.rcophth.ac.uk/standards-
publications-research/the-british-ophthalmological-surveillance-unit-bosu/).  
 
The author, in collaboration with Mr Kamron Khan, set up a BOSU 
epidemiological survey for the reporting of young onset corneal dystrophies. 
In total 73 cases of new-onset corneal dystrophy were reported to the BOSU 
in response to this survey. The notifying clinicians were sent a questionnaire 
about the case, a sample of which is shown in Appendix 1. There were 31 
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respondents (a response rate of 42%). Four questionnaires were incompletely 
filled in, leaving a total of 27 questionnaires that were analysed.  
 
3.2.1 Source of Patient Referral and Demographics 
 
Patient referrals were from six different sources. 8/27 (29.6%) were referred 
by an Optometrist, 8/27 (29.6%) by their Ophthalmologist and 7/27 (25.9%) by 
their GP. 2/27 (7.4%) were reviewed due to an affected parent/relative, 1/27 
(3.7%) as an acute referral for another presentation and 1/27 (3.7%) via 
orthoptic vision screening. The patients’ ethnicities are summarised in Figure 
3.1. 
 
 
 
 
Figure 3.1 Pie chart indicating the ethnicity of young-onset corneal dystrophy 
patients. 
 
 
 
 
 
77.8%
7.4%
3.7%
3.7%
3.7%3.7% White-British
White-Irish
Bangaladeshi
Indian
Pakistani
Mixed Race - White 
and Black Caribbean
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The mean age at presentation was 12 years. 48% were female. There was a 
positive family history in 48% of cases. A documented history of consanguinity 
was found in 4% of cases, and in 26% of cases this was unknown.  
 
3.2.2   Clinical Presentation 
 
Best-corrected visual acuity (BCVA) was assessed using LogMAR visual 
acuity in 25.9% of patients. BCVA at presentation in all patients ranged from 
LogMAR 0.0 to Perception of light (PL), with a mean and median of 0.2.  
Corneal sensation was normal in 6 cases (22%) and not documented in 21 
cases (78%). Symptoms at presentation are summarised in Table 3.1. 
 
 
Table 3.1 Symptoms of young-onset corneal dystrophy patients at presentation 
 
The extent of corneal disease was found to be symmetrical in 81.4% of cases. 
Examples of dystrophies which were reported as having markedly unilateral 
signs included Meesman corneal dystrophy, LCD, RBCD, PPCD and Lisch 
Dystrophy. Some degree of corneal opacity was present in 96% of patients. In 
52% of cases this involved the epithelial or subepithelial layers. Epitheliopathy 
was present bilaterally in 22%, unilaterally in 7% and not documented due to 
the patient’s phobia of drops in 4%. Corneal oedema was present diffusely 
and bilaterally in 11% (3/27) and absent in 78% (21/27) of the patients. All 
cases which exhibited endothelial signs had a diagnosis of an endothelial 
dystrophy (either FECD or PPCD). Focal corneal oedema was present 
unilaterally in 7.5% (2/27) of cases.  
Symptom(s) No. of Patients
None 4
Glare; surface irritation 2
Reduced photopic/scotopic VA 7
Reduced photopic/scotopic VA; glare 3
Reduced photopic/scotopic VA; glare; surface irritation 1
Reduced photopic/scotopic VA; surface irritation 1
Surface irritation 8
Not documented 1
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3.2.3 Investigations, Genetic Testing and Diagnoses 
 
The investigations utilised in all cases are outlined in Figure 3.2. In 74% 
(20/27) of cases slit lamp ophthalmoscopy was sufficient for diagnosis. 
 
 
 
Figure 3.2 Pie chart indicating the investigations performed on newly-identified 
young-onset corneal dystrophy patients. 
 
A summary of all diagnoses is given in Table 3.2. In two cases of stromal 
dystrophy a clinical diagnosis could not be made. In one of these cases whole 
exome next generation sequencing was requested. In the other case, a 
metabolic cause was suspected and a referral to medical genetics was made. 
Genetic tests were also requested for three other cases; one clinical case of 
Thiel-Bhenke dystrophy with affected parents which was confirmed on genetic 
testing, one case of posterior polymorphous dystrophy (PPCD) which was 
found to have a ZEB1 mutation and an additional case of PPCD whose 
results were unknown. 
 
74%
15%
4%
7% Slit lamp alone
Specular 
Microscopy
Imaging 
(investigation not 
specified)
Biopsy/Histology
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Table 3.2 Diagnoses of newly-identified young onset corneal dystrophy patients
Corneal Dystrophy Subtype Diagnosis No. of Patients
Epithelial basement membrane dystrophy 4
Meesman Dystrophy 2
Lisch Dystrophy 1
Macular Dystrophy 1
Unknown 2
Reis-Bucklers Dystrophy 3
Thiel-Bhenke Dystrophy 2
Granular Dystrophy 2
Lattice Dystrophy 1
Posterior Polymorphous Corneal Dystrophy 5
Fuchs Endothelial Dystrophy 4
Epithelial and Subepithelial
Stromal
Epithelial-stromal TGFβ1
Endothelial
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3.2.4   Clinical Management and Follow-up 
 
The most frequent form of management was observation with provision of 
artificial lubricants. Two cases required bandage contact lens use. Surgical 
intervention was required in three cases of endothelial dystrophy (Descemet’s 
Stripping Endothelial Keratoplasty, Descemet’s Stripping Automated 
Endothelial Keratoplasty and Penetrating Keratoplasty) (Figure 3.3). 
 
Figure 3.3 Management strategies utilised in young-onset corneal dystrophy 
patients. BCL = Bandage contact lens (a special type of contact lens used to protect 
the ocular surface). 
 
85% of patients were followed up subsequently at six months in the 
presenting clinic, 7% were referred to another ophthalmologist with a 
specialist interest, 4% were referred to another clinic for another 
ophthalmological problem and 4% were discharged. One patient, who 
suffered from PPCD and had undergone penetrating keratoplasty had vision 
sufficiently reduced to be eligible for CVI. 
 
Comparing the incidence of corneal dystrophy with the 2011 UK census data, 
young-onset corneal dystrophies are extremely rare and this study would 
suggest a minimum UK incidence of 6.7 newly-diagnosed cases per 10 000 
000 population aged below 40 years per annum.  
Management	
Strategy 
Number	of	Patients 
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3.3  Discussion  
 
Corneal dystrophies are mostly bilateral and are often inherited. There is 
however a lack of studies examining the incidence of corneal dystrophies in 
the UK. This chapter describes a study, conducted in conjunction with BOSU, 
aiming to assess the incidence of new onset corneal dystrophies in patients 
below 40 years of age. The results show that corneal dystrophies occur rarely 
in young people, thus highlighting the need to study them collaboratively. 
However, the incidence of 6.7 cases per 10 000 000 population aged below 
40 years per annum may be an underestimate given that the questionnaire 
response rate was only 42%, which can be considered a limitation of this 
study. All of those clinicians who had not identified new cases but who did not 
respond with a questionnaire were reminded by telephone and email. 
 
Another reason that the calculated incidence in this study might be an 
underestimate of the actual incidence may be a tendency to under-report mild 
phenotypes, especially those which may be seen more commonly in those 
below the age of 40 years. An example could be epithelial basement 
membrane dystrophy, a relatively common condition compared with many of 
the other corneal dystrophies reported in this chapter. 
 
Corneal disease causes 2% of CVI in children (Rahi and Cable, 2003) and 
2.6% in adults of working age (Liew et al., 2014). In this study there was one 
case (3.7%) of PPCD that presented with PL visual acuity and was eligible for 
CVI. However, two further patients exhibited moderate visual loss (Snellen 
6/18 - 6/60, approximately 0.5 – 1.0 LogMAR). Furthermore, 22/27 (81.5%) 
experienced symptoms ranging from glare and surface irritation to reduced 
photopic or scotopic visual symptoms, suggesting that the burden of these 
conditions is considerable, even in the presence of good vision.  
 
In the study presented in this chapter, 85.2% of the patients were Caucasian, 
which is comparable with the Census UK data from 2011 (11 December 
2012). However, the Asian/British Asian group are a little overrepresented in 
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the group presented here, with 3/27 (11.1%) compared with 7.5% in the 
Census UK data. Two of the diagnoses in this Asian subgroup were macular 
and granular dystrophies but the diagnosis in the third case was unknown. 
Two of the three cases had a positive family history of corneal dystrophy, one 
of which also had a history of consanguinity.  
 
Overall this study reports a positive family history in 50% of cases. Although 
hereditary factors are known to be important in the pathogenesis of these 
conditions, to our knowledge there are no UK studies examining this. 
However a study based in Saudi Arabia examining 193 corneal dystrophy 
cases involving the stroma indicated a positive family history of between 
37.22 and 44.44% in the various dystrophies that they examined (Alzuhairy et 
al., 2015). This study also found that corneal histopathological examination of 
corneal buttons indicated that a proportion of Macular Corneal Dystrophy 
(MCD) cases had been misdiagnosed on clinical examination alone. In the 
study presented in this chapter there were only two cases that had been 
diagnosed with the assistance of corneal histopathology. One of these was a 
severe case of PPCD in which a penetrating keratoplasty was performed soon 
after presentation. Another was a patient with Lisch Dystrophy in whom a 
biopsy had been carried out on an affected first-degree relative. As 
observation and the provision of ocular lubricants were the most common 
treatments in this study, and surgical intervention was performed in only 
11.1% of newly presenting cases, the fact that biopsy was not utilised to aid 
diagnosis more is perhaps not surprising. Despite advances in anterior 
segment imaging modalities (Hong et al., 2011), 74% of diagnoses were 
made using the slit-lamp examination alone, possibly reflecting a lack of 
availability or necessity of these modalities for corneal dystrophy diagnoses. 
 
The mean age of onset was 12 years old, relatively young compared with that 
reported from another dataset (Musch et al., 2011) which used claims data to  
calculate the prevalence of corneal dystrophies in the US. Their study looked 
at the records of 8 million enrolees in a national managed care network. 27, 
372 cases of corneal dystrophy were identified, with an overall prevalence 
rate 897 cases per million. The study presented in this thesis differs from that 
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reported by Musch et al. Even if endothelial dystrophy cases were to be 
excluded from their data, they identified the majority of their corneal dystrophy 
cases from the 45-88 age group. This BOSU study by its very nature studied 
examined a much younger cohort, but even taking this into account the mean 
age of onset of 12 years old can be considered relatively young. Additionally, 
their study looked at the prevalence of corneal dystrophies, whereas the 
results presented in this thesis looked at new cases. 
 
Endothelial dystrophies were the most common group of dystrophies reported 
in this study, consistent with the US data previously described (Musch et al., 
2011). Of these, PPCD was the most common dystrophy reported here. Of 
the three cases of PPCD that were managed by keratoplasty, two of these 
were lamellar endothelial keratoplasties. Endothelial keratoplasty is now 
performed more commonly than penetrating keratoplasty for endothelial 
failure in the UK (Keenan et al., 2012). As PPCD is documented to have good 
outcomes following keratoplasty (Nischal, 2015), this is perhaps a reason why 
this group of cases were more likely to undergo such surgical management 
than any of the other options. Interestingly, despite the known role of LASIK 
and surface ablation in the management of a variety of corneal dystrophies 
(Woreta et al., 2015), there were no cases of corneal dystrophies managed by 
excimer laser in this study. Corneal sensation was not documented in 78% of 
cases. Given that corneal sensation is known to be subnormal in some 
subtypes of corneal dystrophy (Rosenberg et al., 2001, Ahuja et al., 2012) 
and indeed might have implications for tear production and consequent dry 
eye, we would recommend testing corneal sensation as part of the 
assessment of corneal dystrophy.  
 
Genetic testing was carried out in 4/27 cases, two of which carried a 
diagnosis of PPCD. In one of these PPCD cases, whole exome sequencing 
(WES) revealed a mutation in ZEB1, while in the other the result is unknown. 
WES was carried out in a third case, which was an undetermined stromal 
dystrophy. In one case of Thiel-Bhenke dystrophy, genetic screening was 
carried out on an affected first-degree relative. In another case of stromal 
dystrophy of uncertain diagnosis, a referral to the regional medical genetics 
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department was made for further investigations. The use of Next Generation 
sequencing techniques in the molecular characterisation of corneal 
dystrophies has been a major advance in recent years. This has been 
reflected in the designation of the TGFβ1 corneal dystrophies, a category 
based on the molecular diagnosis of corneal dystrophies rather than the 
anatomical location of pathology, and it has been suggested that the 
existence of a new corneal dystrophy must start with identification of the 
clinical phenotype and culminate in characterisation of the causative gene 
mutation (Weiss et al., 2015). As our understanding of molecular genetics 
advances and pressure on traditional therapeutic options, such as corneal 
graft material, remains high, it may become necessary to look for alternative 
treatment options. The cornea is a highly accessible structure which is 
potentially highly advantageous when directing treatments to the target tissue. 
Numerous efficacious vectors, delivery techniques, and approaches have 
evolved in the last decade (Mohan et al., 2013), but for corneal dystrophy, 
these treatments have not yet found their way into clinical practice. It is not 
inconceivable that the identification of causative mutations might not only 
guide genetic counselling of prognosis and recurrence risks but in the future 
pave the way to the development of gene therapies.  
 
In conclusion, corneal dystrophies are a hereditary group of corneal 
conditions which are extremely rare, with a minimum UK incidence of 6.7 
newly-diagnosed cases per 10 000 000 population aged below 40 years per 
annum.  
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4 Genotype-Phenotype Correlations in CHED, 
Harboyan Syndrome and FECD 
 
4.1  Introduction 
 
CHED is an autosomal recessive condition, which is a cause of congenital 
corneal opacity. It is a rare, bilateral disease affecting the posterior aspect of 
the cornea, characterised by corneal oedema, thickening of the DM layer and 
lack of endothelial cells (Maumenee, 1960, Kirkness et al., 1987). 
Presentation is at birth or in the early neonatal period. FECD is a complex 
late-onset condition, which begins with asymptomatic corneal endothelial 
guttata. Its inherited forms are autosomal dominant (Krachmer et al., 2011). 
 
Recessive mutations in SLC4A11 (MIM*610206) on chromosome 20p13 
cause CHED (formerly CHED2 see Section 1.3.6) (Vithana et al., 2006). 
Harboyan syndrome (MIM#217400) is characterised by CHED in association 
with sensorineural hearing loss. Dominant mutations in SLC4A11 are also a 
rare cause of late-onset FECD (Vithana et al., 2008). The hearing deficit in 
Harboyan syndrome is not present at birth but is typically progressive with 
onset around the age of 10 to 15 years (Desir et al., 2007). Recessive 
mutations in SLC4A11 also account for this phenotype. There have been over 
70 different homozygous or compound heterozygous mutations reported in 
the SLC4A11 gene. (Aldave et al., 2013) The mutations reported suggest that 
the three disorders are allelic (Desir and Abramowicz, 2008, Mehta et al., 
2010) but this has not previously been demonstrated by longitudinal follow-up 
of the CHED patients or conclusively documented in the literature.  
 
This chapter describes two previously reported CHED families (Vithana et al., 
2006) and a newly identified family (courtesy of a collaboration with Dr. Juan 
Carlos Zenteno (JCZ), National Autonomous University Mexico, Mexico City) 
to investigate whether CHED and Harboyan syndrome are the same condition 
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at different stages of development, and whether the parents of CHED patients 
are at risk of developing late-onset FECD .  
 
4.2  Results 
4.2.1 Identification and clinical evaluation of the affected CHED 
cases  
 
Three families and their relatives were identified as described below. Families 
A and B were ascertained for a previous study (Vithana et al., 2006) and their 
phenotype and mutation are reported by Vithana et al 2006. Family C was 
ascertained and the mutation identified in this study.   
 
Clinical examination of the patients with endothelial dystrophy suggested a 
diagnosis of CHED, while family history suggested recessive inheritance. The 
pedigrees are shown in Figure 4.1. 
 
 
Figure 4.1. Family structure of patients with CHED.  Families A, B and C are 
shown. The proband is indicated by an arrow. Data from Family C was provided 
courtesy of JCZ. 
 
Family A was of Pakistani origin and was identified at Bradford Royal 
Infirmary (BRI). Clinical information from both affected individuals from Family 
A was derived from the patient records and outpatient follow-up appointments 
at the BRI Department of Ophthalmology. Patient II.1 presented initially during 
the immediate postnatal period with bilateral cloudy corneas. There was no 
evidence of buphthalmos and his mucopolysaccharide screen was negative. 
Examination under anaesthesia at 1 year of age revealed normal corneal 
diameters and signs consistent with CHED. His anterior chambers were deep 
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and his intraocular pressures (IOP) in both eyes were 20mm Hg. At age 5, he 
was registered partially sighted, with visual acuities of 0.60 and 0.70 logMAR 
in the right and left eye respectively and attended school with support from a 
visual impairment nurse. At age 24, his visual acuities had remained stable 
since partial sight registration. His corneal photograph was taken at this age 
(Figure 4.2). 
 
His younger sister, individual II.2, presented shortly after birth due to a cloudy 
cornea. At this time the cause of her brother’s cloudy cornea was under 
investigation. At 5 months of age, an examination under anaesthesia revealed 
bilateral cloudy corneas 11mm in diameter with an extremely poor fundal 
view. At age 2, her mother noted that she held objects very close to her in 
order to localise them and felt that her vision was significantly worse than her 
brothers’. Her vision was measured as 2.22 logMAR in both eyes. She 
underwent a right penetrating keratoplasty at age 3, but her recovery was 
hindered initially by a blunt trauma one month post-operatively. However after 
3 months she maintained a clear graft. Her left eye underwent penetrating 
keratoplasty at age 4 but was later complicated by rejection and graft failure, 
and was subsequently re-grafted at age 9 and 19. At age 21, she had a clear 
graft in the right eye, but her vision in this eye has remained at 1.00 logMAR 
due to initial amblyopia and high astigmatism following penetrating 
keratoplasty. Her vision in her left eye was hand movements (HM). 
 
Family B was also of Pakistani origin, identified at BRI. Clinical information 
was ascertained from the patient records and Ophthalmology outpatient 
follow-up appointments at the BRI. Individual II.1 was noted after birth as 
having a cloudy cornea. At 5 months of age, she underwent an examination 
under anaesthesia, which revealed generalised stromal oedema and corneal 
diameters of 11mm. Her IOPs were raised at 30mmHg and 40mmHg in the 
right and left eyes respectively. She underwent a goniotomy procedure and 
was commenced on Betagan BD to both eyes to reduce her intraocular 
pressure. Her other diagnoses included moderate learning difficulties and 
microcephaly. At age 16 years old, she maintained stable visual acuities of 
1.00 and 1.07 logMAR in the right and left eyes respectively, and her 
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glaucoma was well controlled. She received continued support from a visual 
impairment teacher at school. 
 
Family C were of Mexican origin, identified and recruited by collaborator JCZ. 
The patient presented at 5 months of age with bilateral corneal opacities that 
had been observed at birth. At 6 months of age, the patient received Timolol 
and Dorzolamide eye drops due to high IOP. At this age, a constant horizontal 
nystagmus was noted in both eyes. He underwent goniotomy due to elevated 
intraocular pressure in the left eye at the age of 3 years. At 10 years, he 
presented with congenital corneal clouding, nystagmus and diffuse corneal 
oedema in both eyes, normal intraocular pressure, no Haab striae, no 
buphthalmos and optic nerve head cupping of 0.7. At age 13, he had vision 
1.82 and 1.60 logMAR in his right and left eye respectively. His corneal 
photograph was taken at this age (Figure 4.2).  
 
 
Figure 4.2  Corneal photographs of affected patients from Families A and C. 
Individual II.1 from Family A was 24 years old and individual II.1 from Family C was 
13 years old at the time of these photographs. The typical ground-glass corneal 
appearance is apparent in both photographs, but more prominent in the individual 
from Family C.   
 
The clinical findings are summarised in Table 4.1.  
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Table 4.1 Summary of the ophthalmic findings from Families A, B and C. Age at 
examination and clinical findings for each CHED patient are shown. Any ophthalmic 
interventions are also highlighted. IOP, intraocular pressure OD, right eye; ONH, 
optic nerve head; OS, left eye; VA, visual acuity
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4.2.2 Audiometric testing in the CHED affected cases 
 
As CHED is associated with progressive sensorineural hearing loss (Desir 
and Abramowicz, 2008), hearing assessments of CHED patients from 
Families A-C (Figure 4.3a) were carried out. A normal audiogram is shown for 
comparison (Figure 4.3b). 
 
Audiometric examination of patient II.1 from Family A at 12 years of age 
carried out at the BRI revealed bilateral mid to high frequency sensorineural 
hearing loss (Figure 4.3a). He was subsequently fitted with bilateral hearing 
aids. Audiometry was repeated at age 21, where some deterioration of 
hearing was measured. His younger affected sibling (patient II.2), whose 
corneal opacity was more marked at presentation, had subjective hearing 
problems at the age of 21. When asked about her auditory symptoms, she 
expressed difficulty hearing others’ conversations when studying at college. 
Audiometry was therefore performed at the BRI and showed a mid-frequency 
bilateral sensorineural hearing loss consistent with these symptoms (Figure 
4.3).  
 
Audiometry in the patient from Family B, at age 11 was unremarkable. This 
was repeated at age 15 where bilateral high frequency hearing loss was found 
(Figure 4.3a).  
 
Audiometric testing in the patient from Family C at the age of 12, disclosed 
bilateral sensorineural hearing loss in the range of 30 to 60 decibels, mainly 
affecting the higher frequencies (Figure 4.3a). 
 
These results confirmed that the CHED patients presented in this thesis go on 
to develop sensorineural hearing loss. Thus their diagnosis changed from 
CHED to Harboyan syndrome on longitudinal follow-up. It could therefore be 
concluded that CHED and Harboyan Syndrome are the same condition at 
different stages of development.        
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Figure 4.3 Audiometry of the CHED affected patients from Families A, B and C. 
a. The graphs show the frequency in hertz (x-axis) and the hearing level in decibels 
(y-axis). The test was performed on the patient at 12 years (Family A, II.1), 21 years 
(Family A, II.2), 15 years (Family B, II.1) and 12 years (Family C, II.1) respectively. 
Note reduced sensorineural hearing loss in the range 30 to 50 decibels at the higher 
frequencies. b. A normal audiogram is shown for comparison (courtesy of Mr Glen 
Waugh, Associate Audiologist at Bradford Royal Infirmary, Bradford.) 
 
a. 
b. 
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4.2.3 SLC4A11 mutation screening to confirm clinical diagnosis of 
CHED 
 
Peripheral blood samples were collected from the affected patient from Family 
C. Genomic DNA was extracted using the standard protocol described in 
Section 2.8.  The sample from the affected patient, along with a control DNA, 
were screened by PCR and Sanger sequencing (Section 2.10 and 2.14). All 
19 exons of SLC4A11 transcript NM_032034 were screened, the primer pairs 
for which are listed in Appendix III. Sequencing of SLC4A11 gene in the 
patient from Family C identified the presence of a homozygous novel mutation 
c.397T->C, p.F133L (Figure 4.4) contained in exon 4. To exclude this variant 
as a polymorphism, the EVS and ExAC databases were checked. The EVS 
contains the whole exome data of 6500 individuals, and variants in the 
SLC4A11 gene were found in 175 Europeans and Americans.  The ExAc 
database contains the whole exome of 60,706 individuals. This variant was 
not present in either database, indicating that it is a rare variant.  
 
 
 
Figure 4.4. Sequence chromatogram from Family C, Individual II.1. This depicts 
the novel mutation in SLC4A11 identified in the Family C Mexican CHED patient. 
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Where mutations have been shown to cause disease, there is often a 
remarkable degree of evolutionary conservation in the corresponding genes 
across species (Strachan and Read, 2011). In order to assess the 
evolutionary conservation of this phenylalanine residue, multiple sequence 
alignment of SLC4A11 proteins was performed (Section 2.18) and is shown in 
Figure 4.5. This indicates that the amino acid residue Phenylalanine in the 
position 133 on the SLC4A11 protein is highly conserved through evolution.  
The pathogenicity assessment of the variant using Polyphen2, SIFT, 
PROVEAN, Mutation Taster and CADD (Section 2.17) are shown in Table 
4.2. All of these assessments except for SIFT indicated that this variant was 
likely to be pathogenic. The SLC4A11 protein BTR1 (bicarbonate transporter 
related protein 1) consists of cytoplasmic, transmembrane and extracellular 
domains (Vilas et al., 2011). This variant lies in the cytosolic domain. 
 
 
Figure 4.5 Protein sequence alignment of the human SLC4A11 protein with 
orthologues around the phenylalanine residue was performed using 
Homolgene. The variant p.F133 is highlighted in red and the surrounding amino 
acids that are identical to the human transcript are shaded in grey. Accession 
numbers for SLC4A11 sequence are NP_114423 (human), XP_001160838.1 
(chimp), XP_002798266.1 (monkey), XP_005634909.1 (dog), NP_001178243.1 
(cow), NP_001074631.1 (mouse), NP_001101245.1 (rat), XP_004936342.1 
(chicken), NP_001153300.1 (zebrafish), NP_001033333.1 (roundworm), 
XP_002936409.2 (frog). Note the p.F133 residue is evolutionarily conserved 
suggesting an important role of this residue in the normal function or structure of 
SLC4A11 NP_114423.  
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Table 4.2 Summary of bioinformatics analyses used to determine the likely 
pathogenicity of the c397T>C mutation in SLC4A11. The databases used were 
Polyphen2, http://genetics.bwh.harvard.edu/pph2/, (Adzhubei et al., 2010), SIFT,  
http://sift.jcvi.org (Ng and Henikoff, 2001), PROVEAN, 
http://provean.jcvi.org/index.php (Choi et al., 2012), Mutation Taster 
http://www.mutationtaster.org (Schwarz et al., 2010b) and CADD 
http://cadd.gs.washington.edu (Kircher et al., 2014). *CADD scores are reported as 
scaled C-scores and values ≥ 20 and ≥ 10 respectively represent the 1% and 10% 
most deleterious changes predicted in the human genome.  
 
All these analyses suggest that the F133L variant identified in Family C is 
pathogenic and is the cause of the CHED/Harboyan phenotype.  
 
4.2.4 Clinical examination and specular microscopy of the 
Parents of CHED affected cases 
 
Homozygous mutations in SLC4A11 cause CHED (Vithana et al., 2006), 
whereas heterozygous mutations in SLC4A11 are a rare cause of dominantly-
inherited FECD (Vithana et al., 2008). Given this, it was considered whether 
the parents of affected CHED patients, themselves heterozygous carriers for 
SLC4A11 mutations could be at risk of developing FECD. Therefore, the 
parents of each CHED patient, where available, were clinically evaluated for 
FECD. 
 
For each family the parents, who were related by consanguinity, did not 
manifest obvious visual problems. They underwent clinical examination 
followed by specular microscopy (SM). SM of the parents in Family A showed 
guttata, tiny excrescences in DM which are a hallmark of early FECD, in the 
44 year old father, whereas the 46-year-old mother’s scan showed moderate 
pleomorphism (disruption of the normal endothelial hexagonal pattern which 
may be seen in the initial stages of FECD before guttata are clearly visible) 
with a normal cell count (Figure 4.6).  
 
Variant Polyphen	2 SIFT PROVEAN Mutation	Taster CADD*
c.397T>C;	p.F133L Possibly	damaging Tolerated Deleterious Disease-causing Scaled	C-score
	(Score	0.479) (Score	0.37) 	(Score	-3.328) 	(Prediction	probability	0.9999) 23.6
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SM examination of the Family B mother at age 38 showed unremarkable 
images with a normal endothelial cell count. The Family B father aged 40 was 
unavailable for examination. Specular microscopic examination of the mother 
in Family C, aged 37 years, revealed guttata but a normal cell count (Figures 
1B and C). The father, aged 42 years, was unavailable for clinical 
examination. 
 
These results suggest that the heterozygous parents of CHED and Harboyan 
patients go on to develop FECD. 
 
Figure 4.6 Corneal endothelium analysis. A, Specular microscopy images of the 
father (I.1) and mother (I.2) of family A and also the mother (I.2) of family C are 
shown. B, The table highlights the values for cell density (per square millimeter), 
coefficient of variation, and percentage hexagonality for the specular microscopic 
images. As a guideline, cell density of 2500 cells per square millimeter at middle age 
is within the normal range, and this value decreases with age. A coefficient of 
variation greater than 0.4 and less than 50% hexagonality are indicative of an 
abnormal endothelium.
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4.3   Discussion  
 
In the results reported in this chapter, two previously described local families 
with CHED affected cases (Vithana et al., 2006) (Families A and B) were 
revisited and one new family (Family C) was recruited by Dr Juan Carlos 
Zenteno, Mexico City. Sanger sequencing of the SLC4A11 gene in the 
patients confirmed a novel homozygous missense mutation c.397T>C; 
p.F133L in Family C. Mutations in families A and B had been reported 
previously (Vithana et al., 2006). 
 
Four patients originally diagnosed with CHED were subsequently found to 
have varying degrees of sensorineural hearing loss at the higher frequency 
range following audiometric examination, suggesting that CHED often 
progresses to Harboyan syndrome. The heterozygous mutation-carrying 
parents of these patients were also investigated for early signs of FECD. Two 
out of the four parents that were available to be examined had guttata in their 
endothelium. Interestingly this additive pattern of inheritance for a mutation in 
SLC4A11 is somewhat similar to LRP5, in which dominant mutations and 
recessive mutations cause different eye phenotypes. Dominant mutations 
cause Familial Exudative Vitreoretinopathy (FEVR) and osteopenia or mild 
osteoporosis (Toomes et al., 2004) whereas recessive mutations cause 
OPPG (early onset retinal dysplasia and severe osteoporosis) (Gong et al., 
2001). Additionally, this is not the first time that mutations in a gene causing 
corneal endothelial disease (Riazuddin et al., 2012) have also been shown to 
cause deafness (Grillet et al., 2009). 
 
The basis for the phenotypic heterogeneity seen in homozygous SLC4A11 
mutation carriers with nonsyndromic CHED or Harboyan syndrome has been 
the subject of much speculation. The onset of progressive hearing loss in 
Harboyan syndrome has been described previously in children as young as 2 
years and adults as old as 33 years (Desir et al., 2007, Mehta et al., 2010). 
However auditory abnormalities have not been directly tested or serially 
monitored in these cases of isolated CHED (Vithana et al., 2006, Jiao et al., 
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2007, Kumar et al., 2007, Ramprasad et al., 2007, Aldave et al., 2007, 
Sultana et al., 2007, Hemadevi et al., 2008, Paliwal et al., 2010), suggesting 
that Harboyan syndrome may have gone undetected. As the type and location 
of null and missense SLC4A11 mutations identified in both conditions is 
similar, with no obvious clustering (Desir and Abramowicz, 2008), and the co-
existence of the conditions CHED and Harboyan syndrome within a family has 
been reported (Mehta et al., 2010), there is little evidence to support a genetic 
basis for the difference between them. Instead, the longitudinal study 
presented in this thesis suggests that CHED cases eventually experience 
some degree of sensorineural hearing loss and that the variable age of onset 
of these symptoms may be related to some unknown differences in the 
expression of genetic modifiers or exposure to environmental triggers.  
 
The auditory phenotype seen in Harboyan syndrome is consistent with the 
observation that SLC4A11 is not only expressed in the corneal endothelial 
cells but also in the fibrocytes of the stria vascularis in the inner ear (Lopez et 
al., 2009, Groger et al., 2010), cells with a common embryonic origin in the 
neural crest. SLC4A11 exists as a transmembrane homodimer (Park et al., 
2004) and transports sodium ions coupled to hydroxide  ions regulating pH in 
the corneal endothelium (Ogando et al., 2013, Jalimarada et al., 2013, Kao et 
al., 2015). It has been postulated that defective SLC4A11 expression could 
lead to compromised pH regulation affecting bicarbonate and lactic acid 
transport and depressing endothelial pump function (Jalimarada et al., 2013). 
Consistent with this theory is the finding that its absence in knockout mice 
causes accumulation of sodium chloride in the corneal stroma, collection of 
fluid in the normally relatively dehydrated cornea and morphological changes 
in fibrocytes resulting in deafness (Lopez et al., 2009, Groger et al., 2010). 
Examination of cells transfected with mutant SLC4A11 constructs shows that 
the mutant protein fails to glycosylate and is retained intracellularly, never 
reaching the cell surface (Vithana et al., 2006, Vithana et al., 2008). 
 
Dominant mutations in SLC4A11 cause FECD (Vithana et al., 2008)  which in 
most cases are caused by missense changes. Cell based biochemical assays 
using SLC4A11 constructs appear to distinguish between the mutations that 
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cause FECD and those that cause CHED (Vilas et al., 2012a). Co-expression 
of mutant SLC4A11 with the wild type construct causes partial rescue of most 
CHED-causing mutants but not those implicated in FECD. This is thought to 
be because, while most SLC4A11 mutations do not affect cell surface 
processing of the wild type SLC4A11, presence of the FECD mutant protein 
reduces wild-type processing at the cell surface, suggesting a possible 
explanation for the dominant inheritance pattern for this disorder. However, 
the work presented in this thesis highlights that parents of CHED patients, 
carrying heterozygous missense mutations in SLC4A11, may go on to 
develop guttata as early signs of FECD onset, which might contradict the 
dominant negative mechanism outlined. Serial audiometric monitoring of the 
CHED parents would perhaps be a more helpful additional investigation in 
determining the genetic mechanism underlying these phenotypes. Not only 
would this aid the early detection of a potential hearing deficit, if heterozygous 
mutations do cause haploinsufficiency of the SLC4A11 gene, then some 
degree of sensorineural hearing loss might be evident in the CHED parents. 
 
Given that CHED (Vithana et al., 2008) and Harboyan syndrome (Desir et al., 
2007) are caused by recessive mutations in SLC4A11 and some FECD cases 
are caused by dominant mutations in SLC4A11, it is perhaps surprising that 
these conditions had never been described within the same family at the time 
the study described in this thesis was performed. However, the increased 
susceptibility of the parents of CHED patients in developing FECD has since 
been described in a non-consanguineous family (Kim et al., 2015b). The 
proband’s 64-year-old father and sister were unaffected, but the 
asymptomatic 62-year-old mother was found to have bilateral guttata. When 
screened, the proband possessed a novel homozygous missense mutation 
c.1158C>A; p.Cys386* on exon 9 of SLC4A11, a mutation also harboured as 
a heterozygousvariant by the proband’s father, mother and sister. This caused 
a premature stop codon, predicted to result in a truncated SLC4A11 protein.  
At 62-years-old the mother presented with FECD. This is consistent with the 
observation that presentation usually occurs in affected patients in the fifth or 
sixth decade (Weiss et al., 2015). It is entirely feasible that the heterozygous 
parents of Family B, aged 38 and 40 years-old, were not yet old enough to 
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present with the clinical features of FECD. This raises the question of the 
value of future screening for FECD in the parents of CHED affected cases. 
Currently pre-symptomatic screening for FECD would not alter the treatment 
provided for FECD, although detection of the disease prior to the advanced 
stages of corneal epithelial involvement (Stage 5, Table 1.4 Introduction) 
might avoid the need to perform a full-thickness graft. Therefore there is 
arguably merit in vision screening of the parents of CHED patients in the 
community by their optometrist or screening of the corneal endothelium for 
guttata by a local ophthalmologist. 
 
Pathogenic variants tend to have markedly higher conservation than benign 
variants (Cooper et al., 2010) and indeed many of the variant pathogenicity 
prediction databases used for the assessment of missense variants 
incorporate conservation assessment into their algorithms (Adzhubei et al., 
2010, Ng and Henikoff, 2001, Schwarz et al., 2010b, Kircher et al., 2014). 
However predicting the pathogenicity of a variant is still fraught with 
challenges. The variant was found to be “Tolerated” in SIFT, yet three of the 
other pathogenicity prediction sites indicated that the variant was pathogenic  
(Table 4.2). The variant’s CADD score was 23.6. Scores of ≥ 20 are thought 
to represent the 1% most deleterious changes predicted in the human 
genome. However, there are many non-pathogenic variants in the human 
genome with CADD scores of above 20. Using a combination of pathogenicity 
databases and comparing the outputs is therefore a reasonable way of 
approaching this challenge.  
 
The 2015 International Corneal Dystrophy (IC3D) classification aimed to 
address much of the confusion surrounding some corneal dystrophy 
classification, and it has been suggested that the existence of a new corneal 
dystrophy must start with identification of the clinical phenotype and culminate 
in characterisation of the causative gene mutation (Weiss et al., 2015).  This 
has been reflected in the designation of the TGFβI corneal dystrophies, a 
category based on the molecular diagnosis of corneal dystrophies rather than 
the anatomical location. In this chapter, it has been concluded that the 
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unaffected heterozygous parents or siblings of CHED patients are at risk of 
developing late-onset FECD, individuals who would otherwise be regarded as 
clinically normal. The work presented in this chapter highlights the impact that 
an accurate molecular diagnosis can have on predicting the clinical prognosis. 
It also indicates that the pathways involved in the pathogenesis of two 
different endothelial dystrophies may share some similarities.  
 
CHED patients from Family B and C were noted to have raised IOP on initial 
examination under anaesthesia. In both patients this was in the absence of a 
previous keratoplasty, which is itself a risk factor for glaucoma (Kirkness and 
Moshegov, 1988). There are however no reports of the expression of 
SLC4A11 in the trabecular meshwork and aqueous outflow pathways (Patel 
and Parker, 2015). Embryologically, congenital glaucoma is a result of 
abnormal neural crest cell migration, whereas CHED results from abnormal 
cell differentiation (Bahn et al., 1984). It is therefore feasible that the two might 
co-exist and indeed this has been reported (Ramamurthy et al., 2007). In the 
absence of molecular confirmation, if faced with the diagnosis of glaucoma in 
CHED, a careful examination would need to be performed in order to exclude 
a diagnosis of PPCD, which is more commonly diagnosed with glaucoma 
(Weiss et al., 2015). 
 
The results presented in this chapter describe a novel mutation in SLC4A11. 
Discovering new mutations, especially missense ones, is of scientific interest 
as it informs future studies on the function of the protein. If a single amino acid 
change on a large protein disrupts protein function, this indicates that the 
amino acid performs a vital function. There is considerable allelic 
heterogeneity in CHED (Aldave et al., 2007) and no obvious correlation 
between the location of SLC4A11 mutations, the consequent domain of the 
SLC4A11 protein affected (Vilas et al., 2011) and the phenotype of CHED, 
Harboyan syndrome or FECD have been noted previously (Figure 4.7). 
However, one recent study has suggested that the cytoplasmic domain may 
play an essential role in the transport function of SLC4A11 (Loganathan et al., 
2016). Nonetheless, one implication a lack of clear mutation hotspots could be 
that, when ascertaining a molecular diagnosis in a newly presenting CHED 
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patient, it is likely that the entire coding region of the gene would need to be 
sequenced in order to find the causative mutation.  
 
Figure 4.7 Topology model for human SLC4A11. Identified point mutations 
causing CHED (blue) FECD (red) and Harboyan Syndrome (orange) are shown. The 
numbers indicate the amino acid position.  The predicted N-glycosylation sites are 
indicated in black. The black and grey arrowheads indicate trypsin cleavage sites 
identified through partial digestion of Myc-SLC4A11 and SLC4A11-Myc respectively. 
Reproduced with permission (Vilas et al., 2011). 
 
To conclude, CHED progresses to Harboyan syndrome in all the cases that 
have been studied and presented in this thesis, such that both conditions 
appear to be the same disease at different stages of development. When 
CHED is diagnosed, patients are frequently referred for audiometric 
assessment. Their hearing may initially fall within normal limits but it has been 
shown that it may progress subsequently. Therefore, CHED patients should 
be monitored for progressive hearing loss. Additionally, parents of CHED 
patients are SLC4A11 mutation carriers appear to be at increased risk of 
developing late-onset FECD and should be monitored for this. 
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The results presented in this chapter were published in the journal Cornea 
(Siddiqui et al., 2014). 
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5 Genetic Analysis of Fuchs Endothelial Dystrophy 
in Yorkshire 
5.1 Introduction 
 
FECD is a slowly progressive disease of the corneal endothelium (Krachmer 
et al., 2011). Its prevalence amongst Caucasians is approximately 4% over 
the age of 40 (Lorenzetti et al., 1967) and it accounts for about 22% of corneal 
transplants in the UK (Keenan et al., 2012). The condition is characterised by 
focal collagenous excrescences in DM called guttata seen on the posterior 
surface of the basement membrane and is accompanied by endothelial cell 
pleomorphism in the early stages. Progressive loss of endothelial cells causes 
loss of endothelial barrier and pump functions, leading to the influx of aqueous 
humour into the cornea resulting in corneal oedema, reduced corneal clarity 
and ultimately vision loss (Waring et al., 1978b). 
 
Early-onset FECD may present as early as the first decade (Weiss et al., 
2015). Missense changes in COL8A2 (MIM*120252) on chromosome 1p34.3-
p32 have been implicated in this rare form of disease (Biswas et al., 2001, 
Gottsch et al., 2005). Late-onset FECD is a common disease, typically 
presenting on average in the fifth decade, although guttata may be clinically 
apparent after the age of 40 (Elhalis et al., 2010). Many cases appear to be 
sporadic, although familial forms with apparent dominant inheritance have 
been documented (Krachmer et al., 1978). Late onset FECD is genetically 
heterogeneous. Rare causative mutations have been identified in SLC4A11 
(MIM*610206) (Vithana et al., 2006, Riazuddin et al., 2010b, Soumittra et al., 
2014, Kim et al., 2015b) as well as ZEB1/TCF8 (MIM*189909) (Riazuddin et 
al., 2010a, Lechner et al., 2013). Furthermore, familial inheritance in single 
pedigrees has been described for dominant loci on chromosomes 5 (FECD5, 
MIM%613269) (Riazuddin et al., 2009), 9 (FECD7, MIM%613271) (Riazuddin 
et al., 2010a) and 13 (FECD2, MIM%610158) (Sundin et al., 2006b), although 
the mutations involved have not yet been identified.  
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During the course of the studies reported in this thesis, rare dominant 
mutations in LOXHD1 (MIM*613072) (Riazuddin et al., 2012), which maps 
close to the FECD3 locus on chromosome 18 (MIM%613267) (Sundin et al., 
2006a)), and AGBL1 (MIM*615496) (Riazuddin et al., 2013), that maps within 
the FECD8 locus on chromosome 15, have been reported to cause late-onset 
FECD (section 1.10.7). Mutations in AGBL1 have not yet been replicated 
independently in another cohort. Recently, 128 FECD cases were examined 
and novel mutations in LOXHD1 were detected, however as this is an 
unpublished thesis, full details of these variants are not yet available (Kuot, 
2015). 
 
FECD has previously been mapped to chromosome 18q and the locus 
designated FECD3. Subsequently, Baratz et al (Baratz et al., 2010) performed 
a small-scale genome wide association study (GWAS) using 130 FECD cases 
and 260 controls. Controls subjects were 60-years-old or over and had no 
observable guttata. This identified one SNP, rs613872, in intron 3 of TCF4 
(MIM*602272) that reached genome-wide significance, with the G allele 
significantly enriched in FECD cases compared with controls. Close to this 
SNP lies an intronic trinucleotide repeat expansion, CTG18.1, which was 
found to be even more strongly associated with FECD and has been shown to 
exist in 79% of cases compared to only 3% of controls (Wieben et al., 2012). 
The TCF4 gene lies within the FECD3 locus on chromosome 18q. Towards 
the beginning of the studies described in this thesis, Riazuddin et al published 
mutations in the LOXHD1 gene, which maps just outside the critical interval 
for the FECD3 locus, as a cause of dominant late-onset FECD (Riazuddin et 
al., 2012). The positions of the rs613872 SNP and CTG18.1 repeat in TCF4, 
the LOXHD1 gene and the FECD3 locus are shown in Figure 5.1. The 
physical position shows that the two genes are within 9.2Mb of each.  
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Figure 5.1 Graphical representation of part of the FECD3 locus and 
surrounding region, including positions of the TCF4 and LOXHD1 genes. All 
physical positions and distances are based on the hg19/GRCh37 version of the 
genome sequence and intervals are relative to the top of the p-arm of chromosome 
18. The gene positions, their length and details of the most common transcript 
isoform for each are depicted. The positions of the TCF4 variants rs17089887, 
rs613872 and CTG18.1, shown to be associated with FECD, are shown.  
 
This chapter describes the genetic analysis of a Caucasian FECD cohort, 
recruited and sampled from Ophthalmology clinics and theatre lists in 
Yorkshire, that consists mostly of single cases but also includes 3 families 
with multiple affected members. The cohort of genomic DNA samples from 
FECD cases was recruited in two phases. At the start of the project, 56 
genomic DNA samples from unrelated FECD cases and 1 family had been 
ascertained by Dr Aine Rice (University of Leeds) and SS. During the course 
of the genetic analysis, a further 61 DNA samples were ascertained and 2 
families recruited. The total FECD cohort contained 117 unrelated cases. 
 
The aim of this study was to analyse this cohort of Yorkshire FECD patients to 
identify genes involved in the pathogenesis of FECD. In the first instance this 
involved investigating LOXHD1 to try and confirm the published data, 
especially given the inconsistencies between the FECD3 mapping data and 
the LOXHD1 mutation identification data. Similarly, the TCF4 expansion was 
investigated to in order to clarify the significance of the original findings. 
Alongside this, WES was used to try and identify the causative mutations in 
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the FECD families and transcriptome analysis of normal corneal endothelia 
was attempted to prioritise candidates in the WES data. 
 
5.2 Results 
5.2.1 Recruitment of local FECD families 
 
Following ethical approval, the proband of a large Caucasian FECD family, 
FECDBRI, was identified in the BRI Ophthalmology Clinics by Mr Nigel 
James, Consultant Ophthalmologist at Bradford Royal Infirmary (Figure 5.2). 
Members of the family were subsequently examined by slit-lamp, recruited 
and sampled at St. James’s University Hospital, Leeds following their 
informed consent. The proband had three affected siblings. One additional 
sibling had very mild pigmented endothelial changes but could not be 
classified as having FECD so her diagnosis remained uncertain. Specular 
microscopy images of the oldest unaffected individual and the proband are 
shown in Figure 5.3. 
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Figure 5.2 Pedigree of the FECD family FECDBRI. Family members for whom DNA was available are labelled. The arrow indicates the 
proband. Individuals II:9 and III:5 have an uncertain diagnosis. 
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A                        B 
Figure 5.3 Specular microscopy of A. an unaffected and B. an affected member 
of the FECDBRI family. A shows the normal polygonal pattern of packed endothelial 
cells B. shows loss of the normal mosaic pattern of the endothelium with reduced 
endothelial cell count, polymegathism and pleomorphism. Several guttata are visible, 
one of which is indicated by the red arrow.  
 
5.2.2 Screening for the previously published FECD causing COL8A2 
mutation in the FECDBRI family 
 
Early onset FECD is a distinct form of FECD (Weiss et al., 2015) caused by 
mutations in the COL8A2 gene (Biswas et al., 2001). Individuals in FECDBRI 
presented with their symptoms between the ages of 40 and 50 years, and 
were therefore thought to have late-onset FECD. However, as one of the 
families first reported with a COL8A2 mutation originated from Yorkshire, the 
possibility that a common founder mutation existed in the FECDBRI family  
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was explored. Primer pairs for exon 2 of COL8A2 (Appendix III) containing 
the published mutation, c.1363C>A, p.Q455K, were used to amplify and 
Sanger sequence the proband’s DNA. For comparison, genomic DNA from an 
affected member of the original pedigree with a COL8A2 mutation was also 
sequenced (Figure 5.4). It was found that the proband in the FECDBRI family 
did not have the COL8A2 mutation, suggesting that the cause of their FECD 
remained unknown. 
 
 
 
Figure 5.4 Sequence chromatograms of COL8A2 exon 2 derived from DNA of 
the FECDBRI proband, a known mutation carrier and wild-type control. The 
heterozygous c.1363C>A, p.Q455K mutation is indicated by an arrow in the mutation 
control.  
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5.2.3 Genetic analysis of the chromosome 18 FECD locus in a local 
FECD family and the Yorkshire cohort 
 
5.2.3.1 Microsatellite linkage analysis across the FECD3 locus on 
chromosome 18 in the FECDBRI family 
 
At the start of this PhD, the plan had been to test this family for linkage to all 
of the known loci (Sundin et al., 2006b, Sundin et al., 2006a, Riazuddin et al., 
2009, Riazuddin et al., 2010a).  In September 2011, CFI spoke to Professor 
Nicholas Katsanis, Duke University Medical Center at a conference. It was 
discussed that his team had identified the causative mutation in the locus on 
chromosome 18. Therefore, it was decided that microsatellite analysis of this 
in the FECDBRI would commence with the locus on chromosome 18 (Sundin 
et al., 2006a). 
 
Genomic DNA from family members was genotyped using microsatellite 
markers as described in Section 2.12. The markers used and their genetic 
distance from the top of the chromosome (according to the Marshfield genetic 
map) (Broman et al., 1998)  were D18S1152 at 80.41 cM, D18S1144 at 82.25 
cM, D18S1103 at 83.46 cM and D18S64 at 84.80 cM. An example of a 
microsatellite genotyping electropherogram is shown in Figure 5.5. The 
genotyped values corresponding to the size of each marker for each family 
member have been plotted onto the pedigree to generate haplotypes (Figure 
5.6). From this analysis, it appears that all the affected cases were found to 
share a common haplotype 268/175/242/190, consistent with linkage to 
FECD3. However, this haplotype was also present in the individual of 
uncertain diagnosis, which might suggest that they are predisposed to 
developing the condition at a later stage or it may be suggest that the 
haplotype has nothing to do with FECD risk and has occurred by chance. 
 
Linkage analysis was carried out using Superlink as described in Section 2.12 
under a dominant model of inheritance with a 99% penetrance and zero 
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phenocopy rate. Disease allele frequency was taken as 0.001. Assuming the 
case with an uncertain diagnosis was affected, the maximum lod score that 
could be obtained was 2.0980. Without these assumptions about clinical 
status and phenocopy, a lod score of 2 would have been significant given the 
previous published linkage study to chromosome 18 (Sundin et al., 2006a). 
However, although the haplotype analysis suggested linkage to chromosome 
18, this could not be confirmed as significant on the basis of statistics as the 
lod score was below 3.0 and suggested that association of this haplotype with 
FECD remained inconclusive. 
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Figure 5.5 Examples of genotyping electropherograms for the chromosome 18 
microsatellite marker D18S1103. Traces for FECDBRI individuals A. II:2 B. II:5 C. 
II:3 are shown.
A. 
B. 
C. 
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Figure 5.6 Chromosome 18 haplotypes across the FECD3 locus for the FECBRI family. The allele sizes for the markers D18S1152, 
D18S1144, D18S1103 and D18S64 are shown from the top to the bottom of the haplotype respectively. A common heterozygous region that is 
indicated in blue is shared amongst the affected individuals, as well as being carried by individuals II.7 and III.5 who are of uncertain diagnosis
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5.2.3.2 The LOXHD1 mutation spectrum in local Caucasian FECD 
cases 
 
Following identification of mutations in LOXHD1 gene on chromosome 18 as 
causative for FECD in February 2012 (Riazuddin et al., 2012), the spectrum of 
LOXHD1 variants in the Yorkshire cohort was assessed. Genomic DNA from 
the proband of FECDBRI and 55 unrelated FECD patients, 10 of whom had a 
family history, were included in this screen. The mean age of these cases at 
venesection was 71.7 +/- 9.5 years, ranging between 48 and 91 years old. 40 
of the 56 cases (71%) were female. The cohort was screened by Sanger 
sequencing for variants in LOXHD1. To do this, primer pairs were initially 
designed against all the 40 exons of transcript NM_144612 and the two 
additional splice variant exons in transcripts NM_001145472.2 and 
NM_001173129 of LOXHD1. The primers were optimized before screening for 
variants in whole genome amplified DNA samples from the patient cohort. All 
variants found on the initial screen were confirmed in an independent PCR 
using unamplified DNA from stock solutions. Primer pairs and reaction 
conditions are shown in Appendix III.  
 
An agarose gel showing amplification of exon 32 in samples 47 to 55 is shown 
in Figure 5.7. 
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Figure 5.7 Agarose gel image after UV illumination showing amplification of 
exon 32 of LOXHD1. Samples 47-55 of the FECD cohort are shown. The expected 
band size is 409bp. NC indicates the negative control. 
 
Sequence variants were considered significant if they were within the coding 
region of the gene or the two base pair splice recognition sites on either side 
of the exon, and were non-synonymous. All variants were found in LOXHD1 
transcript NM_144612. There were no variants found in transcript 
NM_001145472.2 or NM_001173129.   
 
Table 5.1 summarises the 16 variants that were found. All of the sequence 
changes were heterozygous in the subjects. In order to identify the LOXHD1 
variants that were likely to be pathogenic, any variants that had a minor allele 
frequency greater than 4% in either the 1000 Genomes or the Exome Variant 
Server databases were excluded. The threshold of 4% was selected as this 
was the purported frequency of FECD (Lorenzetti et al., 1967). Variants were 
also assessed for pathogenicity using various mutation prediction programs. 
They were considered potentially pathogenic if at least one of these 
predictions was consistent with high pathogenicity, including scores of 
“Possibly” or “Probably Damaging” when assessed by Polyphen (HDIV), 
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“Damaging” on SIFT, “Deleterious” on PROVEAN or “Disease-causing” with 
Mutation Taster (Section 2.17). The LOXHD1 sequence variants that passed 
these filtering criteria are highlighted in Table 5.2. The evolutionary 
conservation of the variants was also assessed using ClustalW (Section 2.18) 
and the multiple sequence alignments are shown in Figure 5.8.  
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Variant
No of samples 
containing variant Samples containing change Polyphen Prediction (HDIV) SIFT prediction PROVEAN Prediction Mutation Taster
1000 genomes Variant 
Frequency (%)
EVS Variant 
Frequency (%)
c.2T>A, p.M1K 4 25, 26, 32, 53 Possibly Damaging Damaging Neutral Polymorphism 3.5 4.0
c.889A>C ,p.T297P 1 3 Benign Tolerated Neutral Polymorphism 0.3 0.1
c.1087G>A, p.V363I 11 3, 9, 11, 14, 18, 21, 23, 29, 31, 36, 53 Benign Tolerated Neutral Polymorphism 7.8 9.0
c.1570C>T, p.R524C 1 31 Probably Damaging Damaging Deleterious Disease Causing 0.0 0.0
c.1876G>T, p.G626C 2 32, 38 Probably Damaging Damaging Deleterious Disease Causing 1.6 1.4
c.1894G>T, p.G632C 2 32, 38 Probably Damaging Damaging Deleterious Disease Causing 1.6 1.4
c.2473G>A, p.V825M 4 33, 38, 41, 48 Benign Tolerated Neutral Polymorphism 7.2 8.7
c.2558G>C, p.R853P 1 40 Benign Tolerated Deleterious Disease Causing 0.0 0.0
c.2825_2827delAGA, 
pK942del
1 40 Unknown Unknown Neutral Polymorphism 2.3 5.8
c.2998C>T, p.R1000W 1 16 Probably Damaging Damaging Deleterious Polymorphism 0.0 0.1
c.3463A>G, p.R1155G 55 All samples except 43 Benign Tolerated Neutral Polymorphism 16.8 83.5
c.4868A>G, p.E1623G 11 1, 6, 9, 11, 17, 23, 26, 36, 37, 38, 47 Probably Damaging Tolerated Deleterious Polymorphism 9.2 11.5
c.5545G>A, p.G1849R 1 31 Probably Damaging Damaging Deleterious Disease Causing 0.0 0.0
c.5616C>A, p.N1872K 2 29, 53 Benign Tolerated Neutral Polymorphism 0.7 0.7
c.6107C>T, p.A2036V 15 4, 5, 6, 11, 18, 19, 20, 21, 25, 26, 29, 31, 35, 41, 56 Benign Tolerated Neutral Polymorphism 22.3 0.0
c.6398G>A, p.R2133H 6 6, 9, 11, 17, 23, 36 Benign Tolerated Deleterious Disease Causing 7.3 8.0  
Table 5.1 All LOXHD1 (NM_144616) variants detected in the first 56 patients recruited in the Yorkshire FECD cohort. An assessment of 
their variant frequency in known databases, pathogenicity prediction and in whom they were identified are depicted. The databases used were 
Polyphen2 (HDIV) http://genetics.bwh.harvard.edu/pph2/, (Adzhubei et al., 2010), SIFT, http://sift.jcvi.org (Ng and Henikoff, 2001), PROVEAN, 
http://provean.jcvi.org/index.php (Choi et al., 2012), Mutation Taster http://www.mutationtaster.org (Schwarz et al., 2010b), 1000 genomes 
(http://www.1000genomes.org) and EVS (http://evs.gs.washington.edu/EVS/databases).  
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Variants Variant frequency: 1000 genomes (%)
Variant frequency: 
Exome variant server 
(%)
Polyphen 
(HDIV) SIFT PROVEAN 
Mutation 
Taster
Sample ID containing the 
variant
c.1570C>T, p.R524C 0.0 0 Probably Damaging Damaging Deleterious Disease Causing 31
c.1876G>T, p.G626C 1.6 1.4 Probably Damaging Damaging Deleterious Disease Causing 32, 38
c.1894G>T, p.G632C 1.6 1.4 Probably Damaging Damaging Deleterious Disease Causing 32, 38
c.2558G>C, p.R853P 0.0 0.0 Benign Tolerated Deleterious Disease Causing 40
c.2998C>T, p.R1000W 0.0 0.1 Probably Damaging Damaging Deleterious Polymorphism 16
c.5545G>A, p.G1849R 0.0 0.0 Probably Damaging Damaging Deleterious Disease Causing 31  
Table 5.2 List of putative pathogenic LOXHD1 variants that were identified in Caucasian FECD cases. The LOXHD1 variants remaining 
after filtering for variant frequency in known databases and pathogenicity prediction. ID for the sample in whom they were identified is also 
given.  
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Figure 5.8  Protein sequence alignment of LOXHD1 orthologues around the 
predicted pathogenic variants that were identified in the FECD cases. Each 
variant, a. p.R524C, b. p.G626C, p.G632C, c. p.R853P, d. p.R1000W and e. 
p.G1894R, is highlighted in red and the surrounding amino acids that are identical to 
the human transcript are shaded in grey. Accession numbers for LOXHD1 sequence 
are NP_653213.6 (human), XP_009432217.1 (chimp), NP_001099602.3 (rat), 
XP_547589.3 (dog), XP_003587840.2 (cow), XP_425221.4 (chicken) and 
XP_007055242.1 (turtle).  
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5.2.3.3 The LOXHD1 mutation spectrum in 1000 Genomes database 
 
The published LOXHD1 study (Riazuddin et al., 2012) used a Mendelian 
model to implicate LOXHD1 in a dominant family but used a case-control 
approach to assess the mutational load. A similar approach was used in this 
thesis except that at this point in the PhD there were no ethnically-matched 
controls that had been examined to exclude endothelial disease. Therefore, 
the 1000 genomes database was utilised for the ascertainment of controls.  
 
For the LOXHD1 variant dataset from population controls, the 1000 Genomes 
database was accessed in July 2014. The database was interrogated for any 
cases of Caucasian origin that had a read depth of 5 for at least 85% of the 
LOXHD1 gene. A dataset of 467 individuals (934 alleles) who satisfied these 
criteria was subsequently mined for sequence variation in LOXHD1. Any 
sequence variants were included into the study if they were within the coding 
region of the gene as well as the two base pair splice recognition sites either 
side of the exon. However synonymous variants were excluded. A complete 
list of the 21 LOXHD1 variants found in controls from the 1000 Genomes 
database is given in Table 5.3. 
 
In order to establish which LOXHD1 variants were more likely to be 
pathogenic, any variants that had a minor allele frequency greater than 4% in 
either the 1000 Genomes or the Exome Variant Server databases were 
excluded. Variants were also assessed for pathogenicity according to the 
same mutation prediction programs used to filter variants found in the FECD 
cohort. As for the FECD cases, they were retained if at least one of these 
predictions was consistent with high pathogenicity such as “Possibly” or 
“Probably Damaging” when assessed by Polyphen (HDIV), “Damaging” on 
SIFT, “Deleterious” on PROVEAN or “Disease-causing” by Mutation Taster 
(Section 2.17). The LOXHD1 sequence variants that passed these filtering 
criteria are highlighted in Table 5.4.  
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Variants
1000 Genome 
Variant Frequency
1000 Genome 
Variant 
Frequency (%) SNP ID
Polyphen 
Prediction (HDIV) SIFT Prediction Provean prediction Mutation Taster Prediction
Variant Frequency 
in EVS (%)
c.2T>A, p.M1K 33/934 3.5 rs36024592 Possibly Damaging Damaging Neutral Polymorphism 4.0
c.410G>A, p.R137H 3/934 0.3 rs151268914 Probably Damaging Tolerated Neutral Disease causing 0.0
c.722A>G, p.N241S 2/934 0.2 rs191697915 Probably Damaging Tolerated Deleterious Polymorphism 0.0
c.889A>C, p.T297P 3/934 0.3 rs117747744 Benign Tolerated Neutral Polymorphism 0.1
c.1087G>A, p.V363I 73/934 7.8 rs10163657 Benign Tolerated Neutral Polymorphism 9.0
c.1876G>T, p.G626C 15/934 1.6 rs34589386 Probably Damaging Damaging Deleterious Disease causing 1.4
c.1894G>T, p.G632C 15/934 1.6 rs35088381 Probably Damaging Damaging Deleterious Disease causing 1.4
c.2027A>G, p.D676G 2/934 0.2 rs16978578 Benign Tolerated Neutral Polymorphism 0.0
c.2080G>T, p.D694Y 1/934 0.1 rs35727744 Probably Damaging Damaging Deleterious Disease causing 0.0
c.2473G>A, p.V825M 68/934 7.2 rs36086089 Benign Tolerated Neutral Polymorphism 8.7
c.2554A>G, p.S852G 2/934 0.2 rs183848033 Probably Damaging Tolerated Deleterious Disease causing 0.0
c.2771G>A, p.R924Q 1/934 0.1 rs140904207 Benign Tolerated Neutral Polymorphism 0.0
c.2825_2827del, 
p.K942del
22/934 2.3 rs142960762 Unknown Unknown Neutral Polymorphism 5.8
c.3269G>A, p.R1090Q 23/934 2.5 rs118174674 Probably Damaging Tolerated Deleterious Disease causing 1.9
c.3463A>G, p.R1155G 157/934 16.8 rs1893566 Benign Tolerated Neutral Polymorphism 83.5
c.4148C>T, p.T1383M 4/934 0.4 rs7244681 Possibly Damaging Tolerated Neutral Disease causing 0.1
c.4217C>T, p.A1406V 3/934 0.3 rs146739496 Possibly Damaging Damaging Neutral Disease causing 0.2
c.4868A>G, p.E1623G 86/934 9.2 rs12606417 Possibly Damaging Tolerated Deleterious Polymorphism 11.5
c.5616C>A, p.N1872K 7/934 0.7 rs61733519 Benign Tolerated Neutral Polymorphism 0.7
c.6107C>T, p.A2036V 208/934 22.3 rs1377016 Benign Tolerated Neutral Polymorphism 0.0
c.6398G>A, p.R2133H 68/934 7.3 rs74316327 Benign Tolerated Deleterious Disease causing 8.0  
Table 5.3 All LOXHD1 variants found in Caucasian controls derived from the 1000 Genomes, together with assessment of likely 
pathogenicity. The cohort of Caucasian samples that were screened for variants consisted of 467 controls. The databases used were 
Polyphen2 (HDIV) http://genetics.bwh.harvard.edu/pph2/, (Adzhubei et al., 2010), SIFT, http://sift.jcvi.org (Ng and Henikoff, 2001), PROVEAN, 
http://provean.jcvi.org/index.php (Choi et al., 2012) and Mutation Taster http://www.mutationtaster.org (Schwarz et al., 2010b). Additionally their 
frequency in the 1000 genomes (http://www.1000genomes.org) and EVS (http://evs.gs.washington.edu/EVS/databases) are shown.  
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Variants Variant frequency: 1000 genomes (%)
Variant frequency: 
Exome variant server 
(%)
Polyphen 
(HDIV) SIFT PROVEAN 
Mutation 
Taster
Sample ID containing the 
variant
c.410G>A, p.R137H 0.2 0.0 Probably Damaging Tolerated Neutral Disease Causing 19752
c.722A>G, p.N241S 0.2 0.0 Probably Damaging Tolerated Deleterious Polymorphism 1492
c.1876G>T, p.G626C 2.3 1.4 Probably Damaging Damaging Deleterious Disease Causing
1149, 1247, 1624, 1779, 7347, 
11840, 20519, 20586, 20758, 
20765, 20792, 20806; homo alt 
1241
c.1894G>T, p.G632C 2.3 1.4 Probably Damaging Damaging Deleterious Disease Causing
1149, 1247, 1624, 1779, 7347, 
11840, 20519, 20586, 20758, 
20765, 20792, 20806; homo alt 
1241
c.2080G>T, p.D694Y 0.2 0.0 Probably Damaging Damaging Deleterious Disease Causing 19734
c.3269G>A, p.R1090Q 2.8 0.0 Probably Damaging Tolerated Deleterious Disease Causing
128, 149, 156, 1167, 1271, 1624, 
1747, 1775, 12154, 20507, 20509, 
20517, 20756, 20761, 20803; homo 
alt 6985
c.4148C>T, p.T1383M 0.3 0.1 Possibly Damaging Tolerated Neutral Disease Causing 1704, 19734 
c.4217C>T, p.A1406V 0.3 0.2 Possibly Damaging Damaging Neutral Disease Causing 135, 1679  
Table 5.4 List of putative pathogenic LOXHD1 variants identified in 1000 Genomes database controls. The LOXHD1 variants remaining 
after filtering for pathogenicity, their allele frequency in known databases, pathogenicity predictions and in whom they were identified are 
depicted. All the sequence changes identified were heterozygous in the subjects apart from three cases designated “homo alt”. The databases 
used were Polyphen2 (HDIV) http://genetics.bwh.harvard.edu/pph2/, (Adzhubei et al., 2010), SIFT, http://sift.jcvi.org (Ng and Henikoff, 2001), 
PROVEAN, http://provean.jcvi.org/index.php (Choi et al., 2012) and Mutation Taster http://www.mutationtaster.org (Schwarz et al., 2010b). 
Additionally their frequency in the 1000 genomes (http://www.1000genomes.org) and EVS (http://evs.gs.washington.edu/EVS/databases) are 
shown
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5.2.3.4 Comparison of the predicted pathogenic LOXHD1 variant findings 
in the Caucasian FECD cohort and 1000 Genomes database 
controls 
 
From Table 5.1 and Table 5.3 some of the variants were present in individuals who 
carried only a single heterozygous LOXHD1 coding variant, while other individuals 
had two or more variants. Although it was not easily possible to establish the phase 
of multiple variants found in a single individual, it was observed that LOXHD1 
variants p.G626C and p.G632C were always found to co-exist in the same 
individuals and were present at exactly the same frequency in the 1000 Genomes 
and Exome Variant Server databases, suggesting that these variants are almost 
certainly in phase and represent a single complex allele. These variants are 
therefore considered to be a single allele in subsequent analyses.  
 
In terms of comparison of the results, there were two ways the analysis could be 
interpreted, either based on the number of predicted pathogenic alleles identified in 
each cohort or the number of cases with predicted pathogenic alleles. Table 5.5 
summarises these comparisons that were derived from Table 5.2 and Table 5.4 for 
FECD and controls respectively. The results highlight that 6 out of 112 (5.4%) 
potentially pathogenic LOXHD1 alleles were identified in the FECD cohort, whereas 
38 out of 934 (4.1%) pathogenic alleles were identified in the controls, suggesting a 
modest 1.33 fold increased prevalence of alleles amongst the FECD cohort 
compared to controls (Table 5.5). The pathogenic LOXHD1 alleles exist in 5 out of 
56 (8.9%) FECD cases compared to 34 out of 467 (7.3%) controls, suggesting a 
1.24 fold increased enrichment amongst the FECD cases (Table 5.5). 
 
In summary, the Yorkshire FECD cohort was screened for sequence variations in the 
LOXHD1 gene, and the results were compared with controls from the 1000 
Genomes database. This analysis revealed only a modest enrichment of LOXHD1 
putative pathogenic alleles in FECD cases compared with controls, suggesting that 
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mutations in LOXHD1 are unlikely to be the major contributor to FECD onset that 
was previously identified on chromosome 18 (Sundin et al., 2006a).  
 
 
Table 5.5 Comparison of LOXHD1 variant findings in FECD cases and controls. The 
frequency of LOXHD1 alleles predicted to be pathogenic (A) and subjects containing a 
putative pathogenic LOXHD1 variant (B) are shown. n= the number of cases, P= the p 
value, OR= odds ratio. 
 
5.2.3.5 Genetic analysis of the TCF4 intronic polymorphism, rs613872, in 
Caucasian FECD cases, ECACC controls and 1000 Genomes 
database population controls 
 
 
In order to identify whether the GWAS SNP that was associated with FECD in 
Caucasians (Baratz et al., 2010) was associated in the Yorkshire FECD cohort, 
genomic DNA from the 56 unrelated FECD patients and 192 normal control DNAs 
obtained from the ECACC, were genotyped for the TCF4 intronic polymorphism, 
rs613872 by Sanger sequencing. The ECACC control cohort were all Caucasians of 
UK origin. The gender balance was 48% (92/192) females in the ECACC human 
random control group compared to 71% (40/56) in the cases and mean age at 
venesection was 38.7 +/- 8.4 and 71.6 +/- 9.5 years respectively. Sequence 
chromatograms of the three representative genotypes are shown in Figure 5.9 and 
the results summarised in Table 5.6. As a comparison for population control dataset, 
the rs613872 genotypes were also downloaded from the 1000 Genomes database 
for 467 unrelated Caucasian individuals. The results showed that the G allele for the 
Cases Controls P OR
n = 56 n = 467
Number of alleles 112 934 0.45 1.33 (0.55 - 3.23)
Predicted pathogenic alleles 6 38
Frequency 0.054 0.041
Number of subjects 56 467 0.65 1.24 (0.46 - 3.33)
Subjects with pathogenic variant 5 34
Frequency 0.089 0.073
A
B
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intronic polymorphism, rs613872, which had previously been shown to be associated 
with FECD (Baratz et al., 2010, Li et al., 2011, Riazuddin et al., 2011, Kuot et al., 
2012, Eghrari et al., 2012, Igo et al., 2012, Stamler et al., 2013), was identified in 
73% (41/56) of FECD cases compared to 32% (62/192) and 26% (123/467) in the 
different control subject groups. These differences were statistically significant (P = 
2.77 x 10-7 and 9.77 x 10-12) with an odds ratio of 3.81 and 4.47 respectively. 
 
 
 
Figure 5.9 Chromatograms from three FECD samples that had been sequenced for the 
polymorphic SNP, rs613872. The TT, TG and GG genotypes are shown. 
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Table 5.6 Summary of SNP rs613872 genotyping on Caucasian FECD cases and population controls. The subjects were 
categorised for rs613872 according to their G/T genotyped allele status. Caucasian controls were from ECACC* or the 1000 Genomes 
database (July 2014)**. The rs613872 genotyped alleles were in Hardy-Weinberg Equilibrium. 
 
 
 
Cases Controls* Controls**
n = 56 n = 192 n = 467
GG 8 7 2.77 x 10-7 3.81 (2.29 - 6.34) 15
GT 33 55 108
TT 15 130 344
P OR (95% CI) P OR (95% CI)
rs
61
38
72
9.77 x 10-12 4.47 (2.95 - 6.76)
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5.2.3.6 Genetic analysis of the trinucleotide expansion, CTG18.1, in 
Caucasian FECD cases and ECACC controls 
 
The FECD and ECACC control cohorts were also genotyped for the 
previously associated TCF4 trinucleotide repeat polymorphism, CTG18.1. The 
existence of the CTG18.1 trinucleotide repeat was established using the short 
tandem repeat (STR) and Triplet-Primed PCR (TP-PCR) previously described 
(Warner et al., 1996). Primer sequences for both assays are detailed in 
Appendix IV. 
 
The STR genotyping assay uses primer pairs flanking the CTG repeat 
sequence and measures unexpanded CTG18.1 alleles up to 43 trinucleotide 
repeats in length. This threshold is determined by the assay. However, this 
assay can fail to amplify expanded alleles, and hence the requirement for 
parallel analysis using the TP-PCR assay. This detects expanded CTG18.1 
alleles by using a trinucleotide repeat specific 3’ primer that binds at numerous 
sites within the CTG repeat paired with a fixed locus-specific 5’ primer, 
resulting in a mixture of products. The TP-PCR assay allows discrimination 
between the cases with a homozygous unexpanded allele and heterozygous 
cases with one unexpanded and one expanded allele. Characteristic traces 
for the TP-PCR assay are shown in Figure 5.10.  
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A 
 
B 
 
C 
 
 
Figure 5.10 TP-PCR electropherograms for assessing CTG18.1 trinucleotide 
repeat. A. Pattern for a subject with 2 unexpanded alleles at CTG18.1 (the sizes 
determined by STR assay), B. An individual with an expansion and one unexpanded 
allele (again the size of the unexpanded allele determined by STR) and C. A case 
with two expanded alleles (since no product on STR assay).
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A summary of the results of the STR and TP-PCR analysis to determine 
CTG18.1 trinucleotide repeat in FECD cases and controls is given in Table 
5.7. The STR assay failed to detect any alleles in 7% (4/56) of FECD cases 
compared to 0% (0/192) in controls. The 4 FECD cases that failed to detect 
any alleles following STR assay gave the characteristic pattern for an 
expanded allele after the TP-PCR assay, suggesting homozygosity for the 
expansion. It was noted that 68% (38/56) of the FECD cases in the study 
described here had at least one expanded CTG18.1 allele compared with only 
7% (14/192) in the control subjects. The differences between the cases and 
controls were analysed using Fischer’s exact test. This was statistically 
significant (P = 3.43 x 10-14) with an odds ratio of 15.88. 
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Table 5.7 Summary of the CTG18.1 trinucleotide repeat analysis on the FECD cases and ECACC controls. The subjects were 
categorised for CTG18.1 according to the presence (X) or absence (S) of the trinucleotide expanded allele. The CTG18.1 genotyped alleles, 
which consist of two category groups (denoted X and S) based on trinucleotide repeat number being greater than or less than 43 repeats in 
length respectively were out of Hardy-Weinberg Equilibrium in cases (P = 0.045)
Cases Controls*
n = 56 n = 192
XX 4 0 3.43 x 10-14 15.88 (7.77 - 32.45)
SX 34 21
SS 18 171
P OR (95% CI)
C
TG
18
.1
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5.2.3.7 Relationship between the TCF4 trinucleotide expansion and 
the LOXHD1 variants found in the FECD cohort  
 
The 5 cases with LOXHD1 variant alleles described in Section 5.2.3.4 were 
investigated for their trinucleotide expansion status. Table 5.8 summarises the 
number of cases with (LOXHD1/X) and without (LOXHD1/S) an expansion. 
The observations show that more than 50% of the LOXHD1 variant cases 
have an expansion polymorphism at CTG18.1, suggesting that the TCF4 
expansion rather than the LOXHD1 variant may be causal in these cases. 
This provides further evidence that LOXHD1 variants are not a significant 
cause of FECD in this cohort. 
 
Co-existence 
Cases 
n = 5 
LOXHD1/X 3 
LOXHD1/S 2 
Table 5.8 Relationship between the LOXHD1 variants and the CTG18.1 
trinucleotide repeat in FECD cases.  
 
5.2.3.8 Recruitment of endothelium-checked controls and 
additional FECD cases 
 
The analysis of LOXHD1 variants and TCF4 expansion in 56 patients 
(Sections 5.2.3.2 to 5.2.3.7) was written up in a manuscript and submitted for 
publication. The reviewers were positive about many aspects of the study, but 
felt that the number of cases in the LOXHD1 part of the study was inadequate 
to confidently refute the findings of the original study. Additionally, they were 
critical of the lack of controls that had been examined for endothelial disease. 
The ECACC controls used for the TCF4 analysis were commercially available, 
but were not age-or sex-matched and had not had their corneas examined. 
Therefore, it was feasible that a proportion of the control individuals who 
carried the TCF4 expansion would go on to develop FECD. Cognisant of this 
 126 
potential weakness in study design, 83 age-matched controls with healthy 
endothelium were identified from Leeds Teaching Hospitals Trust NHS 
Cataract Clinics by Consultant Ophthalmologist, Mr John Buchan and 
recruited at St. James’s University Hospital, Leeds. This control group had a 
mean age at venesection of 76.7 +/- 7.7 years (range 56 – 93 years old) and 
52% (43/83) were female. 
 
During this time, further recruitment of 61 additional FECD cases had also 
taken place onto the NIHR portfolio project UKCRN 11297. In total, the FECD 
cohort now included 117 patients, of whom 65% (71/117) were female and the 
mean age at venesection was 70.8 +/- 9.2 years (range 48-94 years).   
 
The publication of the TCF4 RNA foci experiments (Du et al., 2015, Mootha et 
al., 2015) (Section 5.3.2) provided a clear mechanism of disease for 
mutations in this gene and cemented the decision to further analyse the TCF4 
mutation spectrum in the full cohort of cases and newly-recruited controls. 
This was therefore prioritised over further experiments to assess LOXHD1 
mutation spectrum in the case/control cohort. 
 
5.2.3.9 Genotyping of the TCF4 intronic polymorphism, rs613872, 
and CTG18.1 trinucleotide repeat in the full cohort of 117 
FECD cases and 83 age-matched, endothelium-checked 
controls 
 
The additional 61 FECD samples and 83 endothelium-checked controls were 
genotyped for the TCF4 intronic polymorphism, rs613872, and CTG18.1 
trinucleotide repeat as described before (Sections 5.2.3.2 to 5.2.3.7) and the 
data combined with the previous study to increase its power. A summary of 
the results is shown in Table 5.9. TCF4 rs613872 and CTG18.1 genotypes for 
all patients in the case/control cohort are listed in Appendix VII. 
 
It was observed that 77.2% (85/117) of the FECD cases in the study have at 
least one expanded CTG18.1 allele compared with only 6.0% (5/83) and 
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10.9% (21/192) in the endothelium-checked subjects and the ECACC controls 
respectively. This was statistically significant (P = 1.95 x 10-18 and 8.43 x 10-28 
with odds ratios of 23.20 and 12.47 respectively. The significantly greater 
values between the cases and the different controls used to perform the 
analysis highlights the value in selecting controls that have had their 
endothelium checked. These findings also show that the CTG18.1 expanded 
allele of TCF4 appears to be a major risk allele for FECD in Caucasians. The 
controls were in HWE, but the cases were not. Linkage disequilibrium 
between the rs613872 SNP and the CTG18.1 was 0.79 as calculated by r2 
suggesting that these alleles were inherited together.  
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A.  
Cases Controls
n = 117 n = 83
GG 21 0 5.45x 10 !"14 6.113 (3.646 – 10.25)
GT 71 22
TT 25 61
XX 13 0 1.95x 10 !"18 23.2 (9.181 – 58.64)
SX 72 5
SS 32 78
P OR (95% CI)
rs
61
38
72
C
TG
18
.1
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B.  
 
 
Cases Controls
n = 117 n = 192
GG 21 7 3.384x 10	-15 4.263 (2.958 – 6.145)
GT 71 55
TT 25 130
XX 13 0 8.43x 10 -28 12.46  (7.473 – 20.76)
SX 72 21
SS 32 171
P OR (95% CI)
rs
61
38
72
C
TG
18
.1
 
Table 5.9 Summary of the intronic SNP rs613872 and CTG18.1 genotyping on the full cohort of FECD cases and controls. The subjects 
were categorised for rs613872, according to their G/T genotyped allele status, and for CTG18.1, according to the presence (X) or absence (S) 
of the trinucleotide expanded allele. Caucasian controls were recruited in St James’s University Hospital Cataract Clinics (A).  As a comparison 
the genotyping data from the ECACC human random control group was included (B).  
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5.2.4  Recruitment of two further local FECD families 
 
Two further families, FECDWAK and FECDBAR, were identified at 
Pinderfields Hospital, Wakefield (Figure 5.11 and Figure 5.12) by Mr Andrew 
Chung, Consultant Ophthalmologist at Pinderfields Hospital. The recruitment 
of the family members took place between September 2013 and September 
2015. 
 
FECDWAK had five affected individuals in generation II. The brother of the 
proband was managed clinically by Mr James Ball (JLB) in SJUH and had 
undergone bilateral DSEKs in 2008. Unaffected individuals from generation III 
were recruited at a later point in the study.  
 
The son of the FECDBAR proband, individual III:28, was referred from 
Pinderfields Hospital to St James’s University Hospital for an endothelial graft 
in 2015. DMEKs were carried out by JLB in April and July 2015 to the right 
and left eyes respectively. His daughter IV:1, aged 28, accompanied him to 
his follow-up appointments and expressed some concerns about her vision. 
She was examined and noted to have FECD. Both her and her asymptomatic 
half-brother IV:II, who was phenotypically normal when examined at the slit-
lamp, were recruited, sampled and underwent specular microscopy. The 
specular microscopy images of both grandchildren of the proband are shown 
in Figure 5.13. 
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Figure 5.11 Pedigree of the FECD family FECDWAK. Family members for whom DNA was available are labelled. Individuals from generation 
II were recruited initially, followed by individuals in generation III. The arrow indicates the proband. Individuals in [ ] brackets indicated that the 
offspring were adopted. The dashed line indicates that the parents were the adoptive parents. 
 
I 
II 
III
III
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Figure 5.12 Pedigree of the FECD family FECDBAR. Family members for whom DNA was available are labelled. Individuals from generation 
II and III were recruited 2013-2014. The two individuals from generation IV were recruited in September 2015. The arrow indicates the proband. 
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Figure 5.13 Specular microscopy scans of individuals IV:1 and IV:2 from 
FECDBAR family. The SM scan of IV:1 shows multiple gutatta with associated loss 
of endothelial cells consistent with FECD. The SM scan of IV:2 exhibits the normal 
arrangement of densely packed polygonal endothelial cells (Photos courtesy of Mr 
James Ball, Consultant Ophthalmic Surgeon, St James’s University Hospital, Leeds). 
 
 
5.2.5 Genotyping the multiplex FECD families for TCF4 risk alleles of 
SNP rs613872 and the CTG18.1 trinucleotide repeat 
 
Given that the TCF4 CTG18.1 expansion is a common variant in FECD 
patients (Wieben et al., 2012) and has been shown to segregate with FECD in 
families (Mootha et al., 2014), all members of the three families for whom 
DNA was available were tested for the TCF4 rs613872 SNP and the CTG18.1 
trinucleotide repeat as described before (Sections 5.2.3.5 to 5.2.3.9). 
 
The results for the FECDBRI family are summarised in Figure 5.14. All 
affected individuals in the family possessed the rs613872 TT genotype. The 
CTG18.1 expansion was also absent in all individuals that were tested 
suggesting that the cause of FECD in this family is unknown.  
 
The results for the FECDWAK family are summarised in Figure 5.15. All the 
affected individuals possessed the rs613872 G allele and the CTG18.1 
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expansion that predisposes to FECD onset. Two of the affected individuals 
were found to be homozygous for the expansion. There was no clear 
phenotypic difference in terms of disease severity or age of onset of the 
FECD in those who had a single expanded allele when compared with those 
who had two expanded alleles. There were unaffected cases in generation III 
of FECDWAK who possessed the CTG18.1 expansion but were not old 
enough to manifest signs or symptoms of FECD.  
 
The results for the FECDBAR family are summarised in Figure 5.16. Most of 
the affected individuals were found to possess the rs613872 G allele and a 
CTG18.1 expansion that could account for their FECD phenotype, with the 
exception of one subject who has an rs613872 TT genotype and no expanded 
alleles. It was concluded that this individual with no expanded alleles was 
likely to be a phenocopy for which the cause of FECD is unknown. Following 
the clinical analysis of FECD affected female IV.1 and her unaffected cousin 
IV.2, both were found to be heterozygous for the rs613872 G allele and the 
CTG18.1 expansion, suggesting that the unaffected cousin may be at risk of 
developing FECD at a later stage in life. It was also noted in this pedigree that 
affected family members with a TCF4 CTG18.1 expanded allele existed in 
three successive generations and that the FECD phenotype appeared to 
present at an earlier age at each generation.  
 
On the basis of this segregation analysis, it was concluded that the TCF4 
CTG18.1 expanded allele accounted for the FECD in FECDWAK and 
FECDBAR. In FECDBRI no CTG18.1 expansion was detected, therefore the 
causative mutation remained unknown and warranted further work.  
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Figure 5.14 Segregation of TCF4 rs613872 and the CTG18.1 trinucleotide repeat in FECDBRI. rs613872 is represented by the genotypes 
TT, TG or GG. SS = no expanded allele, SX = one expanded allele and XX = two expanded alleles. The arrow represents the proband.  
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Figure 5.15 Segregation of TCF4 rs613872 and the CTG18.1 trinucleotide repeat in FECDWAK. rs613872 is represented by the genotypes 
TT, TG or GG. SS = no expanded allele, SX = one expanded allele and XX = two expanded alleles. The individual in brackets denote that 
offspring were adopted. The arrow represents the proband.  
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Figure 5.16 Segregation of TCF4 rs613872 and the CTG18.1 trinucleotide repeat in FECDBAR. rs613872 is represented by the genotypes 
TT, TG or GG. SS = no expanded allele, SX = one expanded allele and XX = two expanded alleles. The part of the pedigree containing 
recruited patients is shown. The arrow represents the proband.  
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5.2.6 Next Generation Sequencing 
 
To assist in finding mutations in genes causing FECD in the recruited families 
and cohort of FECD cases, RNA sequencing of normal corneal tissue was 
attempted to determine the normal corneal expression. 
 
5.2.6.1 RNA-seq analysis of the normal corneal endothelium 
 
Determining which genes are expressed in the normal corneal endothelium 
would provide a useful data set with which to prioritise candidate genes for 
analysis in inherited diseases of the corneal endothelium. A study by Chng 
and co-workers took this approach to identify the genes expressed in corneal 
endothelial cells from young and old research-grade donors tissue (tissue 
unsuitable for corneal grafting) as well as from cell culture, by RNA extraction 
using a Qiagen RNeasy column, then performing RNA sequencing (Chng et 
al., 2013).  
 
This study attempted a similar analysis except that the tissue used here was 
corneal endothelial and epithelial/stromal tissue remaining from lamellar graft 
surgery (endothelial tissue remaining when the epithelium and anterior stroma 
was utilised for corneal grafting). This was collected from corneal operating 
theatres at SJUH and immediately stored in RNAlater. RNA was extracted 
simultaneously using 2 methods. These were either using the Trizol method 
according to manufacturer’s instructions or the RNAeasy Plus Universal 
Minikit (Qiagen) (section 2.14). 
 
Following Trizol extraction of 6 tissue samples, an aliquot of the RNA was 
subjected to reverse transcription PCR (RT-PCR) using primers against a 
ubiquitous housekeeping gene, p53, as described in section 2.14. A sample of 
the PCR product was analysed by agarose gel electrophoresis (Figure 5.17). 
The gel shows that no band could be seen for the endothelial samples, 
indicating the absence of a PCR product, which in turn shows that the RNA 
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extraction was unsuccessful. However, the presence of a band for PCR 
derived from the epithelial/stromal tissue confirms that RNA had been 
extracted from those samples. 
 
 
Figure 5.17 Agarose gel showing PCR amplification of cDNA generated by 
reverse transcription RNA from endothelial and epithelial/stromal tissue. L = 
Ladder, Lane 1 = Genomic DNA expected band size 1056bp, Lanes 2-7 = 
Endothelial samples, Lanes 8-13 Epithelial/Stromal Samples, RNA expected band 
size 407bp. NC = No DNA control. No band is visible in Lanes 2-7. There is a visible 
band in lanes 8-11 and 13. 
 
As a further verification, the RNA samples were run on an Agilent 2100 
Bioanalyser, as this has the capacity to detect very small amounts of RNA 
(Figure 5.18). The electropherogram traces indicated that there was 
insufficient RNA extracted from the corneal endothelial samples to proceed 
with RNA sequencing. The RNA Integrity number (RIN) helps to estimate the 
integrity of the total RNA and is determined by the whole electrophoretic trace 
rather than just the ratio of the ribosomal bands alone. It can be used to 
directly compare the RNA integrity of different RNA samples.  
 
Following RNA extraction using the RNAeasy Plus Universal Minikit (Qiagen) 
on 6 further samples and Bioanalyser measurements, the total RNA 
concentration was 2ng/μl, which again was inadequate to proceed with RNA 
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sequencing. Therefore, RNA sequencing of corneal endothelial samples was 
not possible. 
 
One possible explanation for this was that the RNA had degraded during the 
time it was stored in RNAlater. Therefore RNA extractions were carried out on 
6 freshly dissected bovine endothelial samples (section 2.14) using the 
RNAeasy Plus Universal Minikit (Qiagen). Although the RNA concentrations 
were greater than detected in human endothelium, average 8ng/μl, this was 
the total RNA, a proportion of which would be ribosomal RNA.  
 
 
               A. 
 
               B. 
 
Figure 5.18 Bioanalyser electropherogram traces for the detection of RNA 
concentration and quality. The two samples are (A) an endothelial corneal tissue 
sample at an RNA concentration of 3μg/l and RNA Integrity Number (RIN) not 
detectable, and (B) an epithelial/stromal corneal tissue sample at 35ng/μl with RIN 
8.5. FU = Fluoresence units, nt = nucleotide.  
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5.2.6.2 Whole Exome sequencing of FECD Families 
 
The whole exome sequencing of FECD family members was carried out over 
a number of years as samples became available and in small batches to 
reduce the cost. The WES analysis of FECDBAR and FECDWAK was 
performed alongside the TCF4 CTG18.1 expansion analysis described in 
section 5.2.5. As it was concluded from this that the TCF4 trinucleotide repeat 
expansion was causative in these two families, an assessment of the genes 
known to cause FECD was carried out. No further analysis of WES data was 
performed in these two families. 
 
 
5.2.6.2.1 Whole Exome Sequencing Library Preparation and 
Evaluation of the known FECD genes in the three FECD 
families 
 
FECDBRI samples II:3, II.5 and II:10 were processed commercially by 
Otogenetics Corporation whereas samples II:9 and II:2 were processed by the 
author and run on the in-house sequencer (section 2.15). Additionally, 
FECDWAK II:6, II:8, II:10, II:17, II:19, II:21 and FECDBAR II:17, II:19, II:24 
III:28 and III:32 were sequenced in-house.   
 
A representative Bioanalyser trace after the different stages of library 
preparation is shown in Figure 5.19. 
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Figure 5.19 Bioanalyser traces of sheared genomic DNA from the different 
stages of library preparation prior to whole exome sequencing for 
FECDBAR II:17. The stages of library preparation are (a) after shearing, (b) after 
amplification and (c) after hybridisation of the DNA during library preparation for 
exome sequencing. FU = Fluorescence units, bp = base pairs 
 
The resulting FASTQ next generation sequencing output files were analysed 
as detailed in Section 2.22, looking for variants common to all the affected 
cases in the family but absent from the unaffected case if there was one 
sequenced from the family. 
 
Analysis of shared variants was carried out using two methods. Firstly, 
following annotation of the variants using Annovar 
(http://annovar.openbioinformatics.org/en/latest/), the individual lists of 
annotated variants from affected individuals from the same family were 
merged so that variants shared by affected individuals could be analysed 
using the Agile Variant Selector (software designed by Dr Ian Carr, LIMM 
Bioinformatician). This was carried out on all three families. 
 
Pipeline 2 was a more advanced pipeline developed in 2015 after refinements 
were made to Pipeline 1 (Section 2.21) and also incorporated CADD scores at 
the annotation stage, therefore the variant list was further prioritised based on 
this. Pipeline 1 utilised Bowtie2 for the alignment whereas in pipeline 2 
 143 
Novoalign was used. Additionally, Pipeline 2 incorporated the use of the VCF 
on VCF perl script (https://github.com/gantzgraf/vcfhacks) developed by Dr 
David Parry. This script merged the individual VCF files into a single file of 
shared variants, which was then subsequently annotated using Annovar. Both 
pipelines allowed the subtraction of variants from an unaffected individual 
from the total list of shared variants, which was carried out in FECDBRI. Read 
depth was not used for filtering purposes but was taken into account for 
prioritisation of variants. This was carried out on FECDBRI. 
 
Prior to filtering the refined list, variants in the known genes that cause FECD 
COL8A2, SLC4A11, TCF4, TCF8, LOXHD1 and AGBL1 were selected in all 
three families  
 
For FECDBRI, there were 39 variants present, two of which were in the 
coding regions or splice site recognition signal in SLC4A11 (Table 5.10A). 
One was a synonymous variant c.G639A: p.S213S and the other was a non-
synonymous variant c.C77G: p.P26R with a frequency of 0.64 in 1000G, 
graded as non-pathogenic by the pathogenicity prediction tools Polyphen, 
SIFT and Mutation Taster. These variants were therefore excluded. Given the 
tentative linkage of FECDBRI to chromosome 18 (Section 5.2.3.1), an intronic 
TCF4 A>G change at position 53,177,742 from the top of chromosome 18 
(according to the human Genome Browser version, hg19) was also 
highlighted. This variant, termed rs192075715 in the dbSNP database, has a 
frequency of 0.32% in the 1000 Genomes database.  
 
Primers were designed across rs192075715 that were used in the PCR to 
confirm the segregation of this variant in all available FECDBRI family 
members (Appendix IV). This variant was found to segregate with FECD in 
FECDBRI and was also present in the individual of unknown disease status 
II:7 (Table 5.12). 
 
As this intronic variant rs192075715 was only 68 base pairs away from an 
exon, the possibility that it might affect splicing was considered. The wild type 
and variant sequences entered into the BGBP splicing prediction website 
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(http://www.fruitfly.org/seq_tools/splice.html) (Section 2.17.7) predicted that 
there was no effect on splicing. 
 
In FECDWAK, there were 96 variants present in the known genes, all of which 
were intronic except for one synonymous coding variant in TCF4 
rs143944746 (0.09% frequency) (Table 5.10B). All variants were present in 
the 1000 genomes and/or EVS databases at a frequency greater than 2% 
except for two variants in TCF4; rs143944746 and a TCF4 intronic SNP at 
position 53173173 T>A rs17512480 (frequency 1%). 
 
In FECDBAR, there were 199 variants in the genes known to be causative for 
FECD, 20 of which were coding variants (Table 5.10C). Of these 20, 7 were 
common non-synonymous SNPs graded as non-pathogenic by the 
pathogenicity prediction tools Polyphen, SIFT and Mutation Taster. One 
intronic SNP in TCF4 G>A at position 52942827 (rs1788027), which had a 
1000Genome frequency of 50% was common to both FECDWAK and 
FECDBAR.  
 
As the CTG18.1 expanded allele was found to segregate with the FECD 
phenotype in FECDBAR and FECDWAK (section 5.2.5), and as no clear 
pathogenic variants were detected, no further analysis of the WES data on 
these families was carried out in these families. FECBRI was selected for 
further analysis of variants from WES. 
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A. 
 
   
Chr Start End Ref Alt Gene.refGene ExonicFunc.refGene Otherinfo AAChange.refGene EVS 1000g snp137 SIFT Polyphen2 MutationTaster
chr20 3214581 3214581 C T SLC4A11 synonymous3SNV het NM_032034:exon5:c.G639A:p.S213S,SLC4A11 0.186222 0.16 rs3803956 Unknown Unknown Unknown
chr20 3218634 3218634 G C SLC4A11 nonsynonymous3SNV het NM_001174090:exon1:c.C77G:p.P26R Unknown 0.64 rs3810562 0.66 Benign Polymorphism3(Automatic)  
 
   B. 
 
Chr Start End Ref Alt Gene.refGene ExonicFunc.refGene Otherinfo AAChange.refGene EVS 1000g snp137 SIFT PolyPhen2 MutationTaster
chr18 52901846 52901846 C G TCF4 synonymous4SNV het NM_001243226:exon17:c.G1725C:p.P575P 0.001922 0.0009 rs143944746 Unknown Unknown Unknown  
    
   C. 
 
Chr Start End Ref Alt Gene.refGene ExonicFunc.refGene Otherinfo AAChange.refGene EVS 1000g snp137 SIFT PolyPhen2 MutationTaster
chr15 86800209 86800209 C T AGBL1 synonymous3SNV hom NM_152336:exon7:c.C723T:p.P241P 0.645368 0.52 rs1353578 Unknown Unknown Unknown
chr15 86806029 86806029 C T AGBL1 synonymous3SNV hom NM_152336:exon9:c.C852T:p.D284D 0.691817 0.56 rs1566088 Unknown Benign3 Unknown
chr15 86807542 86807542 C T AGBL1 synonymous3SNV hom NM_152336:exon10:c.C1002T:p.A334A 0.160255 0.12 rs10520617 Unknown Unknown Unknown
chr15 86807843 86807843 T C AGBL1 nonsynonymous3SNV hom NM_152336:exon10:c.T1303C:p.S435P 0.169 0.12 rs11857527 Tolerated Unknown Polymorphism
chr15 86807884 86807884 A C AGBL1 synonymous3SNV hom NM_152336:exon10:c.A1344C:p.V448V 0.174007 0.12 rs11856833 Unknown Unknown Unknown
chr15 86814866 86814866 A G AGBL1 synonymous3SNV hom NM_152336:exon14:c.A1866G:p.L622L 0.731923 0.64 rs11858435 Unknown Benign Unknown
chr15 86940622 86940622 T C AGBL1 synonymous3SNV het NM_152336:exon17:c.T2262C:p.T754T 0.607208 0.7 rs4362360 Unknown Benign Unknown
chr15 86940673 86940673 C T AGBL1 synonymous3SNV het NM_152336:exon17:c.C2313T:p.T771T 0.109367 0.09 rs1367647 Unknown Unknown Unknown
chr15 87217613 87217613 A G AGBL1 nonsynonymous3SNV hom NM_152336:exon22:c.A3029G:p.Q1010R 0.8897 0.87 rs8028043 Tolerated Unknown Polymorphism
chr15 87531281 87531281 A C AGBL1 synonymous3SNV hom NM_152336:exon23:c.A3147C:p.T1049T 0.806037 0.82 rs1006030 Unknown Unknown Unknown
chr18 44063598 44063598 G A LOXHD1 nonsynonymous3SNV het NM_144612:exon39:c.C6107T:p.A2036V NA 0.41 rs1377016 Tolerated Benign Polymorphism
chr18 44126909 44126909 T C LOXHD1 nonsynonymous3SNV het NM_144612:exon22:c.A3463G:p.R1155G 0.771572 0.7 rs1893566 Tolerated Unknown Polymorphism
chr18 52895531 52895531 T C TCF4 synonymous3SNV het NM_001243226:exon20:c.A2247G:p.S749S 0.364678 0.38 rs8766 Unknown Unknown Unknown
chr18 53303101 53303101 C G TCF4 nonsynonymous3SNV hom NM_001243226:exon1:c.G28C:p.A10P 0.998774 1 rs611326 Tolerated Unknown Polymorphism
chr20 3210301 3210301 G A SLC4A11 synonymous3SNV het NM_032034:exon13:c.C1659T:p.N553N,SLC4A11 0.093803 0.06 rs41281860 Unknown Unknown Unknown
chr20 3211235 3211235 C T SLC4A11 synonymous3SNV het NM_032034:exon11:c.G1389A:p.T463T,SLC4A11 0.090804 0.06 rs6084312 Unknown Benign Unknown
chr20 3214819 3214819 T G SLC4A11 synonymous3SNV het NM_032034:exon4:c.A481C:p.R161R,SLC4A11 0.480932 0.49 rs3827075 Unknown Unknown Unknown
chr20 3218563 3218563 T C SLC4A11 nonsynonymous3SNV het NM_001174090:exon1:c.A148G:p.R50G NA 0.06 rs79057061 Tolerated Benign Polymorphism3(Automatic)
chr20 3218634 3218634 G C SLC4A11 nonsynonymous3SNV het NM_001174090:exon1:c.C77G:p.P26R NA 0.64 rs3810562 Tolerated Benign Polymorphism3(Automatic)  
Table 5.10 The list of coding variants in the FECDBRI, FECDWAK and FECDBAR affected cases in genes known to cause FECD. The 
databases used were Polyphen2 (HDIV), SIFT, PROVEAN, and Mutation Taster. Additionally their frequency in the 1000 genomes and EVS 
databases are shown (Genome Browser version hg19). 
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5.2.6.2.2  Analysis of WES in FECDBRI to identify the pathogenic 
mutation causing FECD 
 
The refined list containing variants shared by all the affected cases in family 
FECDBRI was filtered by removing the homozygous variants, followed by the 
synonymous and intronic variants. Spice site variants at positions +/-1-5, 
along with exons and exon/splicing variants (variants within the exon but close 
to the intron/exon boundary) were included in the analysis. Variants that had a 
frequency of more than 2% within EVS or 1000 Genomes databases were 
also excluded. The reason for choosing this threshold was that as TCF4 
accounted for the majority of FECD, it was felt likely that the remainder of 
variants would be rare. This left a list of 14 variants, which are shown in Table 
5.11A. The analysis was also repeated using the more advanced Pipeline 2 in 
2015, and after applying CADD scores to the list of variants, the ones with a 
CADD score greater than or equal to 10 were retained. 5 variants were 
highlighted (Table 5.11B). These were all variants that had been found using 
Pipeline 1. This included variants in Oxysterol-binding Protein-like Protein 1A 
(OSBPL1A) c.115_116insAATT: p.C39_K40delinsX, Tandem C2 domains, 
nuclear (TC2N) c.T962C: p.I321T, Tetratricopeptide repeat domain 40 
(TTC40) c.T1814C: p.L605P, URB1 Ribosome biogenesis 1 Homolog (URB1) 
c.C2126T: p.A709V and Crystallin, Zeta-like 1 (CRYZL1) c.C461G: p.A154G. 
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A.  
Alt Gene.refGene ExonicFunc.refGene Otherinfo AAChange.refGene EVS 1000g snp137 SIFT Polyphen2 MutationTaster
G TTC40 nonsynonymous	SNV het NM_001200049:exon15:c.T1814C:	p.L605P Not	present 0.0005 rs146983053 Damaging Probably	Damaging Deleterious
A TDRD3 nonsynonymous	SNV het NM_030794:exon13:c.G1850A:	p.G617D 0.000846 0.0009 rs140870765 Tolerated Benign Deleterious
G SLAIN1 nonsynonymous	SNV het NM_001242868:exon4:c.C1069G:	p.P357A 0.001768 0.0023 rs144139933 Tolerated Damaging Deleterious
G TC2N nonsynonymous	SNV het NM_001128596:exon9:c.T962C:	p.I321T 0.000231 0.0005 rs148609061 Damaging Benign Deleterious
A URB1 nonsynonymous	SNV het NM_014825:exon17:c.C2126T:	p.A709V Not	present 0.0005 rs190315797 Tolerated Benign Polymorphism	(Automatic)
A RPUSD3 nonsynonymous	SNV het NM_173659:exon8:c.C799T:	p.R267C 0.002691 0.0023 rs146799821 Tolerated Benign Deleterious
A IL17RC nonsynonymous	SNV het NM_153460:exon11:c.G970A:	p.A324T 0.013314 0.01 rs115461448 Tolerated Damaging Polymorphism	(Automatic)
- HOMEZ nonframeshift	deletion het NM_020834:exon2:c.1634_1636del:	p.545_546del Not	present Not	present rs148005528 NA NA Unknown
A KCNJ12,KCNJ18 nonsynonymous	SNV het NM_021012:exon3:c.C1206A:	p.D402E Not	present Not	present rs2917720 Tolerated Benign Polymorphism	(Automatic)
T KCNJ12,KCNJ18 nonsynonymous	SNV het NM_021012:exon3:c.G1214T:	p.S405I Not	present Not	present rs73979902 Tolerated Benign Deleterious
G KCNJ12,KCNJ18 nonsynonymous	SNV het NM_021012:exon3:c.A1289G:	p.E430G Not	present Not	present rs5021699 Damaging Damaging Deleterious
AATT OSBPL1A stopgain	SNV het NM_080597:exon2:c.115_116insAATT:	p.C39_K40delinsX 0.002796 Not	present NA Unknown NA Unknown
C CRYZL1 nonsynonymous	SNV het NM_145858:exon7:c.C461G:	p.A154G Not	present Not	present NA Tolerated Possibly	Damaging Deleterious
C RP1L1 nonsynonymous	SNV het NM_178857:exon4:c.C3956G:	p.A1319G Not	present Not	present rs4840501 Tolerated Benign Polymorphism	(Automatic)  
 
   B.  
 
symbol variant gene feature allele consequence cds_position protein_position amino_acids codons existing_variation exon CaddPhredScore
OSBPL1A c.115_116insAATT:	p.C39_K40delinsX ENSG00000141447 ENST00000319481 AATT stop_gained&frameshift_variant 115-116 39 C/*LX tgc/tAATTgc ~rs74793804 2/28 35
TC2N c.T962C:	p.I321T ENSG00000165929 ENST00000435962 G missense_variant 962 321 I/T aTt/aCt rs148609061 9/12 25.2
TTC40 c.T1814C:	p.L605P ENSG00000171811 ENST00000368586 G missense_variant 1814 605 L/P cTc/cCc rs146983053 15/58 25
URB1 c.C2126T:	p.A709V ENSG00000142207 ENST00000382751 A missense_variant 2126 709 A/V gCg/gTg rs190315797 17/39 23
CRYZL1 c.C461G:	p.A154G ENSG00000205758 ENST00000381554 C missense_variant 461 154 A/G gCa/gGa 7/13 21  
Table 5.11 Filtered variants in FECDBRI family common to the affected cases but absent from the unaffected member after whole 
exome sequencing using A. Pipeline 1 (annotated by Annovar) and B. Pipeline 2 (annotated by VEP) in FECDBRI. Pipeline 2 was a 
more advanced pipeline developed in 2015 and incorporated the use of CADD scores (http://cadd.gs.washington.edu). The 5 variants in B were 
all seen in A. and all had CADD scores of above 10 (Genome Browser version hg19).
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The variants were Sanger sequenced in the FECDBRI family to confirm their 
presence in the family members that were exome sequenced and also to 
assess segregation in other family members (Table 5.12). The findings 
showed that all of the variants segregated perfectly with those known to have 
FECD, some segregated with the individual with an unknown disease status 
from generation II, individual II:7. Additionally, family members from 
generation III and IV might have been asymptomatic mutation carriers who 
were not yet old enough to have developed the condition, and so caution 
ought to be considered in interpreting the analysis.  
 
 
Table 5.12 Segregation analysis of the 5 coding variants identified in the 
FECDBRI family after exome sequencing. Affected individuals are highlighted in 
green, unaffected in grey and those of uncertain diagnosis in pink. The variant 
residues are highlighted in blue. Segregation of the intronic SNP, rs192075715, is 
also shown as a comparison. All variants shown are heterozygous. 
 
The OSBPL1A variant c.115_116insAATT: p.C39_K40delsinX represents a 
null variant whereas the other 4 variants are missense changes. Protein 
sequence alignments of the residues affected by these missense changes in 
orthologues highlight that the normal residue in CRYZL1 is fully conserved 
through evolution while the residues altered by other variants are not (Figure 
5.20). It is worth highlighting that CRYZL1, URB1 and OSBPL1A were found 
to be expressed at significant levels in corneal endothelial cells whereas 
TC2N and TTC40 were not (Table 5.14). OSBPL1A is on chromosome 18, but 
not within or near the published locus (Sundin et al., 2006a). The other 
variants were not within the other published loci (Sundin et al., 2006b, 
Riazuddin et al., 2009, Riazuddin et al., 2010a). Based on this evidence, it 
seemed likely that CRYZL1 and OSBPL1A were the best gene candidates for 
further screening. However due to time constraints, Sanger sequencing in an 
FECDBRI
rs1920757150 OSBPL1A0
c.115_116insAATT:p.C39_K40
delinsX
TC2N0
c.T962C:p.I321T
TTC400000
c.T1814C:p.L605P
URB10
c.C2126T:p.A709V
CRYZL10
c.C461G:p.A154G
II:2 AA WT TT TT CC CC
II.3 AG INS TC TC CT CG
II:4 AA WT TT TT CC CC
II:5 AG INS TC TC CT CG
II:7 AG INS TC TC CC CC
II:9 AG INS TC TC CT CG
II:10 AG INS TC TC CT CG
III:5 AG WT TT TT CT CG
III:6 AA INS TT TT CT CG
III:8 AA WT TC TT CC CC
IV:1 AA WT TT TT CT CG
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FECD case/control cohort was not possible. A summary of these variants is 
provided below. 
 
5.2.6.2.3  Oxysterol-binding Protein-like Protein 1A 
 
Oxysterol-binding Protein-like Protein 1A (OSBPL1A) (MIM*606730) has 28 
exons and encodes a member of the oxysterol-binding protein (OSBP) family, 
a group of intracellular lipid receptors (Jaworski et al., 2001). It is differentially 
regulated by FOXC1, which has a role in cell viability and resistance to 
oxidative stress in the eye, and has been implicated in Axenfeld-Rieger 
syndrome, a condition characterised by anterior segment malformations in the 
eye and glaucoma (Berry et al., 2008). As detailed above, it has been shown 
to be expressed in the corneal endothelium (Chng et al., 2013) (Table 5.14). 
The insertion/frameshift variant identified has an allele frequency of 0.18% in 
ExAc (http://exac.broadinstitute.org). It was originally assigned a reference of 
rs74793804 but was removed from dbSNP in 2013 due to mapping errors 
(http://www.ncbi.nlm.nih.gov/SNP/).  
 
5.2.6.2.4  Crystallin, Zeta-like 1 
 
Crystallin, zeta(quinone reductase)-like 1 (CRYZL1) (MIM*603920) is a 13 
exon gene on chromosome 21 which encodes a protein that has sequence 
similarity to zeta crystallin, also known as quinone oxidoreductase (Kim et al., 
1999). The missense variant identified is present in ExAc 
(http://exac.broadinstitute.org) at a frequency of 0.0001%, and the transcript is 
expressed in the corneal endothelium (Chng et al., 2013) (Table 5.14). A 
study assessing the differential response of lens and corneal crystallins in 
degenerative corneas suggested a potential role of crystallins in the 
maintenance of corneal clarity, although the study concluded that lens 
crystallins might play a greater role in this than corneal crystallins. (Gong et 
al., 2012). 
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Figure 5.20 Protein sequence alignment of WES variants segregating in 
FECDBRI with orthologues. A. URB1 c.C2126T:p.A709V, B. CRYZL1 
c.C461G:p.A154G, C. TC2N c.T962C:p.I321T and D TTC40 c.T1814C:p.L605P. 
Analysis was performed using Homologene. Each variant is highlighted in red and 
the surrounding amino acids that are identical to the human transcript are shaded in 
grey. Accession numbers for URB1 are NP_055640.2 (human), XP_531425.3 
(chimp), XP_005638888.1 (dog), NP_001192909.1(cow), NP_083773.1 (mouse), 
NP_001178590.1 (rat), XP_003640527.1 (chicken), XP_002664599.3 (zebrafish), 
NP_001131087.1 (frog)   for CRYZL1 are NP_114423.1 (human), XP_531441.3 
(chimp), XP_001090445.1 (monkey), XP_535585.1 (dog), NP_001030209.2  (cow), 
NP_598440.1 (mouse), NP_001013062.1 (rat), XP_004934579.1 (chicken), 
NP_001002633.1 (zebrafish), NP_001016084.1 (frog) for TC2N are 
NP_689545.1(human),XP_001145068.1 (chimp),XP_001091431.1(monkey), 
XP_547711.1(dog), NP_001180133.1 (cow), NP_001273293.1 (mouse), 
NP_001020323.1 (rat), XP_004941928.1 chicken, XP_005157017.1 zebrafish), 
XP_002933250.2(frog) and for TTC40 are  NP_001186978.2 (human), 
XP_003951835.1 (chimp), XP_005637957.1 (dog), XP_005225941.1 (cow), 
XP_006230566.1 (rat), XP_005157133.1 (zebrafish), XP_002936855.2 (frog). 
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5.2.6.2.5 ExomeDepth analysis of whole exome sequencing data 
from case II.9 in the FECDBRI family 
 
In order to investigate whether the causative mutation in affected cases of the 
FECDBRI family was a large copy number variation (CNV) or other structural 
variation that affects the coding region captured by exome sequencing, 
ExomeDepth analysis was carried out on the WES from affected case II:9. 
The FASTQ files were processed as described in Section 2 using Pipeline 1, 
up to and including the removal of duplicate reads by Picard (Table 2.2). The 
programme requires the exome samples to have good depth of coverage. The 
sample that met these requirements was sequenced in the Next Generation 
facility in Leeds. The other affected samples were sequenced at Otogenetics, 
and therefore had reduced depth of coverage compared to the data from 
individual II:9. For ExomeDepth, control samples were also required, 
preferably those run on the same Illumina sequencing lane as the test 
sample. The other 4 samples run on the same lane as individual II.9 were 
FECD samples from FECDBAR and FECDWAK. 
 
A list of Bayes Factor (BF) scores are shown in Table 5.13. The higher the BF 
score, the more confidence of the presence of a CNV. The BF score 
calculates the log10 of the likelihood of the testing data having a CNV relative 
to the normal copy number at that position using the control exomes. The BF 
does not however have a clearly defined threshold. 
 
The highest BF score in case II.9 was a heterozygous duplication at 
chromosome 10, positions 46,965,003-47,087,911 (hg19) that includes the 
start of SYT15, the entire GPRIN2 and end of NPY4R genes and 
encompasses 8 exons (Figure 5.21). It was noted that only SYT15 and 
GPRIN2 are both expressed in the corneal endothelium (Table 5.14) so any 
aberrant transcripts as a result of the duplication event could be considered 
candidates for FECD.  
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Figure 5.21 The genomic region identified to have a putative CNV in case II.9 from FECDBRI family. 
The interval with a putative CNV is chr10:46965003-47087911 as indicated on the Genome browser version hg19. This 122,909bp duplication 
encompasses the start of the SYT15, the entire GPRIN2 and the end of NPY4R genes.  
 
 
 
 
 
 
Table 5.13 ExomeDepth results of individual II:9 from the FECDBRI family. The variant with the highest BF score is shown in the top row. 
The read ratio of 1.41 indicates that this is a heterozygous duplication event encompassing 8 exons. None of the structural variants listed were 
present in the Conrad database (Conrad et al., 2010). 
 
 
 
 
 
 
 
 
 
start.p end.p Type nexons start end chromosome id BF reads.expected reads.observed reads.ratio Conrad.hg19 exons.hg19
21864 21871 duplication 8 46965003 47087911 chr10 chrchr10:46965003847087911 44.1 2912 4112 1.41 NA NA
154672 154692 deletion 21 32485517 32632844 chr6 chrchr6:32485517832632844 29.6 134 1 0.00746 NA NA
167146 167151 deletion 6 100331793 100336236 chr7 chrchr7:1003317938100336236 29.4 394 187 0.475 NA NA
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Table 5.14 RNA expression levels in old, cultured and young endothelia cells and stroma (Chng et al., 2013). Levels of expression in the 
corneal endothelium are shown for transcripts of genes containing candidate FECD causal variants identified in exome sequencing; OSPBL1A, 
CRYZL1 and URB1; or in Exomedepth analysis of WES; STY15 and GPRIN2. RPKM = Reads Per Kilobase of transcript per Million, RPM = 
reads per million 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RefSeq&ID Gene&ID Total&Length Total&Count RPKM RPM Total&Count RPKM RPM Total&Count RPKM RPM Total&Count RPKM RPM
NM_018030( OSBPL1A( 3301 0 0.00 0.00 22 1.44 4.75 2 0.22 0.72 30 5.04 16.65
NM_145858( CRYZL1( 1697 0 0.00 0.00 43 5.47 9.28 98 20.73 35.17 2 0.65 1.11
NM_014825( URB1( 10769 0 0.00 0.00 50 1.00 10.79 1 0.03 0.36 4 0.21 2.22
NM_031912( SYT15( 5500 3 0.29 1.57 104 4.08 22.44 5 0.33 1.79 0 0.00 0.00
NM_014696( GPRIN2( 1820 0 0.00 0.00 1 0.12 0.22 10 1.97 3.59 0 0.00 0.00
Old&endothelial&cells Cultured&endothelial&cells Young&endothelial&cells Stroma
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5.3   Discussion 
 
FECD is a genetically heterogeneous disease, with mutations in COL8A2, 
SLC4A11, LOXHD1, TCF4, ZEB1 and AGBL1 having been identified as 
causative (Biswas et al., 2001, Vithana et al., 2008, Riazuddin et al., 2012, 
Wieben et al., 2012, Riazuddin et al., 2010a, Riazuddin et al., 2013). In this 
chapter, families and cases were examined to look for the genetic contributors 
to FECD. An assessment of the mutational load of LOXHD1 variants was 
carried out in cases and controls, and the results suggested that LOXHD1 
was not significant contributor to the FECD in the Yorkshire cohort. Whole 
exome sequencing (WES) was carried out on the affected members of 
FECDBRI, FECDBAR and FECDWAK. Additionally, unaffected family 
members of FECDBRI and FECDWAK were also selected for WES. Samples 
from FECDBAR and FECDWAK were analysed for variants in the known 
genes, however as both of these families were found to harbour a CTG18.1 
expansion which fully either (FECDWAK) or partially (FECDBAR) segregated 
with the disease, further analysis of WES variants focussed on FECDBRI in 
which a CTG18.1 expansion was not seen in any family member.  
 
5.3.1 Genetic contribution of LOXHD1 variant alleles causing FECD 
 
The FECD3 locus on chromosome 18q21.2-q21.32 was identified in 2006 
following genome- wide microsatellite linkage analysis on 3 families with 
multiple FECD affected members. The disease allele frequency was set very 
low at 0.0001. Significant linkage was detected using a dominant model of 
inheritance, taking into account non-penetrance and allowing for an 
phenocopy rate of 5% (Sundin et al., 2006a). However only one of the families 
individually reported in this study independently reached a significant lod 
score and is therefore the only one that can be used to define the locus 
boundaries.  LOXHD1, which maps close to (but not within the locus originally 
reported) the FECD3 locus, appeared to be a strong candidate for 
involvement in FECD. Riazuddin et al went on to report an enrichment of 
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mutations in their DNA cohort of 208 cases compared to 838 ethically-
matched controls (Riazuddin et al., 2012), implying that heterozygous 
LOXHD1 missense mutations were implicated in 7.2% of FECD cases.   
 
Work presented in this thesis included Sanger sequencing of the LOXHD1 
gene to screen for mutations in a cohort of 56 unrelated FECD patients. The 
results show that 6/112 (5.4%) potentially pathogenic LOXHD1 alleles were 
identified in FECD cases, whereas 38/934 (4.1%) pathogenic alleles were 
identified in the controls. The abundance of rare pathogenic LOXHD1 alleles 
identified in this study was therefore only modestly elevated at 1.33-fold in the 
FECD cohort compared to controls, considerably less than the 3.53-fold 
enrichment that was described before (Riazuddin et al., 2012) (Table 5.5). 
Riazuddin and colleagues began their analysis assuming Mendelian 
inheritance at this locus, as illustrated by use of linkage data under a 
dominant inheritance model and variant filtering criteria that exclude all 
changes present in the 1000 genomes database. Their conclusion is that 
LOXHD1 alleles are enriched in FECD cases but are nevertheless also 
present in controls, implying complex etiology for this relatively common 
condition. The identification of a rare mutation in familial cases, followed by 
the screening for the mutation in a complex cohort is a strategy that has been 
successfully employed in a previous study, which found a link between 
apolipoprotein E and Alzheimer’s Disease (Strittmatter et al., 1993). 
 
The study by Riazuddin et al (2012) Sanger sequenced a large gene in a 
relatively large patient cohort and also in controls, carried out cell-based 
functional assessments of key mutations, and provided evidence of LOXHD1 
corneal expression as well as altered expression in cornea from a patient, all 
of which are notable strengths. However, their rationale for screening 
LOXHD1 as a candidate gene was based on a study of dominant FECD 
families which showed linkage to the region 18q21.2-q21.32 (the FECD3 
locus (Sundin et al., 2006a)). The fact that they then only identified a LOXHD1 
coding sequence mutation in one of the three families poses questions as to 
whether LOXHD1 mutations account for the published FECD locus. It is 
possible that the other two families may have had a non-coding mutation in 
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LOXHD1, which would have been missed by their screening strategy.  
Though plausible, this could also imply that the two families without a 
LOXHD1 mutation may have had a mutation in another gene at the FECD3 
locus. Although rare, microheterogeneity has been reported in other genetic 
eye conditions (Toomes et al., 2004). However, in the more recent study 
(Riazuddin et al., 2012) it would appear that different microsatellite markers 
were used and the locus boundaries are broader compared with the original 
linkage study (Sundin et al., 2006a) and encompass the region 18q21.1 
where LOXHD1 is located. 
 
It must be acknowledged that the analysis described herein also has 
significant weaknesses. The cohort of 56 FECD patients is modest in size by 
comparison with the 207 cases tested by Riazuddin et al, so may be too 
under-powered to attain significant enrichment for a small effect size. 
Although both studies utilised database controls, the ethnically matched 
control samples from the 1000 Genomes database will undoubtedly include a 
small number of individuals who later go on to develop FECD. The Yorkshire 
endothelial-checked controls were not recruited and sampled until later in the 
study and were therefore not available at the time that the screen was 
performed. Even if these controls had been available, it would be costly both 
financially and in terms of time to screen a control cohort for LOXHD1 
variants. By contrast, the 192 control individuals used by Riazuddin et al were 
all aged over 60 and were phenotyped by slit lamp examination so it can be 
stated with certainty that they did not have FECD. The lower abundance of 
pathogenic LOXHD1 alleles found in the controls used in their study could 
therefore possibly reflect the exclusion of presymptomatic cases from their 
control population. It is, however, unclear whether these same controls were 
among the 288 control individuals sequenced for LOXHD1 at a later stage of 
their study, about whom no information on ethnicity, age or ophthalmic status 
was given. It was not explicitly stated that these were the same controls 
whose variants were listed in their report. Additionally, the prevalence of 
FECD is possibly higher in Europe than the US (Eghrari and Gottsch, 2010) 
and the control individuals analysed from the 1000 Genomes database, 
though all Caucasian, have been drawn from a variety of different populations, 
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so they may not be the best available match for FECD cases from the north of 
England.  
 
Another significant difference between the study by Riazuddin and colleagues 
and the study presented in this thesis is the assessment criteria for variant 
pathogenicity. Riazuddin et al used only a single bioinformatic software 
program, Polyphen2 (Adzhubei et al., 2010) to predict mutation pathogenicity, 
Of the two available versions of the Polyphen database 
(http://genetics.bwh.harvard.edu/pph2/), the HDIV model is the most suitable 
for looking for rare alleles in complex disease, and it was felt to be the most 
appropriate model to use in this study. Riazuddin et al (Riazuddin et al., 2012) 
did not state which model they used, and given the variation in results that the 
two versions produce, and the fact that this was the only pathogenicity 
prediction software used in the study, this could potentially produce variation 
in the results. The analysis presented in this chapter used four prediction 
programs, Polyphen2, SIFT (Ng and Henikoff, 2001), PROVEAN (Choi et al., 
2012) and Mutation Taster (Schwarz et al., 2010a) and included LOXHD1 
variants if they were predicted to be pathogenic by any one. 
 
Unlike Polyphen and SIFT, PROVEAN and Mutation Taster are able to 
process and score small indels as well as missense changes. However, since 
this analysis was performed, more comprehensive algorithms have been 
introduced and are now widely utilised. CADD scores can be used to grade 
nonsense, missense and splice site variants as well as those in intronic 
regions (Kircher et al., 2014). The Eigan score is the most recently published 
approach to the analysis of variant pathogenicity (Ionita-Laza et al., 2016). 
The authors state that this scoring system, which used a large set of variants 
in its development but no labelled training data set, performs better than 
CADD in discriminating between disease-causing and benign variants. Given 
the fact that different pathogenicity prediction tools utilised can give different 
pathogenicity gradings for the same variant, it seems prudent to utilise all of 
the available tools in deciding if a variant is potentially pathogenic.  
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All of the rare LOXHD1 variants described in the previous study (Riazuddin et 
al., 2012) were absent from the 1000 Genomes database whereas the ones 
described in this study were considered if their allele frequency was less than 
or equal to 4% in the databases. This less stringent approach was felt to 
better reflect the approximately 4% FECD frequency in Caucasians over the 
age of 40 years old in the general population (Lorenzetti et al., 1967). 
Furthermore, for the assessment of evolutionary conservation of the amino 
acid residues that were mutated in LOXHD1, numerous orthologues were 
listed in the report by Riazuddin et al (2012). The way that this data was 
presented suggested that the mutations were highly conserved. However, as 
Chimp, Orangutan, Rhesus and Baboon are all higher-order mammals from 
an evolutionary perspective, there seemed limited value in listing these in their 
evaluation. In the assessment of conservation presented in this thesis (Figure 
5.8), the putative LOXHD1 mutations had fewer organisms listed with a 
greater variation in species order, which made the analysis of evolutionary 
conservation more meaningful.  
 
Recessive mutations in LOXHD1 cause non-syndromic sensorineural hearing 
loss (ARNSHL) with defects of mild-moderate and high frequency range 
typically presenting during childhood and adolescence. (Grillet et al., 2009). 
The involvement of mutations in LOXHD1 in endothelial corneal dystrophy 
would therefore have some similarity to the finding that dominant mutations in 
SLC4A11 cause FECD and recessive mutations cause CHED2 and 
sensorineural hearing loss (Harboyan syndrome) (Desir et al., 2007, Siddiqui 
et al., 2014). Late-onset FECD has also been associated hearing loss 
(Stehouwer et al., 2011) but given that these symptoms affect 20-30% of 
patients by the age of 70 and 45-55% by age 80 years old (Roth et al., 2011) 
and that presbyacusis is also a common complex condition with significant 
environmental contributory factors, any link between heterozygous LOXHD1 
mutations and hearing loss should be interpreted with caution. 
 
The failure of the study presented in this thesis to replicate significant 
enrichment of LOXHD1 mutations in FECD cases does not disprove the 
involvement of LOXHD1 variants in FECD. However, considered alongside 
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the lack of LOXHD1 mutations in two out of three linked families that were 
studied in the original report, the presence of the nearby trinucleotide 
expansion in TCF4 which is very strongly associated with FECD (Wieben et 
al., 2012) and the data presented herein, it does cast some doubt on the 
involvement of LOXHD1 variants in FECD. When inspecting the five cases 
with predicted pathogenic LOXHD1 variants for their TCF4 CTG18.1 status, it 
was noted that they were inherited independently of one another, but 
nevertheless 3/5 cases with LOXHD1 predicted pathogenic variants co-
existed with an expanded CTG18.1 trinucleotide variant. This suggests that 
the LOXHD1 variants may contribute to disease symptoms in the absence of 
the major TCF4 FECD-predisposing expanded allele only in a small number 
of cases. 
 
5.3.2 Genetic contribution of TCF4 variant alleles to FECD 
 
In 2010, Baratz et al published the results of a modestly-sized GWAS in which 
a significant association was found in Caucasians with the G allele of an 
intronic SNP rs613872 in the TCF4 gene on Chromosome 18 (Baratz et al., 
2010). In contrast to the LOXHD1 analysis, work presented in this thesis 
replicated this association in the Yorkshire FECD cohort compared with 
controls. The association of rs613872 in TCF4 has also been replicated 
independently in Caucasian populations in a number of other studies (Li et al., 
2011, Riazuddin et al., 2011, Kuot et al., 2012, Igo et al., 2012, Stamler et al., 
2013). In Chinese cases (Thalamuthu et al., 2011) and in one study of Indian 
cases (Nanda et al., 2014) there was an association with another TCF4 
intronic SNP, rs17089887. However, since then one published study of North 
Indian FECD cases has replicated the association with rs613872 (Gupta et 
al., 2015). Igo et al (Igo et al., 2012) found a highly significant association 
between FECD and SNP, rs613872 (P = 2.0 x 10-19) and additionally 
performed a meta-analysis of other studies (Baratz et al., 2010, Li et al., 2011, 
Riazuddin et al., 2011, Kuot et al., 2012). The combined odds ratio for each G 
allele in this meta-analysis was 4.96. Subsequent replication studies have 
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also supported the association of this SNP with FECD (Mootha et al., 2014, 
Stamler et al., 2013).  
 
Researchers have gone on to show that a trinucleotide repeat expansion 
within the TCF4 gene gives an odds ratio of more than 10 for FECD risk in 
Caucasian (Wieben et al., 2012, Mootha et al., 2014), Chinese (Xing et al., 
2014), Indian (Nanda et al., 2014) and Japanese (Nakano et al., 2015) 
populations, and cosegregates with the disease in approximately 50% of 
families with complete and 10% with incomplete penetrance (Mootha et al., 
2014). Mootha et al examined 120 Caucasian subjects and 100 controls and 
found that the two polymorphisms, rs613872 and CTG18.1 were in linkage 
disequilibrium (Mootha et al., 2014). Both rs613872 and the expanded 
CTG18.1 were found to be significantly associated with FECD in the FECD 
cohort presented in this thesis as well as in two of the three FECD families 
recruited, and it can be concluded that TCF4 mutations are a major 
contributor to the pathogenesis of FECD, greater than any other gene 
identified to date. 
 
The major association of the trinucleotide expansion within the TCF4 gene in 
FECD cases previously suggested a number of possible disease 
mechanisms. One possibility, that the expansion could be in linkage 
disequilibrium with a functional variant in TCF4, has already been investigated 
but comprehensive sequencing of the coding regions as well as the splice 
recognition signals have previously failed to identify any potential pathogenic 
variants in cases to account for disease (Riazuddin et al., 2011, Wieben et al., 
2014). This may not be too surprising since haploinsufficiency caused by 
heterozygous gene deletions, nonsense, frameshift, splice-site and missense 
mutations in TCF4 (http://www.LOVD.nl/TCF4/) that impact on the helix-loop-
helix, Rep repressor or second activation protein domains, give rise to the 
neurological condition Pitt-Hopkins Syndrome (MIM#610954). This condition 
is characterised by intellectual disability, developmental delay, intermittent 
hyperventilation and distinctive facial features, as well as problems with the 
eyes, testes and skin (Amiel et al., 2007, Brockschmidt et al., 2007, Zweier et 
al., 2007).  
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Alternatively the expansion could be directly causative, affecting TCF4 gene 
transcription either by inactivating some of the transcript isoforms that are 
generated through different 5’-exon usage (Sepp et al., 2011) or it may 
stabilise transcripts containing the expansion. Recent studies confirm a direct 
causative effect since transcripts containing expanded repeats have been 
shown to form RNA foci in the nuclei of cultured fibroblasts and cornea 
endothelium (Du et al., 2015, Mootha et al., 2015).  
 
In Du et al’s study FECD patients’ endothelia were collected at the time of 
corneal transplant, whereas control tissue was obtained as corneoscleral 
buttons from an eye bank or fresh from enucleation specimens that did not 
involve the anterior segment. Endothelia from four FECD patients with a 
repeat expansion, one FECD patient without an expansion and three 
unaffected individuals were collected. RNAseq data suggested sequences 
from the intron containing the repeat preferentially accumulated in patients 
with FECD. In order to explore the mechanism by which the expanded 
CTG18.1 causes FECD, fibroblast lines from FECD patients were examined. 
They determined that the CTG-CAG trinucleotide repeat expansion was 
transcribed into stable RNA, which causes the formation of CUG RNA foci in 
the affected tissue. There was selective abundance of poly(CUG) RNA foci in 
FECD corneal endothelial cells compared to fibroblasts, suggesting that TCF4 
poly(CUG) transcripts predominantly accumulate in the corneal endothelium, 
leading to FECD. When present, the foci were shown to sequester RNA 
binding proteins such as splicing factor, muscleblind-like 1 (MBNL1). RNAseq 
analysis of the relative abundance of alternatively spliced isoforms for each 
gene demonstrated widespread changes in splicing in many genes including 
those involved in EMT, when four corneal endothelial samples harbouring a 
trinucleotide repeat were compared with three controls samples. This 
suggests that the presence of a trinucleotide repeat leads to aberrant splicing 
in FECD. As TCF4 is known to have a regulatory role in EMT and MBNL1 
splicing alterations have been implicated as an important factor in EMT, the 
RNAseq results that the authors describe indicate a possible disease 
mechanism in patients with a TCF4 trinucleotide repeat (Du et al., 2015). This 
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is the first time a trinucleotide repeat expansion has been identified as being 
causative for FECD.  
 
Another group (Mootha et al., 2015) published similar findings using 
fluorescence-in-situ hybridisation. They examined 8 FECD expansion-positive 
endothelial samples and noted abundant discrete, spheroidal RNA foci, which 
were absent in controls samples that did not harbour a TCF4 expanded 
CTG18.1. There were no correlations between the CTG18.1 repeat length 
and the percentage of cells that contained RNA foci. The authors postulated 
an RNA gain-of-function model in which mutant expanded CUG transcripts 
were stabilized through their interaction with RNA binding proteins to form 
nuclear inclusions triggering corneal endothelium-specific aberrant splicing an 
possibly also apoptosis. Like Du at al, they concluded that RNA nuclear foci 
were pathognomonic for CTG18.1-mediated FECD and that the disease 
mechanism was similar to other rare neurodegenerative trinucleotide 
disorders, such as Myotonic Dystrophy Type I. 
On statistical analysis of the LOXHD1 and TCF4 variants, both control cohorts 
were found to be in HWE, but the cases were not in HWE (there were 
insufficient homozygote expansions to be in HWE). This has also been found 
in previous FECD case control studies (Mootha et al., 2014). Departure from 
the HWE have been documented in other studies and in some cases it has 
been assumed that there was a biological reason for this, whereas others 
assume a genotyping error has occurred (Wittke-Thompson et al., 2005). In 
the study presented in this thesis there could be a number of reasons behind 
the departure from HWE. It is possible, although unlikely, that those 
homozygous for the CTG18.1 expanded allele are disadvantaged in some 
way from an evolutionary perspective, and therefore fewer case with this 
genotype exist in the case population. Another could be that the cases 
selection is not random as FECD is largely a dominant disease, and therefore 
the case population will contain a greater number of heterozygotes than 
homozygotes. Other reasons relate to the TP-PCR assay. Perhaps the 
threshold of “normal” and “disease” is different clinically from that determined 
by the laboratory TP-PCR assay), and that if the threshold were actually lower 
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then there would be a greater number of homozygotes. A Southern Blot would 
be useful in defining this threshold by accurately sizing the CTG18.1 
trinucleotide repeat lengths in cases and controls (this is explored fully in 
Section 5.3.3). 
 
5.3.3 The role of pre-symptomatic testing in FECD diagnosis 
 
The CTG18.1 TCF4 trinucleotide expansion appears to be the major 
presymptomatic factor in causing FECD in Caucasians. Of the 3 families 
presented in this thesis, FECDBAR and FECDWAK had unaffected members 
who were identified as having a CTG18.1 expanded allele, some of whom 
were too young to exhibit clinical signs of the disease. This raises the 
question of whether pre-symptomatic testing would be of value in individuals 
with a family history of FECD, by looking for either a trinucleotide expansion 
or another mutation before the disease had manifested. The role of pre-
symptomatic diagnostic testing in diseases caused by trinucleotide expansion 
mutations is clearer in conditions which present with rare and more severe 
phenotypes than FECD, such as Huntingtons Disease (Katsanis and 
Katsanis, 2013), and where the disease is completely penetrant (Mielcarek, 
2015). The existence of the CTG.18.1 expansion in controls might be due to 
the fact that the threshold of a disease-causing repeats is yet to be 
determined or that the mutation is incompletely penetrant. Therefore pre-
symptomatic testing and genetic counselling in FECD patients is potentially 
fraught with challenges and caveats. Perhaps more information needs to be 
ascertained about the full genetic architecture of FECD, along with more 
comprehensive knowledge of contribution of disease modifiers and 
environmental influences before pre-symptomatic testing can be widely 
available. Certainly, in the cases of FECDWAK and FECDBAR families who 
possess an expanded CTG18.1, it would be of benefit to analyse the exact 
size of the expansion and follow these patients longitudinally.  
 
Of the 83 controls tested using the TP-PCR assay, 5 of the controls, who 
were aged between 64 and 88, were found to have a CTG18.1 expansion. 
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There were many advantages of the PCR based assay used in this study 
(Warner et al., 1996). It allowed the analysis of a large number of cases and 
controls to be performed accurately and relatively cheaply. The limit of this 
assay is that, while it can determine the boundary of a “normal” allele and 
“expanded” allele, clinically this is an arbitrary cut-off point. In Mootha et al’s 
study the authors distinguish between two groups based on an expansion 
greater than or less than 43 repeats (Mootha et al., 2014). However, the 
repeat length is a linear variable, and the exact threshold at which the 
expansion becomes unstable or pathogenic remains unknown. Therefore, 
whether an individual subject with a repeat in the 40 to 60 range has an 
increased risk of disease is also unknown.  
 
There is evidence that repeat length can influence the severity of the disease 
(Mootha et al., 2015), but the Krachmer grading (Table 1.4) on which disease 
severity is based in this study, is not a simple objective measure of disease 
severity as it varies with time over the course of the disease. It is therefore 
entirely possible that repeat length can influence penetrance or severity of 
FECD, but this remains largely speculative. The definition of the threshold for 
a repeat expansion may directly influence the odds ratio. For the association 
between CTG expansion and FECD, the odds ratio may increase with 
increasing repeat length. Hypothetically speaking, it is entirely possible that a 
repeat length of 55 might cause disease, perhaps with a lower odds ratio than 
that estimated in this or other studies, whereas a repeat length of 2000 will 
certainly cause disease, perhaps with a much higher odds ratio. Unlike 
Myotonic Dystrophy Type, the TCF4 CTG18.1 in FECD does not yet have the 
benefit of a long and detailed history of validation. The challenge of better 
defining these boundaries relates to the technical challenges of determining 
large trinucleotide repeat lengths in the laboratory, and Southern blotting will 
almost invariably play a role in defining this. It would be interesting to know 
the exact size of the expansion in the 5 controls in whom an expanded 
CTG18.1 was found. Southern blotting could be a means of ascertaining 
whether the trinucleotide repeat length in these controls exists in the 
intermediate range. This could be an avenue of further work. Additionally, 
long-term follow-up of the controls that possess the CTG18.1 expanded allele 
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to assess for the development of FECD could be useful in determining 
whether the mutation is incompletely penetrant. 
 
5.3.4 Anticipation and trinucleotide instability in FECD patients with 
the CTG18.1 expansion 
 
Trinucleotide expansions are the causative mutation for many genetic 
diseases, including Myotonic Dystrophy Type I and 2 (DM1 and DM2 
respectively), Fragile X and Huntington’s Disease (HD). The mechanism of 
RNA toxicity seen in FECD patients who possess a CTG18.1 expansion is 
similar to that seen in DM1 (McMurray, 2010). Both myotonic dystrophy and 
HD exhibit anticipation, worsening of disease severity and earlier age of onset 
in successive generations (Orr and Zoghbi, 2007). The mechanism by which 
anticipation occurs may vary between trinucleotide repeat diseases. In Fragile 
X and Myotonic Dystrophy, CGG repeats in the non-coding region expand 
almost exclusively through maternal transmission, whereas in HD CAG 
repeats expand more commonly through paternal transmission (McMurray, 
2010) However, the sex preponderance of these diseases remains unaffected 
by this mechanism. 
 
Instability of the repeat sequence is the hallmark of trinucleotide disease and 
can be characterized by anticipation, worsening of the clinical phenotype, of 
progressively younger age of onset in successive generations. There are 
32,448 trinucleotide repeat sequences in the human genome and 878 
trinucleotide repeat sequence-containing genes (Kozlowski et al., 2010). 
While the mechanisms of triplet repeat instability remains unclear, possible 
contributions include polymerase slippage, DNA secondary structure, 
chromatin structure and triplex DNA formations (Longshore and Tarleton, 
1996). When the CTG18.1 was originally identified, some evidence of 
instability was indicated on Southern blotting (Breschel et al., 1997). While 
anticipation is not considered a typical feature of FECD, the presence of the 
CTG18.1 in the FECDBAR family and the earlier age of onset of affected 
individuals in the younger generation suggests that instability of the CTG18.1 
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mechanism might underlie this process. This is particularly true in the case of 
individual IV:1 (Figure 5.12), who was 28 -years-old when she was found to 
have guttata. A Southern blot analysis of individuals II:17, III:28 and IV:I would 
help to determine whether the repeat expansion length was increasing in 
successive generations in this family.  
 
5.3.5 The use of endothelial-checked controls or ECACC population 
controls in FECD studies 
 
For FECD, whether the controls have had their endothelium checked could 
have a profound effect on the findings of studies. From the work presented in 
this thesis, the mean age of the ECACC controls, who had not had their 
endothelium checked, was 38.7 +/- 8.4 years, which was considerably less 
than the mean age of the 56 FECD cases initially recruited. Had these 
controls been examined for endothelial abnormalities, a small proportion may 
had been found to have guttata, indicating that they would go on to develop 
FECD, and this proportion would have increased if they were checked when 
they reached an age equivalent to the patient cohort. This issue was 
addressed with the recruitment of age-matched endothelial checked controls 
from NHS cataract clinics. Unsurprisingly, a greater number of CTG18.1 
expansions had been noted in the ECACC controls compared with the 
endothelial-checked controls. This reduction in the frequency of such pre-
symptomatic signs in controls increased the odds ratio and significance of 
findings when using endothelial-checked as opposed to unchecked population 
controls. 
 
The presence of the expanded allele in a small proportion of the general 
population could have implications for the use of donor corneas to treat 
FECD, as some donor corneas may in fact be taken from pre-symptomatic 
carriers. One might expect that if the cornea belonging to a patient with a 
TCF4 trinucleotide expansion were used for transplant, that the recipient 
might be at risk of developing FECD. However, FECD recurs extremely rarely 
following corneal transplantation. Furthermore, corneas that have been 
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donated for transplantation are checked under light microscopy for abnormal 
corneal endothelial cell morphology. The data presented in this thesis 
suggests that examination of the corneal endothelium appears to be adequate 
in screening out patients with a repeat expansion. This would suggest that, 
until such a time as corneal gene therapies reach the clinic and theatre, there 
is no current need for genotyping corneal graft tissue, as the existing quality 
control appears to exclude abnormal morphology and therefore largely 
excludes those patients that might develop FECD. This data therefore 
highlights the importance of these checks, though one exception might be the 
use of tissue from a very young donor, who might be too young even to show 
these presymptomatic abnormalities.  Around 65% of patients who donate 
their corneas are above the age of 60-years-old (http://www.nerc-
charity.org.uk/cornea-donation), leaving a significant minority who might be 
too young to manifest signs of endothelial disease. A further study examining 
the genotypes of corneal tissue assessed and not ultimately utilised for 
corneal grafting could add weight to this argument. An alternative explanation 
for this lack of recurrence of FECD in grafted individuals is that perhaps on 
occasion a corneal graft harbouring a TCF4 CTG18.1 expanded allele is 
transplanted, but the disease does not manifest itself during the lifetime of the 
patient or the individual experiences graft failure for a different reason prior to 
this. There might therefore still be value in tissue genotyping in younger FECD 
patients being grafted. As genetic mechanisms in FECD continue to be fully 
elucidated, and as patient management becomes increasingly individualised, 
the role of genotyping tissue may become increasingly prominent in the 
future.  
 
5.3.6 The corneal endothelium transcriptome 
 
From the work presented in this thesis, RNA extractions performed on 
endothelial tissue using two different methods were unsuccessful (Section 
2.15). The use of either method led to unmeasurable levels of RNA, and 
therefore RNA sequencing of this tissue could not be carried out. The 
advantages of using graft tissue left over from lamellar graft procedures was 
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that it was tissue that was deemed suitable for corneal transplant and 
accurately dissected into the appropriate layers under sterile operating 
conditions. There is a lengthy exclusion criteria for the use of graft tissue in 
patients (Zuberbuhler et al., 2013). Therefore, the tissue used for grafting has 
come from healthy patients without significant co-pathology.  
 
This strategy worked well for the RNA sequencing of epithelial and anterior 
stromal tissue, where RNA sequencing was successfully carried out for 
another project. One reason for the lack of RNA extracted from endothelial 
corneal tissue was most likely degradation of the RNA from the single 
endothelial monolayer from the time the eyes were enucleated until the time 
they were placed in RNA later. This could have been overcome by using 
tissue from freshly enucleated eyes from donors with other general pathology 
not deemed suitable for corneal transplant. This would have had the 
advantage of being freshly extracted, although overall this tissue might have 
been less suitable as control tissue due to other general pathology in the 
patient, which potentially could affect corneal expression. However, had 
degradation of tissue been the sole reason for failure of extracting sufficient 
quantities of RNA, then one would expect the bovine tissue to yield sufficient 
amounts of RNA, which it did not. It may be that the volumes of endothelial 
tissue used were too small for the RNA kits to extract useful levels of RNA. 
 
A published database of RNA sequencing in control tissue can be used to aid 
the prioritisation of gene candidates following next generation sequencing 
studies (Chng et al., 2013, Du et al., 2015). The study by Du et al (2015) used 
tissue from an eye bank, or eyes enucleated for pathology that did not involve 
the anterior segment. The corneal endothelial tissue was bluntly stripped 
away from the corneal button and the RNA extracted using two different 
Qiagen RNA extraction kits. The authors do not mention whether the patients 
whose eyes were used as controls had any other general pathology.  
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5.3.7  Whole exome sequencing of members of the FECD Families 
 
Two different methods of NGS were employed in FECDBRI. Three affected 
family member’s DNA samples were sent to Otogenetics. However, as the 
read depth and data quality were significantly better at the Leeds NGS facility, 
a fourth affected sample and an unaffected sample were prepared and 
sequenced in Leeds. When the shared variants were analysed, the same 5 
variants were present after analysis with both Pipeline 1 and Pipeline 2 
(Section 2.21).The reason for the use of two NGS pipelines in this study was 
broadly the development and refinement of existing NGS pipelines over time 
with updated guidance on best practice of variant discovery 
(https://www.broadinstitute.org/gatk/guide/topic?name=methods) and 
experience within the VRG. Specifically, in pipeline 1 Bowtie 2 was used for 
the alignment of the FASTQ files, whereas in pipeline 2 Novoalign was the 
utilised. Experience from the members of the VRG and from other research 
groups in the Section of Ophthalmology and Neuroscience indicated that 
Novoalign outperformed Bowtie2 in terms of alignment accuracy, including 
where a large number of indels were present and overall in the identification 
of common and novel variants. Additionally, a published article (Yu et al., 
2012) compared four different aligners including Bowtie2 and Novoalign and 
concluded that all aligners perform similarly, with a slight advantage of using 
Novoalign in terms of accuracy and sensitivity to improved data quality. 
Therefore when Novoalign was ultimately used by most members of the VRG 
and included on the standard NGS pipelines developed by local 
bioinformaticians. 
 
The use of an unaffected individual in the analysis of data significantly 
reduced the number of variants when subtracted from the list of shared 
variants in affected individuals. Individual II:2 of FECDBRI was identified as 
clinically unaffected with FECD, presymptomatic endothelial cell changes 
were also excluded and this individual did not develop the disease during the 
course of the study. However, the issue of non-penetrance in FECD could be 
considered a potential problem in the analysis of exome data that utilises a 
sample from an unaffected individual. If the individual possesses the mutation 
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but does not manifest the disease then this could erroneously exclude a 
causative mutation from the analysis.  
 
In the analysis of exome data, the frequency of each variant in the 1000 
Genomes or ExAc databases is provided. It is therefore possible to filter 
variants on frequency. For the study of rare autosomal recessive disease a 
threshold of <1% is usually employed. While FECD is a relatively common 
disease, mutations in published genes have largely been rare (Biswas et al., 
2001, Vithana et al., 2006, Riazuddin et al., 2010a, Riazuddin et al., 2012, 
Riazuddin et al., 2013). Therefore rather than selecting a threshold of 4%, the 
cited prevalence of FECD (Lorenzetti et al., 1967), a threshold of≤2% was 
selected.  
 
In relation to this, one of the major challenges of studying the segregation of 
putative mutations in a late-onset disease in a pedigree such as FECDBRI 
was the uncertainty of whether members of generation III will develop the 
disease. While individual III:5 did not have definitive signs of FECD, there was 
some evidence of pleomorphism, and the consultant examining her felt that 
she might well be at risk of developing FECD. This has implications for the 
variant segregation of the potential gene candidates in FECDBRI. On Sanger 
sequencing she was found to possess the wild-type allele for OSBPL1A but 
the c.C461G variant of CRYZL1A. As the disease status of the younger 
individuals of generation III in FECDBRI was not ultimately confirmed as they 
may not have been old enough to exhibit clinical signs of FECD, it was difficult 
to make a definite decision on screening the cohort based on this segregation 
analysis. 
 
With all the caveats in this analysis listed above, CRYZL1 and OSPBL1A 
were considered the best candidate genes highlighted by WES of FECDBRI. 
CRYZL1 encodes a corneal crystalline, is expressed in the corneal 
endothelium (Chng et al., 2013), and there is a potential mechanism by which 
a mutation in this gene might compromise corneal clarity (Gong et al., 2012). 
The variant c.C461G:p.A154G is not only rare or absent from publicly 
available databases but is also highly conserved throughout evolution (Figure 
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5.20). OSBPL1A is also expressed in the corneal endothelium (Chng et al., 
2013) and additionally it interacts with FOXC1, a gene known to be involved in 
the development of the anterior segment (Berry et al., 2008). Furthermore, the 
OSBPL1A variant c.115_116insAATT:p.C39_K40delinsX is a stopgain 
mutation which leads to a frameshift  and premature stop codon, so if 
pathogenic would have a clear effect on the protein translation and function. 
However, the relatively frequent occurrence of other OSBPL1A homozygous 
variants in ExAc make a loss-of-function mutation less likely to be disease-
causing. 
 
Had the study been carried out on an early-onset disease and therefore led to 
a clearer result from the Sanger sequencing of variants in FECDBRI, these 
data might have led to the screening of the FECD cohort for mutations in 
these genes. However, doubts over diagnostic accuracy in the younger 
generations, together with restricted PhD lengths, meant that this follow-up 
work was not completed. Although an accurate method of sequencing a gene, 
Sanger sequencing (Sanger and Coulson, 1975) is a time-consuming and 
expensive method of sequencing large genes. Alternative high throughput 
methods avoiding the full costs of exome sequencing include long-range PCR 
followed by sequencing of products on a MiSeq machine, as utilized clinically 
in the screening of BRCA1 mutations (Morgan et al., 2010) or using molecular 
inversion probes (MIPs), a strategy that has been employed in the sequencing 
of genes that cause autism spectrum disorders (O'Roak et al., 2012). Both of 
these methods require meticulous optimisation of primers, which itself can be 
extremely time-consuming, and which can ultimately prove costly. 
Additionally, they can only be used in the screening of a selection of genes, 
unlike WES which provides the coding sequence for all genes in an individual. 
It may be that, as the cost of exome sequencing diminishes further, WES of 
either the entire cohort of FECD patients, or those who did not possess a 
CTG18.1 expansion, might become feasible. This is a potential future avenue 
of this project (Chapter 6). 
 
The rare TCF4 SNP rs192075715 was found to segregate with FECD in the 
FECDBRI family, and when combined with the initial linkage to chromosome 
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18 (Section 5.2.6.2.1), pointed towards the same region of chromosome 18 to 
be linked in the FECDBRI family. However, no expansion was found on TP-
PCR in this family, nor any potential pathogenic variant in LOXHD1. Given 
that the CADD score of SNP rs192075715 is 2.5 and the fact that, using the 
BDBG splicing prediction modeler (Section 2.17.7), it has no discernable 
effect on splicing, it is unlikely that this SNP is itself increasing susceptibility to 
FECD in this family. It remains possible that this SNP is in linkage 
disequilibrium with an FECD causing variant in this region. There are well-
documented examples of causative intronic mutations, such as that seen in 
Lebers Congenital Amaurosis (den Hollander et al., 2006) or mutations within 
a promoter region in PPCD (Davidson et al., 2016). Such mutations would 
have been missed by the strategy presented in this thesis but could be found 
using WGS. The TCF4 CTG18.1 is the first example of an association of a 
trinucleotide repeat with a common, complex disease. Therefore it is possible 
that the causative mutation in FECDBRI is another trinucleotide expansion on 
chromosome 18. A disadvantage of NGS is that it cannot directly sequence 
trinucleotide repeat sequences in the genome. Therefore, in the absence of 
other linkage data, it is not currently possible to ascertain whether other 
trunucleotide repeats cause or are associated with FECD.   
 
Another potential drawback of exome sequencing is, while it is more robust 
when it comes to determining structural variants such as deletions and 
insertions than Sanger sequencing, this cannot be done using the standard 
WES pipelines (Section 2.22). ExomeDepth (Plagnol et al., 2012) addresses 
this by its capacity to determine the presence of indels and larger structural 
variants. The need for controls run on the same next generation sequencing 
lane was a potential disadvantage in this study as the controls were FECD 
patients from different FECD families. The other FECD patients were from 
families which had been identified as having an expanded CTG18.1, therefore 
perhaps this was not a significant limitation. Nonetheless the ExomeDepth 
output presented for the FECDBRI family gave a list of pathogenic structural 
variants, with the highest BF score of 44.1 being a heterozygous duplication 
of 122,909 base pairs on chromosome 10. This was not identified as a 
common duplication in the Conrad database (Conrad et al., 2010) (Section 
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2.23). A large duplication would be challenging to verify on Sanger 
sequencing, however whole genome sequencing (WGS) could be performed 
in another affected individual to assess a limited form of segregation and 
examine the potential breakpoints. A pipeline is being developed locally that 
could perform this analysis on WGS data, and can manage the large FASTQ 
file sizes more efficiently that the standard aligners used in WES. 
 
In the FECD cohort presented in this thesis, 33/117 (28%) of the patients did 
not harbour a CTG18.1 expanded allele. A further study could also evaluate 
these cases by WES to determine their genetic basis. 
 
5.3.8 The contribution of phenocopies in FECD families 
 
An individual affected by a condition despite not having the disease genotype 
is called a phenocopy (Strachan and Read, 2011). Phenocopies have been 
reported previously in large FECD pedigrees where putative causative 
variants have been identified (Sundin et al., 2006a, Riazuddin et al., 2012). 
Additionally they have been reported in rare severe conditions caused by 
trinucleotide repeat expansion (Wild and Tabrizi, 2007, Abbruzzese et al., 
1996). Individual II:19  in FECDBAR exhibited signs of FECD but possessed 
the rs613872 genotype TT and was negative for the CTG18.1 expansion. This 
result was verified with stock DNAs in this individual. This supports the 
concept that FECD is a complex disease, implying that perhaps there are 
significant environmental factors or variants in other genes which played a 
part in the pathogenesis of the disease in this individual. Other explanations 
for the lack of CTG18.1 expanding allele in FECDBAR individual II:19 include 
the possibility of a sample mix up during the DNA extraction process or non-
paternity of the individual.  
  
 174 
6  General Summary, Concluding Remarks and 
Future Directions 
 
This thesis aimed to examine the genetic basis of corneal endothelial 
dystrophies. Chapter 3 looked broadly at corneal dystrophies as a whole, 
examining their incidence in patients below the age of 40 years. This was 
carried out in conjunction with the British Ophthalmic Surveillance Unit. In 
Chapters 4 and 5, the focus turned to corneal endothelial dystrophies. In 
Chapter 4, a rare Mendelian congenital form of endothelial dystrophy, CHED, 
was explored. A newly recruited CHED patient from Mexico was screened by 
Sanger sequencing for mutations in SLC4A11. This patient’s hearing was also 
tested by audiometry along with two other CHED families previously 
confirmed as harboring a mutation in SLC4A11. Additionally, parents of CHED 
patients that were available for testing were examined for evidence of adult 
onset corneal endothelial disease. Chapter 5 focused on the genetic analysis 
of a Caucasian cohort of 117 patients with the more common but potentially 
more genetically complex endothelial dystrophy FECD, recruited and sampled 
for genomic DNA from Ophthalmology clinics and theatre lists in Yorkshire. 
This cohort consisted mostly of single cases but also one member of each of 
3 families with multiple affected members. The genetic analysis evaluated the 
relative contributions of LOXHD1 variants and the TCF4 expansion to 
endothelial disease susceptibility in the FECD cohort compared with controls, 
and to identify the genetic cause of FECD in the families using whole exome 
sequencing and segregation analysis. The major findings of these studies are 
discussed below, together with the implications for diagnostic testing, current 
treatment regimes and future therapies for endothelial dystrophies. 
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6.1 Summary of key findings and future directions. 
6.1.1 A study of young-onset corneal dystrophies in conjunction with 
the British Ophthalmic Surveillance Unit 
 
The aim of the study described in Chapter 3 was to ascertain the incidence of 
new-onset corneal dystrophies in patients presenting below the age of 40. 
This was carried out in conjunction with BOSU, which runs a nation-wide 
surveillance system for the epidemiological study of incidence, clinical 
features and management of rare ophthalmic diseases. For any study 
adopted by the BOSU, reporting cards naming the conditions of interest are 
sent to UK ophthalmologists monthly by the BOSU team. This reduces the 
burden of work for doctors identifying patients and avoids the reporting of 
different conditions to multiple sources. 
 
Corneal dystrophies are an ideal group of conditions to be studied in 
conjunction with BOSU. There are no existing national incidence studies of 
corneal dystrophy, and there is likely to be significant variation in practice. As 
young-onset corneal dystrophy is a relatively rare but important cause of 
severe visual impairment, BOSU provided an ideal way of collaboratively 
identifying rare cases. The study found that the majority of referrals originated 
either from an ophthalmologist or an optometrist. In terms of patient 
demographics, nearly 80% of the patients studied were White-British and 
females accounted for 48% of the patients identified. The mean age at 
presentation was 12 years old and the most commonly-reported type of 
dystrophy was endothelial. The incidence of corneal dystrophy in patients 
younger than 40 years was compared with UK census data and it was 
concluded that young-onset corneal dystrophies are extremely rare and this 
study would suggest a minimum UK incidence of 6.7 newly-diagnosed cases 
per 10 000 000 population aged below 40 years per annum.  
 
The knowledge of epidemiology and presentation gained could be used to 
inform clinicians about the expected presentation, common visual symptoms, 
clinical course and commonly utilised management strategies. In turn 
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clinicians could use this information to help manage and counsel their 
patients. Additionally, knowledge of the epidemiology of corneal dystrophies 
could be utilized for service planning in the NHS. Half of the patients identified 
in the study had a positive family history of a corneal dystrophy. However, a 
molecular diagnosis was sought in only four patients. It would be interesting to 
further explore the results of whole exome sequencing in those patients who 
underwent genetic testing and indeed to perform genetic testing in all of those 
with a family history of corneal dystrophy. The corneal dystrophy classification 
has been recently amended to incorporate those dystrophies caused by 
mutations in the TGFβI gene. It is therefore entirely probable that in the future, 
next generation sequencing will become a routine part of corneal dystrophy 
work-up and management. 
 
6.1.2 Genotype-Phenotype Correlations in CHED, Harboyan 
Syndrome and FECD 
 
CHED is a rare, bilateral autosomal recessive condition affecting the corneal 
endothelium. It is characterized by corneal oedema and opacity. Harboyan 
syndrome is a considered a distinct syndrome consisting of the symptoms of 
CHED combined with later onset sensorineural hearing loss. Both conditions 
are caused by mutations in the SLC4A11 gene. In Chapter 4 of this thesis, a 
new mutation in the SLC4A11 gene, c397T>C F133L, was identified in a 
newly-recruited CHED patient from Mexico. Additionally, sensorineural 
hearing loss was found to be present in this patient and in three other patients 
who had been diagnosed with CHED when they were younger. This 
suggested that, rather than Harboyan syndrome being a distinct condition, it is 
more likely to be the same condition as CHED but at a later stage of 
progression. The study examines just a small number of cases and their 
families. A further study could longitudinally monitor a larger cohort of CHED 
patients to verify this finding of eventual high-frequency sensorineural hearing 
loss determined by audiometry. The results of this chapter suggest that in 
clinical practice, serial monitoring by audiometry should be carried out in 
CHED patients, even if the initial audiometry findings were unremarkable. 
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When individual II.2 from Family A (Figure 4.1) attended her routine 
Ophthalmology appointment at the BRI in 2012, she was coping with low 
vision (acuities of 6/60 in the right eye and hand movements in the left eye), 
and therefore the additional impact of hearing loss to her day-to-day activities 
could not be understated. Repeating the audiometry at this stage meant that 
her hearing impairment was correctly diagnosed and she was fitted with 
bilateral hearing aids. It also enabled her to receive additional social support. 
 
The later onset endothelial dystrophy FECD also results from mutations in 
SLC4A11, but has onset in late adulthood and is the result of heterozygous 
rather than homozygous mutations. This implies that parents of CHED 
patients, who are almost certainly carriers of SLC4A11 mutations, may also 
be at risk of developing endothelial dystrophy in later life. The heterozygous 
parents of the CHED patients examined herein were found to have early signs 
of corneal endothelial disease including guttata and reduced endothelial cell 
counts, implying that they are indeed at increased risk of developing FECD. 
Future studies monitoring the parents for the development of FECD would be 
useful. Additionally, studying more parents of CHED patients for corneal 
disease outcome would further validate the link presented in this thesis 
between CHED patients and FECD in their heterozygous parents, and would 
mean that prognostic information including the likelihood of requiring corneal 
graft surgery could be offered to other parents of CHED patients. 
 
6.1.2.1  Genetic Analysis of Fuchs Endothelial Dystrophy in         
Yorkshire 
 
FECD is a progressive disease of the corneal endothelium. In Chapter 5, the 
genetic basis of FECD was explored. The relative contributions of the TCF4 
SNP rs613872, the intronic CTG18.1 trinucleotide expansion and LOXHD1 
variants in a UK Caucasian FECD cohort were compared in order to clarify 
the significance of the original findings at the FECD3 locus on chromosome 
18. Mutations in LOXHD1 were not found to be significantly enriched in cases 
compared with public databases. The TCF4 CTG18.1 expanded allele, in 
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contrast, was present in 72.6% of cases compared with only 6.0% of 
endothelial-checked controls (odds ratio 23.2). Furthermore, the results of the 
segregation analysis of the TCF4 CTG18.1 expansion in three local FECD 
families showed that the CTG18.1 was also likely to be involved as a 
causative or susceptibility allele in two of the three FECD families.  The 
mutation in the third family, FECDBRI, was not explained by the TCF4 
CTG18.1 expanded allele, and therefore further analysis of the WES in this 
family was carried out. Segregation analysis of five of the variants obtained 
from WES after filtering was performed, two of which, OSBPL1A and CRYZL1 
were considered to be good candidates. However, due to the unknown 
disease status of members of generation III of FECDBRI, segregation 
analysis of the entire family was not sufficiently powerful to provide compelling 
evidence of the involvement of one or both of these variants. Screening of the 
FECD cohort for these variants did not take place, in part for this reason and 
also, due to time constraints of the PhD, which meant that other experiments 
were prioritized.  
 
The main conclusions drawn from this chapter were that, in our cohort, 
LOXHD1 mutations did not appear to be significantly enriched in the FECD 
cases compared with controls, suggesting that the role of LOXHD1 mutations 
is minor. By contrast, in the Leeds FECD cohort there is a highly significant 
association of TCF4 mutations in FECD cases compared with controls, 
suggesting that mutations in TCF4 contribute significantly to the pathogenesis 
and more than any other gene found to date. Nevertheless, there remain a 
proportion of FECD cases which do not carry TCF4 expansions, and some 
unaffected individuals do carry the expanded TCF4 allele yet do not develop 
the condition, which confirms the contribution of other genetic, and potentially 
environmental, factors in protection from or susceptibility to FECD. 
 
In our cohort there were 6% of control individuals who were of an age at 
which FECD might be expected to develop, had normal corneas on 
examination, and yet who possessed an expanded CTG18.1 allele. The TP-
PCR assay was only able to determine whether the allele exceeded 43 
repeats, which was a laboratory rather than clinical threshold. It was 
 179 
considered possible that the threshold of “normal” and “disease” could be 
slightly above or slightly below 43 repeats, and that the control individuals with 
an expanded allele might in fact carry a CTG18.1 allele of this intermediate 
length (around 43 repeats). Future avenues of work include Southern blotting 
to determine the trinucleotide length in controls who possessed the 
expansion, to determine whether their expansion is of an intermediate length. 
This technique would also be of use in individuals from generation III of the 
FECD families, FECDBAR and FECDWAK, who may still be too young to 
manifest signs of the condition and therefore whose clinical status remains 
unknown. If very large repeats were found in these individuals, they could be 
considered at risk of developing FECD and followed longitudinally. Studying 
FECD in families could also give valuable information about how repeat 
lengths are inherited by an individual’s offspring, and would allow clarification 
of whether anticipation had occurred as the expanded allele passed from one 
generation to the next. In this thesis, the three generations of the FECDBAR 
family with affected individuals could be examined for this purpose. 
 
Southern Blotting allows the detection of specific DNA sequences or small 
repeats separated by gel electrophoresis which are then transferred from the 
gel to a porous membrane by capillary action using absorbent paper to soak 
solution through the gel and the membrane. These specific sequences are 
detected in the membrane by hybridization with labelled nucleic acid probes 
(Southern, 2006). It is an accurate means of assessing variable repeat 
lengths, however does have disadvantages. It is expensive, time-consuming 
to perform when large number of samples are processed, and traditionally 
requires the use of radiation. 
 
A major limitation of NGS is its inability to accurately size trinucleotide 
repeats. Newer techniques are evolving, utilising high throughput technology, 
which may make the characterization of trinucleotide repeat lengths a 
possibility without the need for Southern Blotting. Single-molecule real-time 
(SMRT) sequencing generates longer reads than traditional WES (Guo et al., 
2015). This technology utilises a sequencing-by-synthesis approach, in which 
a circular DNA molecule is used as a template for a single DNA polymerase. 
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Linear amplicons are converted to a circular form, and the resulting SMRT 
library is then sequenced using a SMRT cell containing 150,000 DNA 
polymerases. The main advantage of this technique is the creation of single-
molecule reads that exceed 10kb in length. This technology has been used to 
sequence large trinucleotide repeat sequences that are causative for Fragile 
X (Loomis et al., 2013), and there is great potential to use this to accurately 
ascertain the CTG18.1 repeat length in both FECD patients and controls. 
 
As tentative linkage to chromosome 18 was found in FECDBRI in chapter 5, 
whole genome sequencing (WGS) would be of use in order to fully examine 
the FECD3 locus on chromosome 18, as well as rest of the genome, in this 
family. This would screen for large structural variants, especially those in 
genes known to cause FECD. Although this analysis could be carried out 
using WES data, for example using the program ExomeDepth (Section 
2.23.1), WGS provides a much better dataset for such analysis, and includes 
the sequence for intronic and intragenic regions. Therefore, if a large 
structural variant were found, the breakpoints of this could be accurately 
determined. This would also screen for mutations in promoter regions and 
introns, and would specifically assess the presence of the heterozygous 
duplication described in Section 5.2.6.2.5.  
 
As TCF4 is genetically a major contributor to the pathogenesis of FECD, WES 
of the patient samples from the Yorkshire FECD cohort without a TCF4 
CTG18.1 expansion could be carried out in order to screen for mutations in 
the best gene candidates from WES in FECDBRI, CRYZL1 and OSBPL1A. 
This strategy could highlight novel variants in other genes as potential 
causative mutations in FECD, and if performed collaboratively with different 
research groups, could result in sufficient patients recruited to perform a 
GWAS to assess for genetic associations in expansion-negative patients. 
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6.2 Implications of research for corneal dystrophy patients 
 
6.2.1 Strategies in the screening of candidate genes 
 
Despite advances in Next Generation capabilities over recent years, if the 
next step in this project were to involve screening a large cohort of FECD 
patients, the total cost of WES is still prohibitive at this time. It therefore 
becomes necessary to consider the available target enrichment strategies. 
These include those based on hybridisation strategies such as the Agilent 
SureselectQXT kit, the use of molecular inversion probes (MIPS) and PCR 
based enrichment strategies. The method utilised might depend on the ease 
of experimental design, cost, scalability and the uniformity of coverage 
(Kozarewa et al., 2015). The employment of such methods could have been 
useful for example in carrying out the screen of a large gene such as 
LOXHD1 for mutations in a larger cohort of FECD cases and controls, as well 
as for screening for mutations in the other genes known to cause FECD. 
However, at the time that the LOXHD1 screen was carried out, these 
technologies were not freely available or fully developed, and may not have 
proved cost-effective in a cohort of the size studied in this project. Assessing 
the FECD case/control cohort for mutations in OSBPL1A and CRYZL1 might 
have been possible using one of these high throughput methods. However, 
the ideal way of analyzing the FECD cohort if further time allowed would be to 
exclude FECD with expansions by means of Southern Blot, then analyse 
smaller numbers of patients negative for the CTG18.1 expanded allele using 
WES. 
 
6.2.2   Challenges of NGS 
 
One of the current main disadvantages of WES is the associated cost of 
performing it. However, this has diminished in recent years and it is feasible 
that it could be reduced further to allow large cohorts of patients to be exome 
sequenced. The ability to perform WES in a cohort of ethnically-matched 
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examined controls would be invaluable for use in studies of other corneal 
diseases. The major drawback in the use of WES data drawn from databases 
of control individuals in the study of common, complex, late onset disease is 
that inevitably some of these patients sequenced will have, or go on to 
develop, corneal disease, and therefore disease alleles will be present in the 
resulting datasets. The major advantage of an exome sequenced cohort of 
examined patients would be that the number of corneal disease alleles 
present would be reduced, allowing greater power in the detection of 
mutations in case cohorts. 
 
The advent of WGS would increase the ability to assess such cohorts for 
mutations in non-coding or promoter regions. WGS has allowed researchers 
to make a more detailed assessment of intronic and intragenic variants and a 
more comprehensive analysis of structural variants in genomic DNA. There 
are notable examples in ophthalmology (Davidson et al., 2016, Small et al., 
2016) where this technology has led to the detection of a causative mutation 
where previously WES alone had failed to reveal this. However, such 
advances are not without their challenges. Firstly, WGS generates millions of 
genetic variants, and the task of finding the causative mutation amongst these 
is an extremely difficult task. This can be addressed in part by developing 
effective filtering strategies but these strategies are still evolving and this is 
therefore an ongoing issue. Secondly, there are challenges relating to the 
storage of the large files generated from WGS, which can be several hundred 
gigabytes in size and may contain sensitive information about an individual’s 
genetic make-up, which raises additional issues regarding the confidentiality 
of data. Locally in Leeds, this has been addressed with the installation of an 
advanced computational infrastructure with over 2.5 petabytes of secure data 
storage capacity, through the Leeds Institute for Data Analytics (LIDA - 
http://www.lida.leeds.ac.uk/).  
 
Next generation sequencing as a whole is usually requested for a specific 
clinical or research reason, and may yield a primary finding specific to the 
indication for which the test was carried out. However, this approach also 
generates data on other genetic variants, some of which may have medical 
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significance and can be challenging both in their interpretation and in the 
process of reporting back to patients and their clinicians. NGS variants which 
are not related to the diagnostic indication, but which are likely to have 
medical consequences, and for which preventative treatment may be 
beneficial, are referred to as secondary findings.  Variants of unknown 
significance, or those variants of medical significance but for which no 
preventative measures are available, are referred to as incidental findings. On 
the whole, genetic professionals feel that secondary results, but not incidental 
findings, should be offered to adult patients, healthy adults and parents of a 
child with a medical condition (Yu et al., 2014). Among patients themselves 
there is considerable diversity of opinion in terms of what information should 
or should not be returned and most patients feel that they should have a 
choice and participate in this decision. It is therefore crucial that patients are 
allowed to opt out of receiving certain results (Clift et al., 2015). Fortunately 
there are guidelines available to assist those counselling patients in making 
these difficult decisions (Green et al., 2013). The working group involved in 
the development of these guidelines acknowledged that there was insufficient 
evidence about the benefits, risks and costs of disclosing incidental findings to 
make evidence-based recommendations, but felt that secondary findings were 
likely to have a medical benefit for patients and their families undergoing 
sequencing. The current Leeds corneal dystrophy ethics approval covers the 
use of Next Generation Sequencing for WES of patients’ DNA samples, and 
the WES of the CHED and FECD samples used in this study so far have not 
raised any such issues. However, the question of whether the patient does, or 
does not, want to be made aware of secondary findings is not specifically 
addressed in the consent form used. A new ethics approval is currently being 
drafted to address this issue.  
 
6.2.3 Clinical genetic testing of the TCF4 CTG18.1 allele in FECD 
patients 
 
The results presented in Chapter 5 indicate a highly significant association 
between FECD cases and the CTG18.1 expansion, with carriers 23.2 times 
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more likely to develop FECD than non-carriers. It can therefore be concluded 
that TCF4 mutations contribute more to the pathogenesis of FECD than any 
other gene identified to date. This may lead to demand for a clinical genetic 
test to look for an expanded CTG18.1 allele in the families of FECD patients. 
For the TP-PCR assay to become an accredited method of clinical diagnostic 
screening for the CTG18.1 expansion in FECD patients, further validation 
would be required. Analysis of the CTG18.1 allele indicated that the FECD 
cases were not in Hardy Weinberg Equilibrium (HWE). Departure from HWE 
can occur for biological results or as a result of genotyping error. As FECD is 
a dominant disease, the population from which these alleles are drawn are 
largely heterozygous, which could account for the relative lack of homozygous 
CTG18.1 variants. Alternatively, homozygous variants might be evolutionarily 
disadvantaged, resulting fewer than expected homozygotes, although given 
that the disease occurs in otherwise healthy adults, this is unlikely. Errors in 
genotyping as a result of laboratory assay may also be responsible.  If this 
were the case, one possible explanation for this could be that the TP-PCR 
was failing to detect those homozygous for the expanded allele. Designing 
primers enabling the TP-PCR assay to be performed in both directions would 
be an additional confirmatory step to ensure that the genotyping calls were 
correct. Southern Blotting of several FECD patients and examined control 
individuals would also provide further validation by establishing the threshold 
of repeat expansion associated with “normal” and “disease” status. This 
knowledge would be invaluable for genetic counselling of FECD patients with 
an expanded CTG18.1. In both FECDBAR and FECDWAK there are 
apparently normal individuals who carry the CTG18.1 expansion but are 
potentially too young to manifest the symptoms and signs of FECD. A detailed 
understanding of the link between trinucleotide repeat number and FECD 
causation, phenocopy rates and penetrance are essential for correct 
counselling of these individuals. 
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6.2.4   Gene therapy for corneal disease 
 
Much of the focus of gene therapies in eye disease has been on the treatment 
of retinal disorders. One example of this is the gene therapy trials for Leber’s 
Congenital Amaurosis caused by mutations in the RPE65 gene. Long-term 
follow-up of treated patients has indicated improved vision for three years, 
although in the longer term eventual progressive photoreceptor degeneration 
hindered sustained improvements in vision (Cideciyan et al., 2013). 
 
A number of approaches to treating corneal disease using gene therapies 
have also been considered. These include the use of adeno-associated viral 
vectors to facilitate gene transfer, siRNA-based approaches and therapy for 
corneal scarring by ameliorating TGFβI or matrix metalloprotease expression 
in the cornea. However these have yet to be developed to the point of 
reaching clinical trials (Williams and Klebe, 2012). Treatment of CHED by 
gene replacement seems feasible in some respects as, compared with the 
retina, the corneal endothelium is relatively easily accessible. Additionally, as 
the mechanism is thought to be deficiency of the SLC4A11 protein, this 
makes CHED an ideal target for gene replacement. Approaches to gene 
therapy for trinucleotide expansion-type diseases, of which FECD due the 
TCF4 CTG18.1 expansion is thought to be one, are also under development. 
These approaches include the use of Zinc finger nucleases, transcription-
activator–like effector nucleases and CRISPR-Cas nucleases to shorten 
trinucleotide repeats. However the development of these methods is very 
much in its infancy and it is not known whether they will ultimately lead to 
effective therapies (Richard, 2015). 
 
6.2.5  Strategies for cellular replacement in corneal disease 
 
Traditionally, it was thought that endothelial cells do not divide (Bourne, 2003) 
and that therefore, as they die with age, the cells that remain have a limited 
regenerative capacity (Waring et al., 1982). However, a more recent study 
suggests that the corneal periphery contains a reservoir of stem-like cells that 
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replace damaged or dead endothelium (He et al., 2012). As human donor 
corneal tissue for use in corneal transplants is a limited resource and demand 
for it remains high, the possibility of endothelial regeneration is an exciting 
avenue for research. Novel treatments based on this approach might 
overcome the problems with existing graft operations, with the challenges of 
limited availability of graft tissue, graft rejection and the surgical complications 
of infection and glaucoma being avoided. Currently, research is aimed at 
identifying the optimal conditions for the isolation and culture of corneal 
endothelial cells and the results of animal studies in this area are promising 
(Zavala et al., 2013). If the progenitor cells in the corneal periphery could be 
used in this way, corneal endothelium prepared from the patient’s corneal 
endothelial cells, bioengineered to correct the endothelial dystrophy-causing 
defect and grown in culture, could present an exciting therapeutic prospect for 
corneal endothelial disease. Full knowledge of the genetic architecture of 
endothelial dystrophies and their mechanisms of disease are an essential 
step in progressing towards these therapeutic avenues. 
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Appendix I 
A sample of the BOSU Corneal Dystrophy Questionnaire is shown below 
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Appendix II 
 
 
Corneal tissue processing 
 
Donor tissue was tested for the presence of Hepatitis B Surface Antigen, 
Hepatitis C Antibody, Human Immunodeficiency virus (HIV) 1 and 2, Antibody, 
Human T-lymphotropic Virus (HTLV) and 2, Syphilis serology, Hepatitis B 
core Antibody (HBcAb). Following enucleation the donor eye was cleaned in 
3% Povidone-iodine and 0.3% Sodium Thiosulphate prior to corneal excision. 
The corneascleral disc was then stored at 34°C in Eagles Essential Medium 
containing 2% FBS and the following antibiotics: 
 
Penicillin 100 units/ml 
Streptomycin 0.1mg/ml 
Amphotericin B 0.25 µl/ml 
 
Manchester Eye Bank Standards 
 
The corneal endothelium was examined by light microscopy a few days 
before use to ensure its suitability for transplantation in patients with corneal 
endothelial disease/deficiency. Organ-cultured corneas were delivered to 
hospitals in medium containing 5% dextran to reverse the stromal oedema 
that occurs during storage. Corneas with an inadequate endothelium could 
still be suitable for anterior lamellar grafts. The corneas may also be 
transferred to 70% ethanol and stored at room temperature for up to 12 
months or used in glaucoma surgery. Sclera, which was also stored in 70% 
ethanol for up to 12 months, can also be used for glaucoma or other 
reconstructive surgery. Ocular surface stem cells may be isolated from the 
limbus and expanded in ex vivo culture fortreating limbal stem cell deficiency. 
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Appendix III 
	
Primer Pair Sequences 
Standard PCR Conditions and Mastermix were used unless otherwise stated 
SLC4A11 
 
 
 
 
COL8A2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exon Forward*Sequence*5'23' Reverse*Sequence*5'23'
Product*
Size*(bp)
Annealing*Temperature*
(°C)/Programme
1 CCTAGCAGATGGGCTAAGCA GAGCAAAGCCACAGGACTCT 374 59
2,-3 CGAGAGTGGGACAGTCCAG CTCCCTGTTGAGCTGCTCCT 554 61
4,-5 TCCAGGAGCAGCTCAACAG CAGCCCTCTTCTCCCAAGTT 686 59
6 CCAACCAACTTGGGAGAAGA CCTTCAGAGGCCAGGACAT 391 57
7,-,8 AAAACCTGCTGCCAGTTCAT AAAACCTGCTGCCAGTTCAT 589 55
9,-10 ACTGATGGTACGTGGCCTCT CGTCCATGCGTAGAAGGAGT, 567 59
11,-12 TCTACATCCAGGGTGCAGTG ACTCAGCTTGAGCCAGTCCT 660 59
13-14 GAGCCCTTTCTCCCTGAGAT GGTTGTAGCGGAACTTGCTC 623 59
15,-16 CGGGAAATCGAGAGTGAGTT CGTCTCCTTCACGTTCACAA 673 57
17-18 CTGGCCACATGGGACATAG CTAGGCAGGACCCCTCCTC 678 59
19 CAGGAGGGGCTCCAGTCTA CTGTCCCTTGCATTCCACTT 692 57
Exon% Forward%5'-3' Reverse%5'-3'
Product%
Size%(bp)
Annealing%Temperature%
(°C)/Programme
2 AGGTGAGAGGGGACTTCCTG GATGCCAGTCTCATCGAAGG 400 57
 224 
 
 
LOXHD1 
 
* Redesigned primer   
**Primer Pair 5III was a nested primer used for DNA sequencing only 
Hotshot Mastermix was used for Exons 1 - 4, 6, 7, 10, 11,15, 18, 19, 22, 23, 
30-32, 34, 38 and 40, For all of these Hotshot Cycling Conditions were used 
except for 2 and 7 where Touchdown was utilised. 
 
Exon Forward*Sequence*5'23' Reverse*Sequence*5'23'
Product*
Size*(bp)
Annealing*Temperature*
(°C)/Programme
1 CAGAGCTCAGGGAGGAGG AATCAGTGAGGAAGGGCTTG 336 69
2 AAGAGTCCTTTGTGCTTGGG CTTCTCCCCAGAGAAGCAGG 319 Touchdown
3 GGGATGATGGAGGAAGAAGC TGGGAAGTAATTCATACCCAGAA 273 57
4 ATGATGGAGGAAGAAGCGG TGGGAAGTAATTCATACCCAGA 377 57
5 GCTCTGTTATTGACAGTAATGGTGAC GCTCAATAGAGGAGCCCAAA 355 *
6 TGGAAGAGCATCTTTCAGTGG GAGTGGATGCAGATGGACCT 149 57
7 AAAGTAGACTCAAGTGATTGGAAGA GTTTGATCACAGGCCTCCAG 314 Touchdown
8 GTGGAGGAGGAGGGCTTT TTCAGAGAAGTAGCATTCAGGTT 455 57
9 GTCTCTAAATGTGGGGCTGG GAGTGGACTGCCCTCATAGC 329 65
10 GTATACCCCGCCCTTCAGTC TTGGTCCAAAACCTGGCTTA 371 57
11 GCTGAAGAAAGAGCCCAAAG CAGAGGCAAATTTATGTGACAG 287 57
12 TGGCTTCTCTGCAATGAGAT CTAAGGGGCCTGAAGATGC 346 57
13 TCAGCCCAGATGAGAACTAGA CAGCTCAACTTTAACAGGGCA 364 57
14 TTGCCTAACCCATCAGCTCT TTGCTTGCTGGTCATGGTAG 368 57
15 CTCTGGGCCTCCATAGTGAC GCCACCTCTGTGAAACATGA 283 57
16 CTGGATTTTCAATTCCCAGC TCTTCAAAATGTGTTTACCCTTATGT 470 57
17 CTGGAGACCTGGGTTGTGTT TGTCAGCAAGACCTGCTTTG 401 57
18 GGAACAGGCTCAGGAAAGG CGGGTGAGTATTGACTGAGGA 349 61
19 GCCTTGTGCCTGGCTCT TGCCCACCTATTTGGCCT 673 69
20 AGGATCTGGCTGGATCTGAG TGAACAAGTCACACTGCCAA 673 57
21 CTGCCCTGGTTCTTGGG CCTCACCCTCCACCGTC 338 *
22 GACAGGGGAGAGTTTGGGAC ACAGGGGAGGGAAGGAAGAT 368 67
23 GGGAGTGAATCAAGGAAGCC CATAATTAGGATTCCCCTTGGA 304 57
24 TGGAAGTTCAGAAATTTGGTCA CAGATGGCATTCAAATTTCC 339 57
25 CAGCCACCTAAGGAAGGAAG GCCCACAGTCAATCCTGAAG 361 57
26 CTGGTTGTGCTGGTGAAGAA CATCAGGATGAAGGGCATGT 372 57
27 GAAATGCAAAGGGACTCAGG GCTGATCTAGCCAGTAGGTCC 322 57
28 CCATGATCCTTGTCCTTGGT tccTGGGTGAAGAGGCTTAG 367 57
29 CCTAGGCCAGAAGCTTAGCA GATGTCCCCAGGAACCAAG 351 57
30831 AGGTCTGTTCAGTGCAGCAA GATGGTGGGGCTCAAGAAT 658 69
32 GCCCTCAGAGGTCACTTCC CAGGTAGGCTGTTCTTCCCA 409 69
33 GCTGTGGAACTTGGACAGTG GGCATGTGAGAATCAGCCT 329 57
34 ATCTTCTCCCTCACCCCAAA TTTGTGCTTTAACAAGGTCCA 311 65
35 GATCTCCAGGGTTGGGATTC TGGAAGGCCTTATGAAGAAAA 385 57
36 TGTCCACCTGTACCCCTGAC ATCAGAGTCAATGTGCTGCC 389 57
37 GATAACTTGTCCAGGGCCAC CTGTATCTGGCACCTGACCC 377 *
38 GATCAAATGAAGGACCGGAG CTGGTTAGGCCCATTTGTGT 341 61
39 CATCCCTGTTCCCTGGC GAGACCTCATCATACCCTGC 366 57
40 CACCTTGGGAAGGGATCATT GCCAATGCTAGAGGCTTTGA 689 61
32B GAGCACTTCCTTCCCAGTTG GATGCCCCAGTGATGAGTCT: 356 57
40B GAGATGCCCCAATCTCACAT: TGCCAATGCGTTCTCTGTAA: 568 57
5II* GATGGTCATACATCCAATGGC ATTGCAATCAACCCACACAC 622 61
5III* TTTGGAACCAATGTGGACTG AGGACAGGTCACTCCAAACC ** **
21* GTGGGGAGGGGTAGGTCTTA CCCCAGTCTTCTTCCAGGAC 271 57
37* ATGGGTTGTGGGGATGTAGA CCTCCTGAGCCAATGATCTC 281 57
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TCF4  
 
Hotshot was used for rs613872 
 
 
FECDBRI Exome Sequencing Variants 
 
 
 
 
SNP Forward*5'-3' Reverse*5'-3'
Product*
Size*(bp)
Annealing*Temperature*
(°C)/Programme
!rs613872! GTTGGGAACACCCATTTGTC ACCCCAGTAGGGTTGTGATG 275 65
rs192075715 TTCTCATTTATATGTGTCCAACCTG CACCAGATATATTGGGGGAA 253 60
Gene Forward*5'-3' Reverse*5'-3'
Product*
Size*(bp)
Annealing*Temperature*
(°C)/Programme
OSBPL1A TCTGTGGGGTTCTTCCTAGC CACCCTGCAACGGATTTATT 398 59
CRYZL1 GGAGAGAAATAGATCCAGGAGG* CAAATGGATGGCTCATTGCT* 286 55
TC2N TGAGAGCCTTCCAGATCCTC CAAGTCATTGCCATTCTTATTTTC* 466 55
TTC40 GAACCACAACCCTTCCCAC CCACACTTGTCTACTCACCTTTCA 250 59
URB1 TCACTTGCCTTGATTTTGACC* TTCTCAATCTCTTAACACGTCACT* 307 63
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Appendix IV 
 
Standard PCR Mastermix was used for all PCRS using these primers 
 
 
 
Chromosome 18 Linkage Markers 
 
 
 
 
 
 
 
 
 
Marker Physical-Location-
(hg19)
Forward-5'<3' Reverse-5'<3' Size-(bp) Dye
D18S1152 54716520+,+54716915 GTTTGGAGACAGGGCG TTATAGTTCAGGCTCTTGTGTATTT 222,274 HEX
D18S1144 55568578+,+55568922 CTGGATTAGCCAGGCCC TGACTTGTGGACACATCACTC 159,181 TET
D18S1103 56930137+,+56930437 GAATCTCTTGAACCAGGGA AACCAGTAGGCATTTGGAA 206,254 FAM
D18S64 57426031+,+57426378 ATACTGGTGGTGGTTATACAACAT AAATCAGGAAATCGGCA 188,208 FAM
 227 
TCF4 STR and TP-PCR Primers (to measure CTG18.1 expansion) 
 
 
 
 
 
 
 
Primer Ratios: 
 
STR    P1:P2   1:1 
 
TP-PCR   P1:P3:P4  1:1:0.5 
 
 
 
Primer Sequence
P1 AATCCAAACCGCCTTCCAAGT
P2 CAAAACTTCCGAAAGCCATTTCT
P3 TACGCATCCCAGTTTGAGACG
P4 TACGCATCCCACTTTGAGACGCAGCAGCAGCAGCAG
TCF4!CTG18.1!Genotyping
Annealing!Temperature!
(°C)/Programme
STR 61
TP'PCR 60
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Appendix V 
Rs613872 and CTG18.1 Genotype and Demographic Data 
Cases and Controls 
 
 
ID rs613872 CTG18.1 Age2at2Venesection Gender
P1 TT SS 68 F
P2 TG SX 60 F
P3 TT SS 57 F
P4 TG SX 60 M
P5 TT SS 65 F
P6 TG SS 48 M
P7 TT SS 49 F
P8 TG SX 60 F
P9 TG SS 91 M
P10 GG XX 89 F
P11 TT SS 80 F
P12 GG SX 78 F
P13 TG SS 79 F
P14 TG SX 76 M
P15 TT SS 69 M
P16 GG SX 81 M
P17 TG SS 65 F
P18 TG SX 70 F
P19 TT SX 69 F
P20 GG XX 74 M
P21 TG SX 66 F
P22 TG SX 76 F
P23 TT SS 69 M
P24 TG SX 67 F
P25 TT SS 59 M
P26 TT SX 56 F
P27 GG XX 77 F
P28 TT SS 72 F
P29 TG SX 69 F
P30 TG SX 66 F
P31 TG SX 76 F
P32 TT SS 65 M
P33 TG SX 80 F
P34 TG SX 72 F
P35 TG SX 67 M
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P36 TG SX 86 F
P37 TT SS 88 M
P38 TG SX 80 F
P39 TG SX 62 F
P40 TT SS 79 F
P41 TT SS 70 M
P42 TG SX 85 F
P43 TG SX 82 F
P44 TG SX 64 M
P45 GG SX 63 F
P46 TG SX 68 F
P47 TG SX 75 F
P48 TG SS 73 F
P49 TG SX 83 F
P50 TG SX 70 M
P51 GG XX 68 F
P52 TG SX 77 F
P53 TG SX 77 F
P54 TG SX 88 F
P55 TG SX 75 M
P56 GG SX 75 F
P57 TT SS 94 M
P58 GG SX 66 M
P59 TG SX 68 M
P60 TT SS 48 F
P61 TT SS 82 F
P62 TG SX 67 F
P63 TG SX 74 M
P64 TG SX 81 M
P65 TG SX 63 M
P66 TT SS 85 F
P67 TG SX 78 M
P70 TG SS 64 F
P71 TT SS 89 F
P72 GG SX 63 F
P73 GG XX 76 M
P74 TG SX 76 F
P75 TG SX 84 F
P76 TT SS 69 F
P77 TG SX 76 M
P78 TG SX 82 F
P79 GG SX 65 M
P80 TG SX 65 F
 230 
P81 TG SX 68 F
P82 GG XX 64 M
P83 TG SX 73 F
P84 TG SX 68 F
P85 TG SX 68 F
P86 TG SX 69 M
P87 TG SX 71 F
P88 TG SX 69 F
P89 TT SS 76 F
P90 TG SS 85 F
P91 TG SX 56 M
P92 TG SX 73 F
P93 TG SS 69 F
P94 TG SX 74 F
P95 TG SX 79 M
P96 GG XX 69 F
P97 TG SX 59 F
P98 GG SX 68 M
P100 TG SX 60 F
P101 TG SX 73 F
P103 GG XX 54 M
P104 TT SS 52 F
P105 TG SX 67 M
P106 TG SX 80 F
P107 TG SX 72 M
P108 TG XX 66 M
P109 TG SX 66 M
P110 GG SS 71 F
P111 TG SX 68 M
P112 TG SX 67 F
P115 GG XX 72 M
P116 GG XX 73 M
P117 TG SX 73 F
P118 TG SX 62 M
P119 TT SS 58 F
P120 TT SS 63 F
P125 GG XX 74 F
P126 GG XX 68 F
P127 TG SX 58 M
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ID rs613872 CTG18.1 Age2at2Venesection Gender
C1 TT SS 74 M
C2 TT SS 80 F
C3 TT SS 67 F
C4 TG SS 79 M
C5 TT SS 78 M
C6 TT SS 85 M
C7 TT SS 76 M
C8 TT SS 80 F
C9 TT SS 81 F
C10 TT SS 80 F
C11 TT SS 82 M
C12 TT SS 82 F
C13 TG SS 77 M
C14 TT1 SS 78 F
C15 TG SS 80 F
C16 TT SS 67 M
C17 TT SS 75 M
C18 TT SS 67 F
C19 TT SS 84 F
C20 TT SS 77 M
C21 TT SS 78 F
C22 TT SS 77 M
C23 TG SS 76 F
C24 TT SS 62 F
C25 TT SS 78 M
C26 TT SS 56 M
C27 TT SS 74 F
C28 TT SS 81 M
C29 TT SS 69 M
C30 TG SX 88 F
C31 TG SS 81 F
C32 TT SS 70 F
C33 TT SS 74 F
C34 TG SX 83 M
C35 TT SS 87 F
C36 TG SX 73 F
C37 TG SS 86 F
C38 TT SS 83 M
C39 TT SS 66 M
C40 TT SS 68 M
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C41 TT SS 81 M
C42 TG SS 93 M
C43 TG SX 64 M
C44 TG SS 88 M
C45 TT SS 76 F
C46 TG SX 66 M
C47 TT SS 77 M
C48 TG SS 88 F
C49 TT SS 79 F
C50 TT SS 80 M
C51 TG SS 73 F
C52 TG SS 83 M
C53 TG SS 68 F
C54 TT SS 71 M
C55 TT SS 70 F
C56 TG SS 81 F
C57 TT SS 73 M
C58 TT SS 87 M
C59 TT SS 83 F
C60 TT SS 73 F
C61 TT SS 77 F
C62 TT SS 77 M
C63 TT SS 92 F
C64 TT SS 87 M
C65 TT SS 86 F
C66 TT SS 69 F
C67 TT SS 78 M
C68 TG SS 73 F
C69 TT SS 79 F
C70 TT SS 73 M
C71 TG SS 67 M
C72 TT SS 71 F
C73 TT SS 86 F
C74 TT SS 90 M
C75 TT SS 78 F
C76 TT SS 72 F
C77 TG SS 61 M
C78 TT SS 82 M
C79 TT SS 86 F
C80 TT SS 75 F
C85 TT SS 68 M
C86 TG SS 63 F
C87 TT SS 67 M
